AU2019232796B2

AU2019232796B2 - Antibodies to MUC16 and methods of use thereof

Info

Publication number: AU2019232796B2
Application number: AU2019232796A
Authority: AU
Inventors: David Spriggs; Dharmarao Thapi
Original assignee: Memorial Sloan Kettering Cancer Center
Current assignee: Memorial Sloan Kettering Cancer Center
Priority date: 2010-03-26
Filing date: 2019-09-17
Publication date: 2021-10-21
Anticipated expiration: 2031-03-25
Also published as: AU2014271278A1; AU2017202515A1; AU2014271278B2; AU2017202515B2; AU2019232796A1

Abstract

ANTIBODIES TO MUC16 AND METHODS OF USE THEREOF ABSTRACT The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which MUC16 is overexpressed, such as cancer.

Description

ANTIBODIES TO MUC16 AND METHODS OF USE THEREOF

This application is a divisional of No. 2017202515, filed 18 April 2017, which is a divisional of No. 2014271278, filed 3 December 2014, which is a divisional of No. 2011230590, filed 25 March 2011, which derives from PCT/US2011/030025, and which claims priority to U.S. No. 61/317,964, filed 26 March 2010, each of which is herein incorporated by reference in its entirety for all purposes.

This invention was made with government support under PO1-CA52477-16 awarded by the United States Public Health Service (US PHS). The government has certain rights in the invention.

FIELD OF THE INVENTION The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which MUC16 is overexpressed, such as cancer.

BACKGROUND OF THE INVENTION Cell surface markers and shed antigens are used in the diagnosis of several cancers. For example, the CA125 antigen, recognized by the OC125 antibody, is a tissue-specific, circulating antigen expressed in ovarian cancer. The CAl25 antigen is encoded by the MUCI6 gene, cloned by Lloyd and Yin. The full-length gene describes a complex tethered mucin protein present primarily in a variety of gynecologic tissues, especially neoplasms. OC125 and other related antibodies react with glycosylation-dependent antigens present exclusively in the cleaved portion of the molecule. A serum assay can detect elevated levels of the circulating CA25 antigen in many epithelial ovarian cancer patients, and this antigen, derived using the ovarian cell line OVCA433, is recognized bythe OC125 antibody (1-2). The detection of circulating CAl25 in serum has proven to be a useful tool for the management of ovarian cancer patients and clinical trials (3-4). However, CA125 is neither sufficiently sensitive nor specific for general cancer screening (5-6). A variety of CA125 linked antibodies including VK8 and M Ihave subsequently been defined as present on ovarian cancer cells (7-9). Although these antibodies have been used to develop serum assays and various other studies in ovarian cancer, they have significant shortcomings for clinical use in screening or tissue delivery. These antibodies are not useful as screening tools, nor can they detect the proximal residual IUC16 protein fragment after cleavage. This has limited their diagnostic and therapeutic applications. For example, OC125, M11, and most other antibodies prepared against ovarian cancer cell extracts are directed at complex, glycosylation-dependent antigens. These antigens are exclusively present in the shed portion of MUC16 and cannot be employed to follow the biology of the proximal portion of MUC16 and may not accurately reflect tissue distribution since the glycosylation patterns can vary substantially among tissues. Because the vast majority ofMUC16 reactive antibodies, including OC125, react with the glycosylation-dependent antigen present exclusively in the cleaved portion of the molecule, the true distribution of MUC16 expression is not known(21). There is currentlyno antibody available to track the fate of the remainingMUC16 protein fragment after cleavage and CA125 release. Thus, there remains a need for the identification of antibodies that are directed against sequences in the peptide backbone of MUC16, and that are useful for diagnosis and treatment of cancers in which MUC16 is expressed and/or overexpressed.

SUMMARY OF THE INVENTION The invention provides an antibody, or an antigen-binding fragment thereof, that specifically binds to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from the group of a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide CQVSTFRSVPNRHHTGVDSLC (SEQ ID NO:19). In one embodiment, the antibody internalizes into a cell. While not intending to limit the invention to a particular sequence of MUC 16 ectodomain, in one embodiment, the MUC16 ectodomain polypeptide comprises a polypeptide selected from the group of Polypeptide 1 NFSPLARRVDRVAIYEE (SEQ ID NO:01) and Polypeptide 2 TLDRSSVLVDGYSPNRNE (SEQ ID NO:02). In another embodiment, the antibody lacks specific binding to a glycosylated MUC16 extracellular domain. In yet a further embodiment, the antibody specifically binds to the Polypeptide 2 (SEQ ID NO:02) of the MUC16 ectodomain polypeptide, and wherein the antibody comprises a variable heavy (VH) chain encoded by SEQ ID NO:06, and a variable light (VL) chain encoded by SEQ ID NO:07. In yet another alternative embodiment, the antibody specifically binds to the Polypeptide 2 (SEQ ID NO:02) of the MUC16 ectodomain polypeptide, and wherein the antibody comprises a variable heavy (VH) chain encoded by SEQ ID NO:04, and a variable light (VL) chain encoded by SEQ ID NO:05. In a further embodiment, the antibody specifically binds to the Polypeptide 1 (SEQ ID NO:01) of the MUC16 ectodomain polypeptide, and wherein the antibody comprises a variable heavy (VH) chain encoded by SEQ ID NO:08, and a variable light (VL) chain encoded by at least one of SEQ ID NO:09andSEQIDNO:10. In one embodiment, the MUC16 cytoplasmic domain polypeptide comprises VTTRR RKKEGEYNVQ QQ (SEQ ID NO:18). More preferably, but without limitation, the MUC16 cytoplasmic domain polypeptide comprises Polypeptide 3 CGVLVTTRRRKKEGEYNVQQQ(SEQIDNO:03). In an alternative embodiment, the MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide comprises CQVSTFRSVPNRHHTGVDSLC (SEQ ID NO:19). More preferably, but without limitation, the MUC16 extracellular domain polypeptide comprises Polypeptide 4 KSYF SDCQVSTFRS VPNRHHTGVD SLCNFSPL (SEQ ID NO:15). In yet another alternative embodiment, the antibody specifically binds to the Polypeptide 4 (SEQ ID NO:15) of the MUC16 extracellular domain polypeptide, and wherein the antibody comprises a variable heavy (VH) chain encoded by SEQ ID NO:11, and a variable light (VL) chain encoded by SEQ ID NO:12. In a further alternative embodiment, the antibody is selected from the group of a chimeric antibody, a monoclonal antibody, a recombinant antibody, an antigen-binding fragment of a recombinant antibody, a humanized antibody, and an antibody displayed upon the surface of a phage. In another embodiment, the antigen-binding fragment is selected from the group of a Fab fragment, a F(ab')2 fragment, and a Fv fragment. In an alternative embodiment, the antibody, or antigen-binding fragment thereof, is covalently linked to a cytotoxic agent or a prodrug of a cytotoxic agent. In a preferred embodiment, the antibody is a monoclonal antibody produced by a hybridoma cell line. The invention also provides an isolated monoclonal antibody, or an antigen-binding fragment thereof, produced by a hybridoma cell line, wherein the antibody specifically binds to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from the group of a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide !5 CQVSTFRSVPNRHHTGVDSLC(SEQIDNO:19). In one embodiment, the MUC16 ectodomain polypeptide comprises Polypeptide 1 (SEQ ID NO:01) and the antibody is selected from the group of 9B11.20.16,10A2, 2F4,23D3,30B1, and 31B2. In an alternative embodiment, the MUC16 ectodomain polypeptide comprises Polypeptide 2 (SEQ ID NO:02), and wherein the antibody is selected from the group of 4H11.2.5 ,13111, 29G9, 9C9.21.5.13, 28F8, 23G12, 9C7.6, 11B6, 25G4, W 5C2.17, 4C7, 26B2, 4A5.37, 4A2, 25113, and 28F7.18.10. In yet a further embodiment, the MUC16 cytoplasmic domain polypeptide comprises Polypeptide 3 CGVLVTTRRRKKEGEYNVQQQ (SEQ ID NO:03), and wherein the antibody is selected from the group of 31A3.5.1, 19D1, 10F6, 22E10, 22F1, 3118, 22F11, 4D7, 24G12, 19G4, 9A5, 4C2, 31C8,27G4,and6H2. In another alternative embodiment, the MUC16 extracellular domain polypeptide comprises Polypeptide 4 KSYF SDCQVSTFRS VPNRHHTGVD SLCNFSPL (SEQ ID NO:15), and wherein the antibody is selected from the group of 24B3 and 9C7. The invention additionally provides a composition comprising (a) any one or more of the antibodies, or antigen-binding fragments thereof, that are described herein, and (b) a pharmaceutically acceptable carrier. Also provided by the invention is a hybridoma cell line that produces a monoclonal antibody that specifically binds to a polypeptide, or antigenic portion thereof, selected from the group of a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide CQVSTFRSVPNRHHTGVDSLC (SEQ ID NO:19). The invention additionally provides a method for detecting a disease that comprises overexpression of MUC16 in a subject, comprising a) providing i) a sample from a subject, and ii) any one or more of the antibodies, or antigen-binding fragments thereof, that are described herein, b) contacting the sample with the antibody under conditions for specific binding of the antibody with its antigen, and c) detecting an increased level of binding of the antibody to the sample compared to a control sample lacking the disease, thereby detecting the disease in the subject. In one embodiment, the disease is cancer. In a preferred embodiment, the cancer is selected from the group of ovarian cancer and breast cancer. While not intending to limit the method of detection, in one embodiment, detecting binding of the antibody to the sample is iunohistochemical, enzyme-linked immunosorbent assay (ELISA), fluorescence-activated cell sorting (FACS), Western blot, immunoprecipitation, and/or radiographic imaging. Also provided herein is a method for treating a disease that comprises overexpression of MUC16, comprising administering to a subject having the disease a therapeutically effective amount of any one or more of the antibodies, or antigen-binding fragments thereof, that are described herein. In one embodiment, the disease is cancer, as exemplified by ovarian cancer and breast cancer. The invention also provides an isolated antibody, or an antigen-binding fragment thereof, that specifically binds to a MUC16 polypeptide or to an antigenic portion thereof, wherein the MUC16 polypeptide is selected from the group of a) TLDRKSVFVDGYSQNRDD (SEQ ID NO:21), b) KSYFSDCQVLAFRSVSNNNNHTGVDSLCNFSPL (SEQ ID NO:22), c) SLYSNCRLASLRPKKNGTATGVNAICSYHQN (SEQ ID NO:23), d) KSYFSDCQVNNFRS, e) TLDRSSVLVDGYSQNRDD, and ) TLDRSSVLVDGYSQNRDD. In one embodiment, the antibody is selected from the group of a monoclonal antibody, a chimeric antibody, a recombinant antibody, an antigen-binding fragment of a recombinant antibody, a humanized antibody, and an antibody displayed upon the surface of a phage. In a preferred embodiment, the antibody is a monoclonal antibody produced by hybridoma cells selected from the group of 12B10-3G10, 10C4 3H5, 10C4-1F2, 10C4-2H8, 10C4-1G7,17F2-3G5,17F2-3F6,17F2-2F9,17F2-lE1l, 12B10-3F7, 12B10-2F6,12B10-2F10, 25E9-3, 25E9-5, 25E9-1, 25E9-16, 21B8-1H11, 21B8-3G6,21B8-3H9, 21B8-1G8, 21E1-1E3, 21El-1G9, 21El-2G7, 21El-3G12, 4H1-2E1, 4H1-2E3, 4H1-3E1, 4H1 3H3,15A8-2E2,15A8-2E10, 15A8-2E11, 15A8-3D2,22B5-1F6,22B5-3G9,22B5-2G8, and 22B5-3F11. Ina particular embodiment, the MUC16 polypeptide is TLDRKSVFVDGYSQNRDD (SEQ ID NO:21), and the antibody comprises a variable heavy (VH) chain sequence SEQ ID NO:27, and a variable light (VL) chain sequence SEQ ID NO:29, such as the monoclonal antibody produced by hybridoma cell 12B10-3G10. In an alternative embodiment, the antigen-binding fragment is selected from the group of a Fab fragment, a F(ab')2 fragment, and a Fv fragment. In a more preferred embodiment, the antibody, or antigen-binding fragment thereof, is covalently linked to a cytotoxic agent and/or to a prodrug of a cytotoxic agent. In a further embodiment, the antibody specifically binds to human MUC16 (SEQ ID NO:25). In another embodiment, the antibody internalizes into a cell. In an alternative embodiment, the antibody lacks specific binding to a glycosylated MUC16 extracellular domain. The invention also provides a composition comprising (a) any one or more of the invention's antibodies and/or antigen-binding fragments thereof, and (b) a pharmaceutically acceptable carrier. The invention further provides a hybridoma cell that produces an antibody, or an antigen binding fragment thereof, that specifically binds to a MUC16 polypeptide or to an antigenic portion thereof, wherein the MUC16 polypeptide is selected from the group of a) TLDRKSVFVDGYSQNRDD (SEQ ID NO:21), b) KSYFSDCQVLAFRSVSNNNNHTGVDSLCNFSPL (SEQ ID NO:22), c) SLYSNCRLASLRPKKNGTATGVNAICSYHQN (SEQ ID NO:23), d) KSYFSDCQVNNFRS, e) TLDRSSVLVDGYSQNRDD, and f) TLDRSSVLVDGYSQNRDD. The invention also provides an isolated nucleotide sequence comprising a polynucleotide that encodes at least one of a variable heavy (VH) chain sequence and the variable light (VL) chain sequence of an antibody that specifically binds to a MUC16 polypeptide, wherein the MUC16 polypeptide is selected from the group of a) TLDRKSVFVDGYSQNRDD (SEQ ID NO:21), b) KSYFSDCQVLAFRSVSNNNNHTGVDSLCNFSPL (SEQ ID NO:22), c) SLYSNCRLASLRPKKNGTATGVNAICSYHQN (SEQ ID NO:23), d) KSYFSDCQVNNFRS, e) TLDRSSVLVDGYSQNRDD, and f) TLDRSSVLVDGYSQNRDD. In one embodiment, the MUC16 polypeptide is TLDRKSVFVDGYSQNRDD (SEQ ID NO:21) and the polynucleotide encoding the variable heavy (VH) chain sequence comprises SEQ ID NO:26, and wherein the polynucleotide encoding the variable light (VL) chain sequence comprises SEQ ID NO:28. The invention also provides a method for producing an antibody that specifically binds to a MUC16 polypeptide or to an antigenic portion thereof, comprising administering to a subject an immunologically effective amount of a MUC16 polypeptide selected from the group of a) TLDRKSVFVDGYSQNRDD (SEQ ID NO:21), b) KSYFSDCQVLAFRSVSNNNNHTGVDSLCNFSPL (SEQ ID NO:22), c) SLYSNCRLASLRPKKNGTATGVNAICSYHQN (SEQ ID NO:23), d) KSYFSDCQVNNFRS, e) TLDRSSVLVDGYSQNRDD, and f) TLDRSSVLVDGYSQNRDD. The invention additionally provides a method for identifying a subject as having disease, comprising determining the level, in a sample from the subject, of specific binding of any one or more of the invention's antibodies and/or antigen-binding fragments thereof, with the MUC16 polypeptide or with the antigenic portion thereof, wherein detecting an altered level of the specific binding relative to a control sample identifies the subject as having disease. In one embodiment, the disease is cancer exemplified by ovarian cancer and breast cancer. In another embodiment, the method further comprises detecting an altered level of binding of the antibody to the sample compared to a control sample. Optionally, the detecting is selected from the group of immunohistochemistry, enzyme-linked immunosorbent assay (ELISA), fluorescence-activated cell sorting (FACS), Western blot, immunoprecipitation, and radiographic imaging. The invention also provides a method for reducing one or more symptoms of disease comprising administering to a subject in need thereof a therapeutically effective amount of any one or more of the invention's antibodies and/or antigen-binding fragment thereof. In one embodiment, the disease is cancer, exemplified by ovarian cancer and breast cancer. Optionally, the method further comprises detecting a reduction in one or more symptoms of the disease after the administration step.

BRIEF DESCRIPTION OF THE DRAWINGS Figure 1: Three MUC16 carboxy terminus peptides were synthesized at the MSKCC Microchemistry Core Facility. Polypeptide 1 is near the putative cleavage site, Polypeptide 2 is before the transmembrane, and Polypeptide 3 is the internal peptide, which is inside the transmembrane. Figure 2: Comparison staining of high-grade serous ovarian carcinomas using OC125 (left panel) and 4H I(right panel)

Figure 3: Immunohistochemical scoring of OC125 and 4H11 on tissue microarrays of high grade ovarian serous carcinoma. Only membranous and/or cytoplasmic staining was considered positive. Score 0: No staining; Score 1: <5% strong or weak; Score 2: 5-50% strong or weak; Score 3: 51-75% strong or 51-100% weak; Score 4: 76-99% strong; Score 5: 100% strong. Figure 3A: OC125 (Score 0); Figure 3B: OC125 (Score 1); Figure 3C: OC125 (Score 2); Figure 3D: OC125 (Score 3); Figure 3E: OC125 (Score 4); Figure 3F: OC125 (Score 5); Figure 3G: 4H11 (Score 0); Figure 3H: 4H11 (Score 1); Figure 31: 4H11 (Score 2); Figure 3J: 4H11 (Score 3); Figure 3K: 4H11 (Score 4); Figure 3L: 4H11 (Score 5). Figure 4: Western blot analysis. Figure 4A: Western blot analysis of GST-AMUC1601 4 D fusion protein with monoclonal antibodies 9C9.21.5.13 and 4H11.2.5. Figure 4B: Western blot analysis of SKOV3-phrGFP-AMUC16°14 and SKOV3-phrGFP-AMUC16°334 protein extract and probed with monoclonal antibodies 9C9.21.5.13 and 4H11.2.5. Figure 5A: MUC16 carboxy terminus monoclonal antibodies binding affinity on OVCAR3 cells (Panels A-D). Figure 5B: Internalization of radio-labeled 4Hl l and OC125 monoclonal antibodies on SKOV3-phrGFP-AMUC16e334 stable transfected cells. Figure 6A-D: Comparison staining intensities of OC125 and 4H11 monoclonal antibodies on tissue microarrays containing cancers of the prostate (2A, concordant), lung (2B, discordant), breast (2C, discordant), and pancreas (2D, discordant). Figure 7: FACS analysis as described in the Material and Methods section was performed with commercial antibodies and MUC16 carboxy terminus monoclonal antibodies on OVCAR3 wt, SKOV3-phrGFP-AMUC16c4 and SKOV3-phrGFP-AMUC16°'4 stable transfected cell lines. Figure 8: Nucleotide sequence encoding antibody variable heavy (VH) chain and antibody variable light (VL) chain. (A) 4A5 VH (SEQ ID NO:04), (B) 4A5 VL (SEQ ID NO:05), (C) 4H11

VH (SEQ ID NO:06), (D) 4H11 VL (SEQ ID NO:07), (E) 9B11 V (SEQ ID NO:08), (F) 9B11 VLA !5 (SEQ ID NO:09), (G) 9B11 VL.B (SEQ ID NO:10), (H) 24B3 VH (SEQ ID NO:11), (I) 24B3 VL (SEQ ID NO:12). Figure 9: (A) Homo sapiens MUC16 (GenBank NP_078966) (SEQ ID NO:13), (B) Polypeptide 1 (SEQ ID NO:01), (C) Polypeptide 2 (SEQ ID NO:02), (D) Polypeptide 3 (SEQ ID NO:03), (E) Transmembrane domain (SEQ ID NO:14), (F) Polypeptide 4 (SEQ ID NO:15) containing a cysteine loop polypeptide (SEQ ID NO:19). Figure 10: Schematic of MUC16 structure. Figure 11. Design and in vitro analysis of MUC-CD targeted CARs. (A) Schematic diagram of the first generation 4H11z and second generation 4H11-28z retroviral vectors. 4H11scFv: MUC16 specific scFv derived from the heavy (VH) and light (VL) chain variable regions of the monoclonal antibody 4H11; CD8: CD8 hinge and transmembrane domains; CD28: CD28 transmembrane and cytoplasmic signaling domains; ( chain: T cell receptor ( chain cytoplasmic signaling domain; LTR: long terminal repeat; black box: CD8 leader sequence; grey box: (Gly4 Ser)3 linker; arrows indicate start of transcription. (B) FACS analysis of human T cells retrovirally transduced to express either the 4H11z or 19z1 CAR. (C) 4H1lz+ but not 19zl* T cells expand on 3T3(MUC-CD/B7.1) AAPC. CAR+ were co-cultured on 3T3(MUC-CD/B7.1) AAPC monolayers at 3 x 106 CAR T cells/well of a 6 well plate. Proliferation of CAR T cells, normalized to the CAR' T cell fraction as assessed by FACS for the CAR fraction in combination with viable T cell counts obtained on days 2, 4 and 7, as assessed by trypan blue exclusion assays. Figure 12. In vitro comparison of T cells modified to express the first generation 4H11z CAR to T cells modified to express the second generation co-stimulatory 4H11-28z CAR. (A) CAR T cells were co-cultured on MUC-CD monolayers with (right panel) or without B7.1 (left panel). 3 x 106 CAR T cells were co-cultured on AAPC monolayers in 6 well tissue culture plates in cytokine-free medium. Total viable T cell counts were assessed on days 2, 4 and 7, by trypan blue exclusion assays. 4H11-28z+ T cells markedly expanded when compared to 4H11z T cells upon co-culture with 3T3(MUC-CD) AAPCs, **p=0.0023 (4H11z compared to 4H11-28z). In contrast, both 4H11z and 4H11-28z+ T cells expanded similarly on 3T3(MUC-CD/B7.1) AAPCs, p=0.09, (4H11z compared to 4H111-28z). Control 19-28z+ T cells did not proliferate on 3T3(MUC CD), **p=0.0056 (19-28z compared to 4H11z), **p=0.0011 (19-28z compared to 4H11-28z), or on 3T3(MUC-CD/B7.1), **p=0.0026 (19-28z compared to 4H11lz), **p=0.0087 (19-28z compared to 4111-28z). (B) 4H111-28z but not 4H11z+ T cells secrete IL-2 upon co-culture with 3T3(MUC CD) AAPCs. Tissue culture supernatants at day 2 following activation on 3T3(MUC-CD) AAPCs were analyzed for cytokine secretion. 4H11-28z+ T cells, in contrast to 4H11z T cells, demonstrated enhanced secretion of IL-2 consistent with T cell co-stimulation mediated through the !5 4H11-28z CAR. ***p=0.0008 (19z1 or 19-28z compared to 4H11z), **p=0.0026 (19z1 or 19-28z compared to 4H11-28z), **p=0.0046 (4H11z compared to 4H11-28z). Furthermore, both 4H11 28z' and 4H11iz T cells secreted IFNy. *p=0.01 (4H11z compared to 4111 -28z). Control 19z1 and 1928z transduced T cells failed to secrete either IL-2 or IFN. **p=0.0034 (19z1 compared to 4111lz), **p=0.036 (19-28z compared to 4H11z), ***p=0.0008 (19-28z compared to 41111-28z). (C) Expansion of CAR+ T cells following 3 cycles of stimulation on 3T3(MUC-CD/B7.1). Human T cells transduced to express either 4H11z or 4H11-28z CARs demonstrated a >2 log expansion over 2 cycles of stimulation on 3T3(MUITC-CD/B7.1) AAPCs. Arrows indicate 1st and 2nd cycles of restimulation on AAPCs. (D) FACS analysis of the CAR T cell fraction of 4H11-28z T cells increased following each weekly cycle of stimulation. (I) FACS following initial transduction, (II)

FACS at 7 days following first stimulation on AAPCs, (III) FACS at 7 days following second stimulation on AAPCs. These data are representative of one of three different experiments using three different healthy donor T cell populations, all of which demonstrated similar proliferation and cytokine secretion patterns. Figure 13. MIUC-CD targeted T cells specifically expand and lyse MUC-CD+ tumor cells. (A) Cytotoxicity assay of 4H11lz and 4H111-28z- T cells targeting OV-CAR(MUC-CD) tumor cells demonstrates efficient cytotoxicity mediated by T cells from healthy donors modified to express the first and second generation MUC-CD targeted CARs. Control T cells modified to express the first and second generation CD19-targeted 19z1 and 19-28z CARs failed to demonstrate significant lysis of target tumor cells. (B) Healthy donor T cells modified to express the 4H111-28z CAR equally lyse primary patient ascites-derived MUC-CD+ tumor cells when compared to T cells modified to express the control 19-28z CAR. This data represents 1 or 3 experiments targeting primary tumor cells from 3 ovarian carcinoma patients with similar results. (C) Autologous T cells isolated from peripheral blood, when modified with the 4H11-28z CAR, exhibit significant lysis of autologous MUC-CD' ascites-derived tumor cells when compared to control 19-28z+ autologous T cells. These data represent 1 of 3 experiments utilizing T cells and autologous tumor cells from 3 different ovarian carcinoma patients with similar results. (D) Antigen specific proliferation of MUC-CD targeted CFSE labeled T cells after co-culture with OV-CAR3(MUC-CD) tumor cells. CFSE labeled CAR T cells were co-cultured with MUC-CD expressing OV-CAR3 tumor cells at 1:1 ratio for 5 days. Proliferation ofCFSE labeled T cells was assessed by FACS demonstrating efficient proliferation of both 4H11z* and 4H11-28z* T cells but not control 19-28z- T cells. (E) CFSE results were further confirmed by absolute T cell numbers assessed on days 2, 4 and 7 following co-culture with OV-CAR3(MUC-CD) tumor cells. (F) FACS analysis of the expression of 4-1BBL on OVCAR3(MUC-CD) cells. OV-CAR3(MUC-CD) cells were stained with anti human 4-1BBL antibody (thick line) or with isotype control (thin line). FACS analysis demonstrated expression of 4-1BBL on OV-CAR3(MUC-CD) tumor cells. Further FACS analyses failed to reveal expression of the co-stimulatory ligands B7.1, B7.2, or OX-40L. Figure 14. Eradication of OV-CAR3(MUC-CD) tumors after intra-peritoneal treatment with first and second generation of MUC-CD targeted T cells. (A) Intraperitoneal injection of OV CAR3(MUC-CD) tumors in untreated SCID-Beige mice results in abdominal distension and nodular peritoneal tumors. SCID-Beige mice were injected intraperitoneally with 3x06 OV CAR3(MUC-CD) cells. At 5 weeks post intraperitoneal injection of OV-CAR3(MUC-CD) tumor cells mice developed ascities as evidenced by a distended abdomen (center panel) when compared to a tumor free mouse (left panel). Post mortem visualization of the peritoneum demonstrates nodular tumor masses (arrows) within the abdominal cavity (right panel). (B) Intraperitoneal injection of 4H11z and 4H1-28z+ T cells either delay tumor progression or fully eradicate disease. Kaplan-Meier survival curve of SCID-Beige mice treated with first or second generation of MUC-CD targeted T cells. SCID-Beige mice were infused ip with 3x106 OV-CAR3(MUC-CD) tumor cells on day 1 followed by 3x10 7 4Hlz+ or 4H111-28z+ T cells on day 2. All untreated mice or mice treated with control 19zl* T cells developed established tumors and were sacrificed by day 50. In contrast, 27% of mice treated with either 4H11z+ or 4H11-28z+ T cells remained without clinical evidence of disease by day 120. *p=0.01 (4H1lz compared to 19z1), **p=0.0023 (4H11 28z compared to 19z1), p=0.63 (4H11z compared to 4H11-28z). Figure 15. MUC-CD targeted 4H11-28z* T cells successfully traffic to ip OV CAR3(MUC-CD/GFP-FFLue) tumors following systemic intravenous infusion resulting in equally efficient anti-tumor efficacy when compared to ip 4H11-28z+ treated tumor bearing mice. (A) Kaplan-Meier survival curve of SCID-Beige mice treated ip or iv with 4H11-28z+ T cells. SCID Beige mice were injected intraperitoneally with 3x10 6 OV-CAR3(MUC-CD/GFP-FFLuc) tumor cells followed by either iv or ip infusion of 3x10 7 4H11-28z+ T cells. Tumor eradication is enhanced after either ip or iv infusion of 4H11-28z- T cells when compared to control treated mice. Both ip and iv 4H11-28z+ T cell treated mice exhibited statistically enhanced survival

(***p<0.0001 and **p=0.0038, respectively) when compared to 19-28z+ T cell treated control cohorts. Conversely, difference in survival between the ip and iv 4H111-28z+ T cell cohorts was not statistically significant (p=0.22). (B) BLI of tumor progression of representative ip and iv 4H11 28z+ T cell treated mice with ultimately progressive disease following treatment compared to BLI of tumor progression in a representative control 19-28z+ T cell treated mouse. (C) Systemically injected CFSE stained 4H 1-28z+ T cells traffic to advanced ip OV-CAR(MUC-CD) tumors. Presence of iv injected CFSE labeled 19-28z+ control T cells (left panel) and 4H111-28z+ T cells (right panel) I day following infusion into SCID-Beige mice with advanced OV-CAR(MUC-CD) tumors (injected 7 days earlier), as assessed by FACS analysis of single cell OV-CAR3(MUC-CD) tumor suspensions, reveals a marked population of 4H11-28z+ but not control 19-28z+ T cells within peritoneal OV-CAR3(MUC-CD) tumors. Figure 16. Eradication of advanced OV-CAR3(MUC-CD) tumors in SCID-Beige mice by ip infusion of 4H11-28z+ T cells. SCID-Beige mice were injected ip with 3x10 6 OV-CAR3(MUC CD/GFP-FFLuc) tumor cells 7 days prior to ip treatment with 3x10 7 4H11-28z+ T cells. (A) BLI of 4H11-28z+ T cell treated mice with either relapsed disease (middle row) or eradicated disease (bottom row) compared to a representative 19-28z+ T cell treated control mouse. (B) Kaplan-Meier survival curve of SCID-Beige mice with advanced OV-CAR3(MUC-CD/GFP-FFLuc) tumors treated ip with 4H11-28z T cells. All 4H11-28z' T cell treated mice demonstrated enhanced survival when compared to'control 19-28z+ T cell treated mice (**p=O.0011), with an overall long term survival of 25% at day 120. Figure 17: CD8 leader sequence, CD3 zeta chain intracellular domain sequence, (G4S)3 serine-glycine linker sequence, CD8 transmembrane domain sequence, and CD28 transmembrane

+ intracellular domains (-STOP) sequence. Figure 18: SFG_4H11z sequence. Figure 19: SFG-4H11-28z sequence. Figure 20: (A) Mouse MUC16-CD Peptide 1 (SEQ ID NO:21), Mouse first Cysteine Loop Peptide 2 (SEQ ID NO:22), and Mouse second Cysteine Loop Peptide 3 (SEQ ID NO:23). (B) Alignment of mouse MUC16 (SEQ ID NO:24) and human MUC16 (SEQ ID NO:25) amino acid sequences. A cysteine was added to the peptide sequence at the N terminus of Peptide 1 and Peptide 3 for better conjugation with KLH. Figure 21: 1D8 extract with 1:10 dilution of Mouse MUC16 monoclonal Primary Supernatants. Figure 22: BR5-FVB1 extract with 1:10 dilution of Mouse MUC16 monoclonal Primary Supernatants Figure 23: Western Blot showing 38 hamster's monoclonal antibody Supernatants on ID8 cell extracts. Figure 24 (A) Nucleotide sequence encoding 12B10-3G10-VH (SEQ ID NO:26), (B) 12B10-3G10-VH Amino Acid sequence (SEQ ID NO:27), (C) Nucleotide sequence encoding 12B10-3G10-VL (SEQ ID NO:28) (Note the VL has an optional NotI site added by the primer for cloning, and (D) 12B10-3G10-VLAmino Acid sequence (SEQ ID NO:29). Figure 25: FACS Analysis with Purified 12B10-3G10 mAb on ID8 (mouse), OVCAR-3 (human) and BR5-FVB1 (mouse) cell lines.

DEFINITIONS To facilitate understanding of the invention, a number of terms are defined below. The terms "purified," "isolated," and grammatical equivalents thereof as used herein, refer to the reduction in the amount of at least one undesirable component (such as cell, protein, nucleic acid sequence, carbohydrate, etc.) from a sample, including a reduction by any numerical percentage of from 5% to 100%, such as, but not limited to, from 10% to 100%, from 20% to 100%, from 30% to 100%, from 40% to 100%, from 50% to 100%, from 60% to 100%, from 70% to 100%, from 80% to 100%, and from 90% to 100%. Thus purification results in an "enrichment," i.e., an increase in the amount of a desirable component cell, protein, nucleic acid sequence, carbohydrate, etc.). The term "antibody" refers to an immunoglobulin (e.g., IgG, IgM, IgA, IgE, IgD, etc.). The basic functional unit of each antibody is an immunoglobulin (Ig)mononer (containing only one immunoglobulin ("Ig") unit). Included within this definition are polyclonal antibody, monoclonal antibody, and chimeric antibody. The variable part of an antibody is its "V domain" (also referred to as "variable region"), and the constant part is its "C domain" (also referred to as "constant region") such as the kappa, lambda, alpha, gamma, delta, epsilon and mu constant regions. The "variable domain" is also referred to as the "Fv region" and is the most important region for binding to antigens. More specifically, variable loops, three each on the light (VL) and heavy (VH) chains are responsible for binding to the antigen. These loops are referred to as the "complementarity determining regions" ("CDRs" and "idiotypes." The immunoglobulin (Ig) monomer of an antibody is a "Y"-shaped molecule that contains four polypeptide chains: two light chains and two heavy chains, joined by disulfide bridges. Light chains are classified as either (.) or kappa (). A light chain has two successive domains: one constant domain ("CL") and one variable domain ("VL"). The variable domain, VL, is different in each type of antibody and is the active portion of the molecule that binds with the specific antigen.The approximate length of a light chain is 211 to 217 amino acids. Each heavy chain has two regions, the constant region and the variableregion. The There are five types of mammalian Ig heavy denoted a a, 8,, y, and t. The type of heavy chain present defines the class of antibody; these chains are found in IgA, IgD, IgE, IgG, and IgM antibodies, respectively. Distinct heavy chains differ in size and composition; a and y contain approximately 450 amino acids, while p and z have approximately 550 amino acids. Each heavy chain has two regions, the constant region ("CH") and the variable ("VH") region. The constant region (CH) is identical in all antibodies of the same isotype, but differs in antibodies of different isotypes. Heavy chains y, a and 6have a constant region composed of three tandem (in a line) Ig domains, and a hinge region for added flexibility. Heavy chains stand have a constant region composed offour immunoglobulin domains. The variable region (VH) of the heavy chain differs in antibodies produced by different B cells, but is the same for all antibodies produced by a single B cell or B cell clone. The variable region of each heavy chain is approximately 110 amino acids long. The term "specifically binds" and "specific binding" when made in reference to the binding of two molecules (e.g. antibody to an antigen, etc.) refer to an interaction of the two molecules that is dependent upon the presence of a particular structure on one or both of the molecules. For example, if an antibody is specific for epitope "A" on the molecule, then the presence of a protein containing epitope A (or free, unlabelled A) in a reaction containing labeled "A" and the antibody will reduce the amount of labeled A bound to the antibody. The term "capable of binding" when made in reference tothe interaction between a first molecule (such as antibody, polypeptide, glycoprotein, nucleic acid sequence, etc.) and a second molecule (such as antigen, polypeptide, glycoprotein, nucleic acid sequence, etc.) means that the first molecule binds to the second molecule in the presence of suitable concentration of salts, and suitable temperature, and pH. The conditions for binding molecules may be determined using routine and/or commercially available methods The terms "antigen," "immunogen," "antigenic," "immunogenic," "antigenically active," "immunologic," and "immunologically active" when made in reference to a molecule, refer to any substance that is capable of inducing a specific humoral immune response (including eliciting a soluble antibody response) and/or cell-mediated immune response (including eliciting a CTL response). Antigenic peptides preferably contain at least 5, at least 6, at least 7, at least 8, at least 9, and more preferably at least 10 amino acids. To elicit antibody production, in one embodiment, antigens maybe conjugated to keyhole limpet hemocyanin (KLH) or fused to glutathione-S transferase (GST). A "cognate antigen" when in reference to an antigen that binds to an antibody, refers to an antigen that is capable of specifically binding to the antibody. In one embodiment, the antigen comprises an epitope. The terms "epitope" and "antigenic determinant" refer to a structure on an antigen, which interacts with the binding site of an antibody or T cell receptor as a result of molecular complementarity. An epitope may compete with the intact antigen, from which it is derived, for binding to an antibody. As used herein the terms "portion" and "fragment" when made in reference to a nucleic acid sequence or protein sequence refer to a piece of that sequence that may range in size from 2 contiguous nucleotides and amino acids, respectively, to the entire sequence minus one nucleotide and amino acid, respectively. A "subject" that may benefit from the invention's methods includes any multicellular animal, preferably a mammal. Mammalian subjects include humans, non-human primates, murines, ovines, bovines, ruminants, lagomorphs, porcines, caprines, equines, canines, felines, aves, etc.). Thus, mammalian subjects are exemplified by mouse, rat, guinea pig, hamster, ferret and chinchilla. The invention's compositions and methods are also useful for a subject "in need of reducing one or more symptoms of' a disease, e.g., in need of reducing cancer metastasis and/or in need of reducing one or more symptoms of cancer, includes a subject that exhibits and/or is at risk of exhibiting one or more symptoms of the disease. For Example, subjects maybe at risk based on family history, genetic factors, environmental factors, etc. This term includes animal models of the disease. Thus, administering a composition (which reduces a disease and/or which reduces one or more symptoms of a disease) to a subject in need of reducing the disease and/or of reducing one or more symptoms of the disease includes prophylactic administration of the composition (i.e., before the disease and/or one or more symptoms of the disease are detectable) and/or therapeutic administration of the composition (i.e., after the disease and/or one or more symptoms of the disease are detectable). The invention's compositions and methods are also useful for a subject "at risk" for disease (such as cancer) refers to a subject that is predisposed to contracting and/or expressing one or more symptoms of the disease. This predisposition may be genetic (e.g., a particular genetic tendency to expressing one or more symptoms of the disease, such as heritable disorders, etc.), or due to other factors (e.g., environmental conditions, exposures to detrimental compounds, including carcinogens, present in the environment, etc.). The term subject "at risk" includes subjects "suffering from disease," i.e., a subject that is experiencing one or more symptoms of the disease. It is not intended that the present invention be limited to any particular signs or symptoms. Thus, it is intended that the present invention encompass subjects that are experiencing any range of disease, from sub-clinical symptoms to full-blown disease, wherein the subject exhibits at least one of the indicia (e.g., signs and symptoms) associated with the disease. "Cancer cell" refers to a cell undergoing early, intermediate or advanced stages of multi step neoplastic progression as previously described (Pitot et al., Fundamentals of Oncology, 15-28 (1978)). This includes cells in early, intermediate and advanced stages of neoplastic progression including "pre-neoplastic cells (i.e., "hyperplastic cells and dysplastic cells), and neoplastic cells in advanced stages of neoplastic progression of a dysplastic cell. "Metastatic" cancer cell refers to a cancer cell that is translocated from a primary cancer site (i.e., a location where the cancer cell initially formed from a normal, hyperplastic or dysplastic cell) to a site other than the primary site, where the translocated cancer cell lodges and proliferates. "Cancer" refers to a plurality of cancer cells that may or may not be metastatic, such as ovarian cancer, breast cancer, lung cancer, prostate cancer, cervical cancer, pancreatic cancer, colon cancer, stomach cancer, esophagus cancer, mouth cancer, tongue cancer, gum cancer, skin cancer (e.g., melanoma, basal cell carcinoma, Kaposi's sarcoma, etc.), muscle cancer, heart cancer, liver cancer, bronchial cancer, cartilage cancer, bone cancer, testis cancer, kidney cancer, endometrium cancer, uterus cancer, bladder cancer, bone marrow cancer, lymphoma cancer, spleen cancer, thymus cancer, thyroid cancer, brain cancer, neuron cancer, mesothelioma, gall bladder cancer, ocular cancer (e.g., cancer of the cornea, cancer ofuvea, cancer of the choroids, cancer of the macula, vitreous humor cancer, etc.), joint cancer (such as synovium cancer), glioblastoma, lymphoma, and leukemia. "Sample" and "specimen" as used herein are used in their broadest sense to include any composition that is obtained and/or derived from a biological source, as well as sampling devices (e.g., swabs), which are brought into contact with biological or environmental samples. "Biological samples" include those obtained from a subject, including body fluids (such as urine, blood, plasma, fecal matter, cerebrospinal fluid (CSF), semen, sputum, and saliva), as well as solid tissue. Biological samples also include a cell (such as cell lines, cells isolated from tissue whether or not the isolated cells are cultured after isolation from tissue, fixed cells such as cells fixed for o histological and/or immunohistochemical analysis), tissue (such as biopsy material), cell extract, tissue extract, and nucleic acid (e.g., DNA and RNA) isolated from a cell and/or tissue, and the like. These examples are illustrative, and are not to be construed as limiting the sample types applicable to the present invention. "Overexpression of MUC16" by a cell of interest (such as a cancer cell) refers to a higher level of MUC16 protein and/or mRNA that is expressed by the cell of interest compared to a control cell (such as a non-cancerous cell, normal cell, etc.). "Internalize" when in reference to a cell refers to entry from the extracellular medium into the cell membrane and/or cytoplasm. "Glycosylated" when in reference to a sequence (e.g., an amino acid sequence or nucleotide D sequence) refers to a sequence that is covalently linked to one or more saccharides. "Pharmaceutical" and "physiologically tolerable " composition refers to a composition that contains pharmaceutical molecules, i.e., molecules that are capable of administration to or upon a subject and that do not substantially produce an undesirable effect such as, for example, adverse or allergic reactions, dizziness, gastric upset, toxicity and the like, when administered to a subject. Preferably also, the pharmaceutical molecule does not substantially reduce the activity of the invention's compositions. Pharmaceutical molecules include "diluent" (i.e., "carrier") molecules and excipients. "Immunogenically effective" and "antigenically effective" amount of a molecule interchangeably refer to an amount of the molecule that is capable of inducing a specific humoral immune response (including eliciting a soluble antibody response) and/or cell-mediated immune response (including eliciting a cytotoxic T-lymphocyte (CTL) response). "Treating" a disease refers to reducing one or more symptoms (such as objective, subjective, pathological, clinical, sub-clinical, etc.) of the disease.

The terms "reduce," "inhibit," "diminish," "suppress," "decrease," and grammatical equivalents (including "lower," "smaller," etc.) when in reference to the level of any molecule (e.g., amino acid sequence, and nucleic acid sequence, antibody, etc.), cell, and/or phenomenon (e.g., disease symptom, binding to a molecule, specificity of binding of two molecules, affinity of binding of two molecules, specificity to cancer, sensitivity to cancer, affinity of binding, enzyme activity, etc.) in a first sample (or in a first subject) relative to a second sample (or relative to a second subject), mean that the quantity of molecule, cell and/or phenomenon in the first sample (or in the first subject) is lower than in the second sample (or in the second subject) by any amount that is statistically significant using any art-accepted statistical method of analysis. In one embodiment, the quantity of molecule, cell and/or phenomenon in the first sample (or in the first subject) is at least 10% lower than, at least 25% lower than, at least 50% lower than, at least 75% lower than, and/or at least 90% lower than the quantity of the same molecule, cell and/or phenomenon in the second sample (or in the second subject). In another embodiment, the quantity of molecule, cell, and/or phenomenon in the first sample (or in the first subject) is lower by any numerical percentage from 5% to 100%, such as, but not limited to, from 10% to 100%, from 20% to 100%, from 30% to 100%, from 40% to 100%, from 50% to 100%, from 60% to 100%, from 70% to 100%, from 80% to 100%, and from 90% to 100% lower than the quantity of the same molecule, cell and/or phenomenon in the second sample (or in the second subject). In one embodiment, the first subject is exemplified by, but not limited to, a subject that has been manipulated using the invention's compositions and/or methods. In a further embodiment, the second subject is exemplified by, but not limited to, a subject that has not been manipulated using the invention's compositions and/or methods. In an alternative embodiment, the second subject is exemplified by, but not limited to, a subject to that has been manipulated, using the invention's compositions and/or methods, at a different dosage and/or for a different duration and/or via a different route of administration compared to the first subject. In one embodiment, the first and second subjects may be the same individual, such as where the effect of different regimens (e.g., of dosages, duration, route of administration, etc.) of the invention's compositions and/or methods is sought to be determined in one individual. In another embodiment, the first and second subjects may be different individuals, such as when comparing the effect of the invention's compositions and/or methods on one individual participating in a clinical trial and another individual in a hospital. The terms "increase," "elevate," "raise," and grammatical equivalents (including "higher," "greater," etc.) when in reference to the level of any molecule (e.g., amino acid sequence, and

nucleic acid sequence, antibody, etc.), cell, and/or phenomenon (e.g., disease symptom, binding to a molecule, specificity of binding of two molecules, affinity of binding of two molecules, specificity to cancer, sensitivity to cancer, affinity of binding, enzyme activity, etc.) in a first sample (or in a first subject) relative to a second sample (or relative to a second subject), mean that the quantity of the molecule, cell and/or phenomenon in the first sample (or in the first subject) is higher than in the second sample (or in the second subject) by any amount that is statistically significant using any art-accepted statistical method of analysis. In one embodiment, the quantity of the molecule, cell and/or phenomenon in the first sample (or in the first subject) is at least 10% greater than, at least 25% greater than, at least 50% greater than, at least 75% greater than, and/or at least 90% greater than the quantity of the same molecule, cell and/or phenomenon in the second sample (or in the second subject). This includes, without limitation, a quantity of molecule, cell, D and/or phenomenon in the first sample (or in the first subject) that is at least 10% greater than, at least 15% greater than, at least 20% greater than, at least 25% greater than, at least 30% greater than, at least 35% greater than, at least 40% greater than, at least 45% greater than, at least 50% greater than, at least 55% greater than, at least 60% greater than, at least 65% greater than, at least 70% greater than, at least 75% greater than, at least 80% greater than, at least 85% greater than, at least 90% greater than, and/or at least 95% greater than the quantity of the same molecule, cell and/or phenomenon in the second sample (or in the second subject). In one embodiment, the first subject is exemplified by, but not limited to, a subject that has been manipulated using the invention's compositions and/or methods. In a further embodiment, the second subject is exemplified by, but not limited to, a subject that has not been manipulated using the invention's compositions and/or methods. In an alternative embodiment, the second subject is exemplified by, but not limited to, a subject to that has been manipulated, using the invention's compositions and/or methods, at a different dosage and/or for a different duration and/or via a different route of administration compared to the first subject. In one embodiment, the first and second subjects may be the same individual, such as where the effect of different regimens (e.g., of dosages, duration, .5 route of administration, etc.) of the invention's compositions and/or methods is sought to be determined in one individual. In another embodiment, the first and second subjects maybe different individuals, such as when comparing the effect of the invention's compositions and/or methods on one individual participating in a clinical trial and another individual in a hospital. The terms "alter" and "modify" when in reference to the level of any molecule and/or phenomenon refer to an increase or decrease. Reference herein to any numerical range expressly includes each numerical value (including fractional numbers and whole numbers) encompassed by that range. To illustrate, and without limitation, reference herein to a range of "at least 50" includes whole numbers of 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, etc., and fractional numbers 50.1, 50.2 50.3, 50.4, 50.5, 50.6, 50.7, 50.8,

50.9, etc. In a further illustration, reference herein to a range of "less than 50" includes whole numbers 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, etc., and fractional numbers 49.9, 49.8, 49.7, 49.6, 49.5, 49.4, 49.3, 49.2, 49.1, 49.0, etc. In yet another illustration, reference herein to a range of from "5 to 10" includes each whole number of 5, 6, 7, 8, 9, and 10, and each fractional number such as 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, etc.

DESCRIPTION OF THE INVENTION The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which MUC16 is overexpressed, such as cancer. Using synthetic peptides, the inventors raised novel-specific antibodies to the carboxy terminal portion of MUC16, retained by the cell, proximal to the putative cleavage site. These antibodies were characterized using fluorescence-activated cell-sorting analysis, enzyme-linked immunoassay, Western blot analysis, and immunohistochemistry. Each of the selected monoclonal antibodies was reactive against recombinant GST-AMUC16°14 protein and the MUC16 transfected SKOV3 cell line. Three antibodies, 4H11, 9C9, and 4A5 antibodies demonstrated high affinities by Western blot analysis and saturation-binding studies of transfected SKOV3 cells, and displayed antibody internalization. Immunohistochemical positivity with novel antibody 4H11 was similar to OC125, but with important differences, including diffuse positivity in lobular breast cancer and a small percentage of OC125-negative ovarian carcinomas which showed intense and diffuse 4H11 antibody binding. The invention's compositions and methods are useful for diagnostic and therapeutic applications, as well as biologic studies such as membrane receptor trafficking and intracellular events. Diagnostic applications include, for example, detection of cancer using immunohistochemical, radiographic imaging, enzyme-linked immunosorbent assay (ELISA), fluorescence-activated cell sorting (FACS), Western blot, and/or immunoprecipitation detection. The invention is further described under (A) MUC16, (B) Prior Art Antibodies, (C) Invention's Antibodies, (D) Hybridoma Cell Lines, (E) Conjugates Of The Invention's Antibodies Linked To Cytotoxic Agents And/Or Prodrugs, (F) Detecting Muc6 Portions And Diagnostic Applications, and (G) Therapeutic Applications.

A. MUC16 "MUC16," "MUC-16" and "Mucin 16" interchangeably refer to a type I membrane protein that is part of a family of tethered mucins. A schematic of Muc16 is in Figure 10, and an exemplary human Mue16 amino acid sequence (SEQ ID NO:13) is shown in Figure 9A. An alignment of mouse MUC16 (SEQ ID NO:24) and human MUC16 (SEQ ID NO:25) amino acid sequences is shown in Figure 20B. The term "type 1 protein"refers to a "membrane protein"that is at least partially embedded in the lipid bilayer of a cell, virus and the like, and that contains a transmembrane domain (TM) sequence embedded in the lipid bilayer of the cell, virus and the like. The portion of the protein on the NH 2 -terminal side of the TM domain is exposed on the exterior side of the membrane, and the COOH-terminal portion is exposed on the cytoplasmic side. Recently, the sequence of the cDNA-encoding MUC16/CA125 was described by Yin and Lloyd in 2001 and completed by O'Brien in 2002 (10-12). The complete MUC16 protein has various components consisting of a cytoplasmic tail with potential phosphorylation sites, a transmembrane domain, and an external domain proximal to an apparent cleavage site. Distal to the cleavage site, the released external domain contains 16-20 tandem repeats of 156 amino acids, each with many potential glycosylation sites (11). The overall repeat structure (Figure 10) is well conserved across mammals, but the repeats are not completely identical in exact amino acid composition. The MUC16 protein is part of a family of tethered mucins that includes both MUC Iand MIUC4 (13). MUC1 is present in a variety of tissues and appears to signal through a beta catenin pathway, interact with EGF receptor, mediates drug resistance and can act as an oncogene (14-17). The MUC4 protein is also expressed in a variety of tissues but is common on neoplasms of the gastrointestinal track (18-20). In contrast, the CAl25 antigen has been more restricted in its distribution and is present primarily in gynecologic tissues and overexpressed in Millerian neoplasms (21). However, the CA125 antigen, recognized by the OC125 antibody, is a heavily glycosylated antigen expressed in the tandem repeat region of the larger MUC16 protein. This glycoprotein is typically shed from a putative cleavage site in the extracellular domain of the MUC16 peptide backbone. Thus, "MUC16" protein contains (a) a "cytoplasmic domain," (b)a "transmembrane domain," and (c) a "extracellular domain." The MUC16 extracellular domain contains a cleavage site between a non-glycosylated ectodomain and a large glycosylated ectodomain of tandem repeats. The terms "cytoplasmic domain," "cytoplasmic tail," and "CT" are used interchangeably to refer to a protein sequence, and portions thereof, that is on the cytoplasmic side of the lipid bilayer of a cell, virus and the like. Methods for determining the CT of a protein are known in the art Elofsson et al. (2007) Annu. Rev. Biochem. 76:125-140; Bernsel et al. (2005) Protein Science 14:1723-1728). The terms "transmembrane domain" and "TM" are used interchangeably to refer to a protein sequence, and portions thereof, that spans the lipid bilayer of a cell, virus and the like. Methods for determining the TM of a protein are known in the art (Elofsson et al. (2007) Annu. Rev. Biochem. 76:125-140; Bernsel et al. (2005) Protein Science 14:1723-1728). The terms "ectodomain" and "extracellular domain" are interchangeably used when in reference to a membrane protein to refer to the portion of the protein that is exposed on the D extracellular side of a lipid bilayer of a cell, virus and the like. Methods for determining the ectodomain of a protein are known in the art (Singer (1990) Annu. Rev. Cell Biol. 6:247-296 and High et al. (1993) J. Cell Biol. 121:743-750, and McVector software, Oxford Molecular). The exemplary Mucl6 of Figure 9 contains (a) a "MUC6 cytoplasmic domain" from amino acid 14476 to 14507, vttrr rkkegeynvq qqcpgyyqsh ldledlq (SEQ ID NO:16), that interacts with the intracellular signal transduction machinery; (b) a "MIUC16transmembrane domain" from amino acid 14452 to 14475, fwaviligl agllgvitcl icgvl (SEQ ID NO:14) that spans the plasma membrane; and (c) a "MUC16 extracellular domain"amino acid 1 to 14392 (SEQ ID NO:13) that contains a cleavage site between an non-glycosylated ectodomain and a large glycosylated ectodomain of tandem repeats. The "MUC16 ectodomain" is exemplified by nfsplar rvdrvaiyee flrmtrngtq lqnftldrss vlvdgyspnr nepltgnsdl p (SEQ ID NO:17) from amino acid 14394 to 14451 of SPQ ID NO:13 of Figure 9A. The exemplary MUC16 ectodomain contains both Polypeptide 1 (nfsplar rvdrvaiyee (SEQ ID NO:01), which is from amino acid 14394 to 14410 of SEQ ID NO:13), and Polypeptide 2 (tldrss vlvdgyspnr ne (SEQ ID NO:02), which is from amino acid 14425 to 14442 of SEQ ID NO:13), against which the invention's exemplary antibodies were produced. Polypeptide 3, cgvlvttrr rkkegeynvq qq (SEQ ID NO:03) is from amino acid 14472 to 14492 of SEQ ID NO:13, and contains both a transmembrane domain portion (cgvl) and a cytoplasmic domain portion (vttrr rkkegeynvq qq (SEQ ID NO:18)). Thus, the CGVL is optional in SEQ ID NO:03, as it is part of the transmembrane domain. Polypeptide 4 (ksyf sdcqvstfrs vpnrhhtgvd slcnfspl (SEQ ID NO:15), is located in a non glycosylated portion of the Mucl6 extracellular domain, is from amino acid 14367 to 14398 of SEQ ID NO:13, and contains a cysteine loop polypeptidecqvstfrsvpnrhhtgvdslc (SEQ ID NO:13).

B. Prior Art Antibodies The expression of the MUC16/CA125 antigen has long been associated with gynecologic tissues. "CA125," "CA-125," "Cleaved CA125," and "cleaved CA-125," interchangeably refer to the glycosylated external domain of the tethered mucin MUC16, that is distal to the cleavage site (Payne et al., U.S. Pat. No. 7,202,346). This released external domain contains 16-20 tandem repeats of 156 amino acids, each with potential glycosylation sites. An apparent cysteine-based disulfide loop of 19 amino acids is present in all repeats and the N-terminal end contains a hairbrush structure that is heavily 0-glycosylated (11). The deduced size would be 2.5 MD for the protein part, and with added carbohydrates, this could increase to 5 MD (10, 26). CA125, though it is not sensitive or specific enough to be used as a general screening tool, is routinely used to monitor patients with ovarian carcinoma. The tests used to measure CA125 are antibody based detection methods, as are the immunohistochemical stains routinely performed for diagnostic purposes. The epitope specificity of 26 antibodies to MUC16 was studied in the first report from the International Society of Oncodevelopmental Biology and Medicine (ISOBM) TD-1 Workshop and the application of 22 antibodies to immunohistochemistry was reported in the second report from the TD-1 workshop (7, 21). The existing antibodies were grouped as OC125 like, M11-like, or OV197-like and all of the known antibodies recognized CA125 epitopes in the repeating, glycosylated elements in the external domain of the tethered mucin MUC16, distal to the putative cleavage site. The vast majority of MUC16-reactive antibodies, including OC125, react with the glycosylation-dependent antigen present exclusively in the cleaved portion of the molecule so the true distribution of MUC16 expression is not known (21). There is currently no antibody available to track the fate of the remainingMUC16 protein fragment after cleavage and CA125 release.

C. Invention's Antibodies In order to better explore the biology of human MUC16, the inventors have derived monoclonal antibodies against the extracellular portion of the MUC16-carboxy terminus, proximal to the putative cleavage site, as well as one monoclonal antibody against the internal cytoplasmic domain. In contrast to prior antibodies, these are derived against the peptide backbone of MUC16 and are not directed at complex glycoprotein epitopes. Since these epitopes are proximal to the cleavage site, they are unlikely to be found in the circulation and provide novel targets for diagnostic methods and therapeutic interventions. Data herein demonstrate the identification and characterization of exemplary antibodies developed against the MUC16 peptide backbone.

The inventors have developed novel antibodies that are directed at the non-cleaved, non glycosylated peptide backbone of MUC16. These are exemplified by both 4H11 and 9C9 antibodies, which react with peptide sequences in the non-cleaved ectodomain ofMUC16 and are detectable on the surface of ovarian cancer cell lines and in paraffin-fixed tissues from human ovarian cancer surgical specimens. The antibodies show high affinity and are readily internalized by ovarian cancer cells when bound to the ectodomain of MUC16. This suggests that the proximal portion of MUC16 has an independent biology from the more distal, cleaved portion of the mucin. It also suggests that the proximal portions of MUC16 could provide convenient targets for diagnostic and therapeutic interventions. Targeting the peptide backbone of MUC16 provides D highly specific tissue delivery for genetically engineered cells, liposomes, or antibody conjugates, including conjugates with the invention's antibodies. The invention's antibodies, exemplified by antibody 4H11, are useful as tools in immunohistochemistry. Date herein show that 4H11 is relatively specific to high-grade ovarian serous carcinoma. Invasive lobular breast carcinoma is the major exception and shows extensive MUC16 protein as detected by4H11. Lobular carcinoma of the breast has unique biology which is characterized by a propensityto metastasize to serosal surfaces (27). Since MUC16 is the cognate binding partner of mesothelin, this may have important implications for lobular cancer (28). The discordance rates for OC125 and 4H11 also suggest that 4H11 might provide additional, independent information from OC125 in a subset of ovarian carcinomas. Some tumors that are negative with OC125 retain cytoplasmic and extracellular portions of the MUC16 glycoprotein, portions of the molecule that are likely involved in transduction of signals potentially important in the malignant phenotype. Thus, in one embodiment, the invention provides an isolated antibody, or an antigen binding fragment thereof, that specifically binds to a polypeptide, or antigenic portion thereof, wherein the polypeptide is exemplified by a) MUC16 ectodomain polypeptide (exemplified by NFSPLAR RVDRVAIYEE FLRMTRNGTQ LQNFTLDRSS VLVDGYSPNR NEPLTGNSDL P (SEQ ID NO:17)), b) MUC16 cytoplasmic domain polypeptide (exemplified by VTTRR RKKEGEYNVQ QQ (SEQ ID NO:18), which is contained within each of CGVLVTTRR RKKIEGEYNVQ QQ (SEQ ID NO:03) and LVTTRR RKKEGEYNVQ QQ (SEQ ID NO:20)), and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide CQVSTFRSVPNRHHTGVDSLC (SEQ ID NO:19). One advantage of the invention's antibodies is that the antibody internalizes into a cell, thereby being useful in applications for delivery inside a cell, such as disease therapy. "Internalized" when in reference to a molecule that is internalized by a cell refers to passage of the molecule that is in contact with the extracellular surface of a cell membrane across the cell membrane to the intracellular surface of the cell membrane and/or into the cell cytoplasm. Methods for determining internalization are disclosed herein, including the detection of radiolabeled molecule inside the cell (Figure 5B). In one embodiment, the invention's antibodies specifically bind to MUC16 ectodomain polypeptide that comprises a polypeptide selected from the group consisting of Polypeptide 1 NFSPLARRVDRVAIYEE (SEQ ID NO:01) and Polypeptide 2 TLDRSSVLVDGYSPNRNE (SEQ IDNO:02). Data herein show that the invention's antibodies specifically bind to GST-AMUC16° 114 (Example 2, Table IA). The specificity of the invention's antibodies is in contrast to prior art antibodies (e.g., VK8, M1 and OC125 antibodies) that did not bind to GST-AMUC16°14 purified protein or cell lysates of the SKOV3-phrGFP-AMUC16c4 cell line (Example 2, Figure 2). In a further embodiment, the invention's antibodies lack specific binding to a glycosylated MUC16 extracellular domain, exemplified by the cleaved CA-125 described in Payne et al., U.S. Pat. No. 7,202,346. While not intending to limit the sequence of the VL and VH regions of the invention's antibodies, in one embodiment, the antibody specifically binds to the Polypeptide 2 (SEQ ID NO:02) of the MUC16 ectodomain polypeptide, wherein the antibody comprises a variable heavy (VH) chain encoded by SEQ ID NO:06 (i.e., the antibody 4H11 variable heavy (VH) chain amino acid sequence of Figure 8), and a variable light (VL) chain encoded by SEQ ID NO:07 (i.e., the antibody 4H11 variable light (VL) chain amino acid sequence of Figure 8). In a particular embodiment, the antibody is chimeric, wherein at least one of the VL and VH chains is fused to a human immunoglobulin constant region. Also without intending to limit the sequence of the VL and VH regions of the invention's antibodies, in one embodiment, the antibody specifically binds to the Polypeptide 2 (SEQ ID NO:02) of the MUC16 ectodomain polypeptide, wherein the antibody comprises a variable heavy (VH) chain encoded by SEQ ID NO:04 (i.e., the antibody 4A5 variable heavy (VH) chain nucleotide sequence of Figure 8), and a variable light (VL) chain encoded by SEQ ID NO:05 (i.e., the antibody 4A5 variable light (VL) chain nucleotide sequence of Figure 8). In a particular embodiment, the antibody is chimeric wherein at least one of the VL and VH chains is covalently linked to a human immunoglobulin constant region. Still without intending to limit the sequence of the VL and VH regions of the invention's antibodies, in one embodiment, the antibody specifically binds to the Polypeptide 1 (SEQ ID NO:01) of the MUC16 ectodomain polypeptide, wherein the antibody comprises a variable heavy (VH) chain encoded by SEQ ID NO:08 (i.e., the antibody 9B11 variable heavy (VH) chain nucleotide sequence of Figure 8), and a variable light (VL) chain encoded by at least one of SEQ ID NO:09 (i.e., antibody 9B11 variable light (VL.A) chain nucleotide sequence of Figure 8), and SEQ ID NO:10 (i.e., the antibody 9B11 variable light (VL.B) chain nucleotide sequence of Figure 8). In a particular embodiment, the antibody is chimeric wherein at least one of the VL and VH chains is covalently linked to a human immunoglobulin constant region. While not intending to restrict the source of antigen to which the invention's antibodies bind, in one embodiment, the MUC16 ectodomain polypeptide is expressed by a cell. Data herein show that the invention's exemplary antibodies bind to SKOV3 cells transduced with phrGFP AMUC16° 4 (Example 2). D While not limiting the sequence of antigen to which the invention's antibodies bind, in a further embodiment, the invention's antibodies specifically bind to a MUC16 cytoplasmic domain polypeptide that comprises VTTRR RKKEGEYNVQ QQ (SEQ ID NO:18). In a particular embodiment, the MUC16 cytoplasmic domain polypeptide comprises Polypeptide 3 CGVLVTTRRRKIEGEYNVQQQ(SEQIDNO:03). In some embodiment, the MUC16 cytoplasmic domain polypeptide is expressed by a cell. For example, data herein show that the 4 invention's exemplary antibody binds to SKOV3 cells transduced with phrGFP-AMUC16c° (Example 2). In a particular embodiment, the cell is permeabilized to facilitate internalization of the antibody into the cell so that it comes into contact with its cytoplasmic antigen. Still without limiting the sequence of antigen to which the invention's antibodies bind, in a further embodiment, the invention's antibodies bind to a MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide CQVSTFRSVPNRHHTGVDSLC (SEQ IDNO:19). Ina more preferred embodiment, the MUC16 extracellular domain polypeptide comprises Polypeptide 4 KSYF SDCQVSTFRS VPNRHHTGVD SLCNFSPL (SEQ ID NO:15). Still without intending to limit the sequence of the VL and VH regions of the invention's Z5 antibodies, in one embodiment, the antibody specifically binds to Polypeptide 4 (SEQ ID NO:15) of the MUC16 extracellular domain polypeptide, wherein the antibody comprises a variable heavy (VH) chain encoded by SEQ ID NO:11 (i.e., the antibody 24B3 variable heavy (VH) chain amino acid sequence of Figure 8), and a variable light (VL) chain encoded by SEQ ID NO:12 (i.e., the antibody 24B3 variable light (VL) chain amino acid sequence of Figure 8). The invention contemplates chimeric antibodies (see U.S. Pat. No. 7,662,387), monoclonal antibodies, recombinant antibodies, an antigen-binding fragment of a recombinant antibody, a humanized antibody, and an antibody displayed upon the surface of a phage (U.S. Pat. No. 7,202,346). In particular, the invention contemplates antibody fragments that contain the idiotype ("antigen-binding region" or "antigen-binding fragment") of the antibody molecule. For example, such antigen-binding fragments include, but are not limited to, the Fab region, F(ab')2 fragment, pFc'fragment, and Fab' fragments. The "Fab region" and "fragment, antigen binding region," interchangeably refer to portion of the antibody arms of the immnoglobulin "Y" that function in binding antigen. The Fab region is composed of one constant and one variable domain from each heavy and light chain of the antibody. Methods are known in the art for the construction of Fab expression libraries (Huse et al., Science, 246:1275-1281 (1989)) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. In another embodiment, Fe and Fab fragments can be generated by using the enzyme papain to cleave an immunoglobulin monomer into two Fab fragments and an Fe fragment. The enzyme pepsin cleaves below the hinge region, so a "F(ab')2 fragment" and a "pFc' fragment" is formed. The F(ab')2 fragment can be split into two "Fab' fragments" by mild reduction. The invention also contemplates a "single-chain antibody" fragment, i.e., an amino acid sequence having at least one of the variable or complementarity determining regions (CDRs) of the whole antibody, and lacking some or all of the constant domains of the antibody. These constant domains are not necessary for antigen binding, but constitute a major portion of the structure of whole antibodies. Single-chain antibody fragments are smaller than whole antibodies and may therefore have greater capillary permeability than whole antibodies, allowing single-chain antibody fragments to localize and bind to target antigen-binding sites more efficiently. Also, antibody fragments can be produced on a relatively large scale in prokaryotic cells, thus facilitating their production. Furthermore, the relatively small size of single-chain antibody fragments makes them less likely to provoke an immune response in a recipient than whole antibodies. Techniques for the production of single-chain antibodies are known (U.S. 4,946,778). The variable regions of the heavy and light chains can be fused together to form a "single-chain variable fragment" ("scFv fragment"), which is only half the size of the Fab fragment, yet retains the original specificity of the parent immunoglobulin. The "Fe region" and "Fragment, crystallizable region" interchangeably refer to portion of the base of the immnoglobulin "Y" that function in role in modulating immune cell activity. The Fe region is composed of two heavy chains that contribute two or three constant domains depending on the class of the antibody. By binding to specific proteins, the Fe region ensures that each antibody generates an appropriate immune response for a given antigen. The Fe region also binds to various cell receptors, such as Fc receptors, and other immune molecules, such as complement proteins. By doing this, it mediates different physiological effects including opsonization, cell lysis, and degranulation of mast cells, basophils and eosinophils. In an experimental setting, Fe and Fab fragments can be generated in the laboratory by cleaving an immunoglobulin monomer with the enzyme papain into two Fab fragments and an Fe fragment. The invention contemplates polyclonal antibodies and monoclonal antibodies. "Polyclonal antibody" refers to an immunoglobulin produced from more than a single clone of plasma cells; in contrast "monoclonal antibody" refers to an immunoglobulin produced from a single clone of plasma cells. Generic methods are available for making polyclonal and monoclonal antibodies that are specific to a desirable polypeptide. For the production of monoclonal and polyclonal antibodies, various host animals can be immunized by injection with the peptide corresponding to any molecule of interest in the present invention, including but not limited to hamsters, rabbits, 3 mice, rats, sheep, goats, etc. For preparation of monoclonal antibodies, any technique that provides for the production of antibody molecules by continuous cell lines in culture may be used (See e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY). These include, but are not limited to, the hybridoma technique originally developed by Kbhler and Milstein (K6hler and Milstein, Nature, 256:495-497 (1975)), techniques using germ-free animals and utilizing technology such as that described in PCT/US90/02545, as well as the trioma technique, the human B-cell hybridoma technique (See e.g., Kozbor et al., Imrmunol. Today, 4:72 (1983)), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96 (1985)). In some particularly preferred embodiments of the present invention, the present invention o provides monoclonal antibodies. Also contemplated are chimeric antibodies. As used herein, the term "chimeric antibody" contains portions of two different antibodies, typically of two different species. See, e.g.: U.S. Pat. No. 4,816,567 to Cabilly et al.; U.S. Pat. No. 4,978,745 to Shoemaker et al.; U.S. Pat. No. 4,975,369 to Beavers et al.; and U.S. Pat. No. 4,816,397 to Boss et al. Chimeric antibodies include monovalent, divalent or polyvalent immunoglobulins. A monovalent chimeric antibody is a dimer (HL) formed by a chimeric H chain associated through disulfide bridges with a chimeric L chain. A divalent chimeric antibody is tetramer (H 2 L 2 ) formed by two HL dimers associated through at least one disulfide bridge. A polyvalent chimeric antibody can also be produced, for example, by employing a He region that aggregates (e.g., IgM H chain). The invention also contemplates "humanized antibodies," i.e., chimeric antibodies that have constant regions derived substantially or exclusively from human antibody constant regions, and variable regions derived substantially or exclusively from the sequence of the variable region from a mammal other than a human. Humanized antibodies preferably have constant regions and variable regions other than the complement determining regions (CDRs) derived substantially or exclusively from the corresponding human antibody regions and CDRs derived substantially or exclusively from a mammal other than a human. Thus, in one embodiment, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are generally made to further refine antibody performance. In general, the humanized D antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a nonhuman immunoglobulin and all or substantially all of the FR residues are those of a human immunoglobulin sequence. The humanized antibody may also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. Humanized antibodies may be generated using methods known in the art, e.g., U.S. Pat. No. 5,225,539 to Winter et al., including using human hybridomas (Cote et al., Proc. Natl. Acad. Sci. U.S.A.80:2026-2030 (1983)) or by transforming human B cells with EBV virus in vitro (Cole et al., in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, pp. 77-96 (1985)). Additional methods include, for example, generation of transgenic non-human animals which contain human inmunoglobulin chain genes and which are capable of expressing these genes to produce a repertoire of antibodies of various isotypes encoded by the human immunoglobulin genes (U.S. Pat. Nos. 5,545,806; 5,569,825 and 5,625,126). Humanized antibodies may also be made by substituting the complementarity determining regions of, for example, a mouse antibody, into a human framework domain (PCT Pub. No. W092/22653). Importantly, early methods for humanizing antibodies often resulted in antibodies with lower affinity than the non-human antibody starting material. More recent approaches to humanizing antibodies address this problem by making changes to the CDRs. See U.S. Patent Application Publication No. 20040162413, hereby incorporated by reference. In some embodiments, the invention's humanized antibodies contain an optimized heteromeric variable region (e.g. that may or may not be part of a full antibody other molecule) having equal or higher antigen binding affinity than a donor heteromeric variable region, wherein the donor heteromeric variable region comprises three light chain donor CDRs, and wherein the optimized heteromeric variable region comprises: a) a light chain altered variable region comprising; i) four unvaried human germline light chain framework regions, and ii) three light chain altered variable region

CDRs, wherein at least one of the three light chain altered variable region CDRs is a light chain donor CDR variant, and wherein the light chain donor CDR variant comprises a different amino acid at only one, two, three or four positions compared to one of the three light chain donor CDRs (e.g. the at least one light chain donor CDR variant is identical to one of the light chain donor CDRs except for one, two, three or four amino acid differences). Chimeric antibodies containing amino acid sequences that are fused to constant regions from human antibodies, or to toxins or to molecules with cytotoxic effect, are known in the art (e.g., U.S. Pat. Nos. 7,585,952; 7,227,002; 7,632,925; 7,501,123; 7,202,346; 6,333,410; 5,475,092; 5,585,499; 5,846,545; 7,202,346; 6,340,701; 6,372,738; 7,202,346; 5,846,545; 5,585,499; D 5,475,092; 7,202,346; 7,662,387; 6,429,295; 7,666,425; and 5,057,313). Antibodies that are specific for a particular antigen maybe screened using methods known in the art (e.g., U.S. Pat. No. 7,202,346) and disclosed herein. For example, In the production of antibodies, screening for the desired antibody can be accomplished by radioimmunoassay, ELISA (enzyme-linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, in situ immunoassays (e.g., using colloidal gold, enzyme or radioisotope labels), Western blots, precipitation reactions, agglutination assays

(e.g., gel agglutination assays, hemagglutination assays, etc.), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention. As is well known in the art, the immunogenic peptide should be provided free of the carrier molecule used in any immunization protocol. For example, if the peptide was conjugated to KLH, it may be conjugated to BSA, or used directly, in a screening assay. In one embodiment, the invention's antibodies are monoclonal antibodies produced by a hybridoma cell line. In a particular embodiment, the monoclonal antibody specifically binds to a MUC16 ectodomain polypeptide that comprises Polypeptide 1 (SEQ ID NO:01), as exemplified by the antibody selected from the group consisting of 9B11.20.16, 10A2, 2F4, 23D3, 30B1, and 31B2 (Tables 1 and 2). In a preferred embodiment, the antibody is 9B11. In another embodiment, the monoclonal antibody specifically binds to a MUC16 ectodomain polypeptide that comprises Polypeptide 2 (SEQ ID NO:02), wherein the antibody is exemplified by 4H11.2.5, 13H1, 29G9, 9C9.21.5.13, 28F8, 23G12, 9C7.6, 11B6, 25G4, 5C2.17,

4C7, 26B2, 4A5.37, 4A2, 25H3, and 28F7.18.10 (Tables 1 and 2). In a preferred embodiment, the antibody is exemplified by 4H11.2.5, 4A5.37, 9C9.21.5.13, 28F7.18.10, 9C7.6, and 5C2.17. In a further embodiment, the monoclonal antibody specifically binds to a MUC16 cytoplasmic domain polypeptide that comprises Polypeptide 3 CGVLVTTRRRKKEGEYNVQQQ (SEQ ID NO:03), wherein the antibody is exemplified by 31A3.5.1, 19D1, 10F6, 22E10, 22F1, 3H8, 22F11, 4D7,24G12, 19G4, 9A5, 4C2,31C8, 27G4, and 6H2 (Tables 1 and 2). Inapreferred embodiment, the antibody is 31A3.5.1. In another embodiment, the monoclonal antibody specifically binds to a MUC16 extracellular domain polypeptide that comprises Polypeptide 4 KSYF SDCQVSTFRS VPNRHHTGVD SLCNFSPL (SEQ ID NO:15), wherein the antibody is exemplified by 24B3 and 9C7 (Table 2). The invention's antibodies and methods for their use (both diagnostic and therapeutic) are disease specific. "Specificity" of a method and/or molecule for disease, such as "specificity for cancer" which is interchangeably used with "cancer specificity", refers to the proportion (e.g., percentage, fraction, etc.) of negatives (i.e., healthy individuals not having disease) that are correctly identified, i.e., the percentage of healthy subjects who are correctly identified as not having disease. Specificity may be calculated according to the following equation:

Specificity = number of true negatives / (number of true negatives + number of false positives).

Thus, in some embodiments, the invention's compositions and/or methods have a "cancer specificity" greater than 50%, including any numerical value from 51% to 100%, such as 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%,88%,89%,90%,91%,92%,93%,94%,95%,96%,97%,98%, and 99%. Whilea100% specificity is most desirable, i.e., not predicting anyone from the healthy group as having cancer, it is not necessary. Data herein demonstrate the invention's cancer specificity (Table 3). In alternative embodiments, specificity is expressed (together with sensitivity) as a statistical measure of the performance of a binary classification test, such as using a Receiver Operator Characteristic (ROC) curve". For any test, there is usually a trade-off between specificity and sensitivity. For example: in cancer screening tests of human subjects, it is undesirable to risk falsely identifying healthy people as having cancer (low specificity), due to the high costs. These costs are both physical (unnecessary risky procedures) and financial. This trade-off can be represented graphically using a ROC curve. "Receiver Operator Characteristic curve" and "ROC curve" refer to a plot of the true positive rate (AKA sensitivity) versus true negative rate (AKA 1 specificity). The measured result of the test is represented on the x axis while the y axis represents the number of control (e.g., healthy) or case (e.g., cancer) subjects. For any given cut point (each point along the x axis) a sensitivity and specificity of the assay can be measured. The range of sensitivity and specificity for any given assay can range from 0% to 100%, depending on the selected cut point. For this reason, in some preferred embodiments, the AUC is used as the standard measure of an assay's specificity and/or sensitivity. The "area under the curve" ("AUC") for the ROC curve plot is equal to the probability that a classifier will rank a randomly chosen positive instance higher than a randomly chosen negative one. Thus, AUC is a general measure of a tests ability to successfully discriminate between case (e.g., cancer) and control (e.g., healthy) subjects. Random chance would generate an AUC of 0.5. Therefore, in one embodiment, useful tests preferably have AUC's greater than 0.50, including any value from 0.51 to 1.00, such as from 0.55 to 1.00, from 0.60 to 1.00, from 0.65 to 1.00, from 0.70 to 1.00, from 0.75 to 1.00, from 0.80 to 1.00, from 0.85 to 1.00, from 0.90 to 1.00, from 0.95 to 1.00, and most preferably 1.00. AUC values greater than 0.50 include 0.51, 0.52, 0.52, 0.54, 0.55, 0.56, 0.57, 0.58, 0.59, 0.60, 0.61, 0.62, 0.63, 0.64, 0. 65, 0.66, 0.67, 0. 68, 0.69, 0.70, 0.71, 0.72, 0.73, 0.74, 0.75, 0.76, 0.77, 0.78, 0.79, 0.80, 0.81, 0.82, 0.83, 0.84, 0.85, 0.86, 0.87, 0.88, 0.89, 0.90, 0.91, 0.92, 0.93, 0.94, 0.95, 0.96, 0.97, 0.98, and 0. 99. The invention's antibodies and methods for their use (both diagnostic and therapeutic) are disease sensitive. "Sensitivity" of a method and/or molecule for disease, such as "sensitivity for cancer" which is interchangeably used with "cancer sensitivity," refers to the proportion (e.g., percentage, fraction, etc.) of positives (i.e., individuals having cancer) that are correctly identified as such (e.g. the percentage of people with cancer who are identified as having the condition). Sensitivity may be calculated according to the following equation; Sensitivity = number of true Z5 positives / (number of true positives + number of false negatives). Thus, in some embodiments, the invention's compositions and/or methods have a "disease sensitivity," such as "cancer sensitivity," greater than 50%, including any numerical value from 51% to 100%, such as 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, and99%. While a 100% sensitivity is most desirable (i.e., predicting all subjects from the cancer group as having cancer), it is not necessary. In alternative embodiments, the invention's compositions and/or methods have a "disease sensitivity," such as "cancer sensitivity," equal to or lower than 50%, including any numerical value from 0% to 50%, such as 1%, 2%,3%,4%,6%,6%,7%,8%,9%,10%,11%,12%,13%, 14%,15%,16%,17%,18%,19%,20%,21%,22%,23%,24%,25%,26%,27%,28%,29%,30%, 31%,32%,33%,34%,35%,36%,37%,38%,39%,40%,41%,42%,43%,44%,45%,46%,47%, 48%, and 49%. In some embodiments, sensitivity is expressed (together with specificity) as a statistical measure of the performance of a binary classification test, such as using AUC of a ROC curve, as discussed above with respect to specificity.

D. Hybridoma Cell Lines In addition to the invention's novel antibodies, the invention also provides hybridoma cell lines that produce these antibodies. "Hybridoma cell" refers to a cell line produced by fusing a specific antibody-producing B cell with a myeloma (B cell cancer) cell that is selected for its ability to grow in tissue culture and for an absence of antibody chain synthesis. The antibodies produced by the hybridoma cell are all of a single specificity and are therefore monoclonal antibodies (in contrast to polyclonal antibodies). In a particular embodiment, the invention provides hybridoma cell lines that produce a monoclonal antibody that specifically binds to a polypeptide, or antigenic portion thereof, selected from the group consisting of a) MUC16 ectodomain polypeptide (e.g., NFSPLAR RVDRVAIYEE FLRMTRNGTQ LQNFTLDRSS VLVDGYSPNR NEPLTGNSDL P (SEQ ID NO:17)), b) MUC16 cytoplasmic domain polypeptide (e.g., VTTRR RKKEGEYNVQ QQ (SEQ ID NO:18)), and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide CQVSTFRSVPNRHHTGVDSLC(SEQIDNO:19). TheMUC16polypeptideSEQIDNO:18is contained within LVTTRR RKKEGEYNVQ QQ (SEQ ID NO:20). Thus, SEQ ID NO:20 contains both a transmembrane domain amino acid (L) and a cytoplasmic domain portion VTTRR RKKEGEYNVQ QQ (SEQ ID NO:18), i.e., the L is optional, as it is part of the transmembrane domain. The MUC16 polypeptide SEQ ID NO:18 is also contained within CGVLVTTRR RKKEGEYNVQ QQ (SEQ ID NO:03). Thus, SEQ ID NO:03 contains both a transmembrane domain portion (CGVL) and a cytoplasmic domain portion VTTRR RKKEGEYNVQ QQ (SEQ ID NO:18), i.e., the CGVL is optional, as it is part of the transmembrane domain.

E. Conjugates Of The Invention's Antibodies Linked To Cytotoxic Agents And/Or Prodrugs The invention contemplates conjugate antibodies. A "conjugate" antibody refers to an antibody of the present invention covalently linked to a cytotoxic agent and/or a prodrug of a cytotoxic agent. "Cytotoxic agent" refers any agent that is capable of reducing the growth of, and/or killing, a target cell. A "prodrug" represents an analog of a cytotoxic agent that substantially lacks cytotoxic activity until subjected to an activation step. Activation steps may include enzymatic cleavage, a chemical activation step such as exposure to a reductant, or a physical activation step such as photolysis. The covalent linkage between the invention's antibodies and the cytotoxic agent or prodrug can include cleavable linkages such as disulfide bonds, which may advantageously result in cleavage of the covalent linkage within the reducing environment of the target cell. Such conjugates are useful as tumor-cell specific therapeutic agents. In one embodiment, the cytotoxic agent is a small drug molecule (Payne et al., U.S. Pat. No. 7,202,346). In another embodiment, the cytotoxic agent a maytansinoid, an analog of a maytansinoid, a prodrug of a maytansinoid, or a prodrug of an analog of a maytansinoid (U.S. Pat. Nos. 6,333,410; 5,475,092; 5,585,499; 5,846,545; 7,202,346). In another embodiment, the cytotoxic agent maybe a taxane (see U.S. Pat. Nos. 6,340,701 & 6,372,738 & 7,202,346) or CC 1065 analog (see U.S. Pat. Nos. 5,846,545; 5,585,499; 5,475,092 & 7,202,346). In another embodiment, the cytotoxic agent is exemplified by an auristatin, a DNA minor groove binding agent, a DNA minor groove alkylating agent, an enediyne, a duocarmycin, a maytansinoid, and a vinca alkaloid (U.S. Pat. No. 7,662,387). In a further embodiment, the cytotoxic agent is an anti-tubulin agent (U.S. Pat. No. 7,662,387). In yet another embodiment, the cytotoxic agent is exemplified by dimethylvaline valine-dolaisoleuine-dolaproine-phenylalanine-p-phenylenediamine (AFP), dovaline-valine dolaisoleunine-dolaproine-phenylalanine (MMAF), and monomethyl auristatin E (MAE) (U.S. Pat. No. 7,662,387). In an additional embodiment the toxic agent is exemplified by radioisotope emitting radiation, immunomodulator, lectin, and toxin (U.S. Pat. No. 6,429,295). In particular, the radioisotope emitting radiation is an alpha-emitter selected from the group consisting of m.Bi, 2 Bi, and 21 At, or a beta-emitter selected from the group consisting of 186Re and 90 Y, or a gamma-emitter 11 (U.S. Pat. No. 7,666,425).

In an alternative embodiment, the toxin is exemplified by ricin, the A-chain of ricin, and pokeweed antiviral protein (U.S. Pat. No. 5,057,313). In yet another embodiment, the cytotoxic agent is an anti-cancer drug selected from the group consisting of methotrexate, 5-fluorouracil, cycloheximide, daunomycin, doxorubicin, chlorambucil, trenimon, phenylenediamine mustard, adriamycin, bleomycin, cytosine arabinoside or Cyclophosphamide (U.S. Pat. No. 5,057,13).

F. Detecting Mue16 Portions And Diagnostic Applications The invention provides a method for detecting a disease that comprises overexpression of MUC16 in a subject, wherein the method comprises a) providing i) a sample from a subject, and ii) any one or more of the invention's antibodies, b) contacting the sample with the antibody under conditions for specific binding of the antibody with its cognate antigen, and c) detecting an increased level of binding of the antibody to the sample compared to a control sample lacking the disease, thereby detecting the disease in the subject. Generic methods for detecting disease using antibodies are known in the art (Payne et al., U.S. Pat. No. 7,202,346). The invention's methods are particularly useful in detecting cancer, such as ovarian cancer and breast cancer. The invention's methods are not limited to a particular approach to detecting binding of the invention's antibodies to their antigens. In one embodiment, detecting binding to the invention's antibodies typically involves using antibodies that are labeled with a detectable moiety, such as radioisotope (e.g., 3H, 14C, 1P, 15S, and/or 1251), fluorescent or chemiluminescent compound (e.g., fluorescein isothiocyanate, rhodamine, and/or luciferin) and/or an enzyme (e.g., alkaline phosphatase, beta-galactosidase and/or horseradish peroxidase). Methods for conjugating antibodies to a detectable moiety are known in the art (e.g., Hunter, et al., Nature 144:945 (1962); David, e at., Biochemistry 13:1014 (1974); Pain, et al., J. Immunol. Meth. 40:219 (1981); and Nygren, J. Histochem. and Cytochem. 30:407 (1982). Thus, the invention's antibodies may be employed in immunoassays, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays, including immunohistochemistry, enzyme-linked immunosorbent assay (ELISA), fluorescence-activated cell sorting (FACS), and Western blots. For example, with respect to immunohistochemical detection, data herein demonstrate that antibody 4H11 is useful in detecting high-grade ovarian serous carcinoma, lobular cancer (28), and a subset of ovarian carcinomas that are negative with OC125 and that retain cytoplasmic and extracellular portions of the MUC16 glycoprotein.

The antibodies of the invention also are useful for radiographic in vivo imaging, wherein an antibody labeled with a detectable moiety such as a radio-opaque agent or radioisotope is administered to a subject, preferably into the bloodstream, and the presence and location of the labeled antibody in the host is assayed. This imaging technique is useful in the staging and treatment of malignancies. The invention's antibodies are additionally useful as affinity purification agents. In this process, the antibodies are immobilized on a suitable support, such a Sephadex resin or filter paper, using methods well known in the art, to capture and purify molecules that contain antigens that specifically bind to the invention's antibodies. D G. Therapeutic Applications The invention provides methods for treating a disease that comprises overexpression of MUC16, comprising administering to a subject having the disease a therapeutically effective amount of any one or more of the invention's antibodies. Generic methods for treating disease with antibodies are known in the art (Payne et al., U.S. Pat. No. 7,202,346). The invention's methods are particularly useful in treating cancer, such as ovarian cancer and breast cancer. These methods are also applicable to primary cancer, metastatic cancer, and recurrent cancer. The term "administering" to a subject means providing a molecule to a subject. This may be done using methods known in the art (e.g., Erickson et al., U.S. Patent 6,632,979; Furuta et al., U.S. Patent 6,905,839; Jackobsen et al., U.S. Patent 6,238,878; Simon et al., U.S. Patent 5,851,789). The invention's compositions may be administered prophylactically (i.e., before the observation of disease symptoms) and/or therapeutically (i.e., after the observation of disease symptoms). Administration also maybe concomitant with (i.e., at the same time as, or during) manifestation of one or more disease symptoms. Also, the invention's compositions may be administered before, concomitantly with, and/or after administration of another type of drug or therapeutic procedure (e.g., surgery). Methods of administering the invention's compositions include, without limitation, administration in parenteral, oral, intraperitoneal, intranasal, topical and sublingual forms. Parenteral routes of administration include, for example, subcutaneous, intravenous, intramuscular, intrastemal injection, and infusion routes. In one embodiment, the invention's compositions comprise a lipid for delivery as liposomes. Methods for generating such compositions are known in the art (Borghouts et al. (2005). J Pept Sci 11, 713-726; Chang et al. (2009) PLoS One 4, e4171; Faisal et al. (2009) Vaccine 27, 6537-6545; Huwyleret al. (2008) Int J Nanomedicine 3, 21-29; Song et al. (2008) Int J Pharm 363, 155-161; Voinea et al. J Cell Mol Med 6, 465-474).

Antibody treatment of human beings with cancer is known in the art, for example in U.S. Pat. Nos. 5,736,137; 6,333,410; 5,475,092; 5,585,499; 5,846,545; 7,202,346; 6,340,701; 6,372,738; 7,202,346; 5,846,545; 5,585,499; 5,475,092; 7,202,346; 7,662,387; 7,662,387; 6,429,295; 7,666,425; 5,057,313. The invention's antibodies may be administered with pharmaceutically acceptable carriers, diluents, and/or excipients. Examples of suitable carriers, diluents and/or excipients include: (1) Dulbecco's phosphate buffered saline, pH about 7.4, containing about 1 mg/ml to 25 mg/ml human serum albumin, (2) 0.9% saline (0.9% w/v NaCl), and (3) 5% (w/v) dextrose. The invention's antibodies are typically administered in a therapeutic amount. The terms "therapeutic amount," "pharmaceutically effective amount," therapeuticallyy effective amount," and "biologically effective amount," are used interchangeably herein to refer to an amount that is sufficient to achieve a desired result, whether quantitative or qualitative. In particular, a pharmaceutically effective amount is that amount that results in the reduction, delay, and/or elimination of undesirable effects (such as pathological, clinical, biochemical and the like) that are associated with disease. For example, a "therapeutic amount that reduces cancer" is an amount that reduces, delays, and/or eliminates one or more symptoms of cancer. For example, specific "dosages" of a ""therapeutic amount" will depend on the route of administration, the type of subject being treated, and the physical characteristics of the specific subject under consideration. These factors and their relationship to determining this amount are well known to skilled practitioners in the medical, veterinary, and other related arts. This amount and the method of administration can be tailored to achieve optimal efficacy but will depend on such factors as weight, diet, concurrent medication and other factors, which those skilled in the art will recognize. The dosage amount and frequency are selected to create an effective level of the compound without substantially harmful effects. When present in an aqueous dosage form, rather than beinglyophilized, the antibody typically will be formulated at a concentration of about 0.1 mg/ml to 100 mg/ml. Depending on the type and severity of the disease, about 0.015 to 15 mg of antibody/kg of patient weight is an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. For repeated administrations over several days or longer, depending on the condition, the treatment is repeated until a desired suppression of disease symptoms occurs. The methods of the present invention can be practiced in vitro, in vivo, or ex vivo.

EXPERIMENTAL The following examples serve to illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof.

EXAMPLE Materials And Methods The following is a brief description of the exemplary materials and methods used in the subsequent Examples.

D Cell Cultures: OVCAR3, SKOV3, and A2780 cell lines were obtained through the American Type Culture Collection (ATCC, Manassas, VA) and sustained in culture according to the ATCC literature. For the creation of MUC16+ transfected cell lines, the carboxyterminus portion of the MUC16 cDNA was introduced as green fluorescent protein fusion proteins using the Vitality phrGFP vector expression system (Stratagene, La Jolla, CA). Stable cell lines were selected using geneticin (G418, Invitrogen, Grand Island, NY) in their respective culture media and isolated by expression of Green Fluorescence Protein. Stable transfectants were routinely maintained in G418 in their culture media respectively. TheAMUC16c14 transfectants have cell surface expression of MUC16 protein from the putative cleavage site to the carboxyterminus (AA 1776 to 1890) (12).

Monoclonal Preparation: Using the MUC16 sequence, peptide sequences encoding elements of the AMC16 114 amino acid sequence were synthesized at the Memorial Sloan-Kettering Cancer Center (MSKCC) Microchemistry Core Facility. The inventors synthesized 3 polypeptides (Figure 1) and modified Polypeptide 1 and Polypeptide 2 with a cysteine at the N-terminus for better conjugation to KLH. Equal concentrations of the KLH-conjugated peptides were mixed and then used as the immunogen for 5 BALB/c mice. The inventors selected 1 of the 5 mice whose serum showed the highest reactivity to individual peptides by ELISA, and the MSKCC Monoclonal Antibody Core Facility performed the fusion and selected the antibodies using standard protocols. After 10 days of fusion, supernatants were selected and screened for reactivity by ELISA against the individual synthetic peptides.

ELISA:

Sandwich ELISA was performed to see the positivity of the antibodies to individual peptides and GST-AMUC160 114 fusion protein following routine core facility protocol for ELISA assay.

FACS Analyses: Adherent target cells were removed by 0.05% Trypsin and 0.1% EDTA, washed, and counted by a hemocytometer. Cells were distributed into multiple Eppendorf tubes with at least 0.5-1 x 106 cells per tube. Cells were washed with phosphate buffered saline (PBS) containing 1% FCS and 0.025% Sodium Azide (FACS buffer). For internal FACS staining, cells in the Eppendorf tubes were permeabilized with 1:10 diluted FACS Permeabilizing Solution 2 (BD BioSciences, San Jose, CA) for 10 minutes at room temperature and then washed twice with ice cold FACS buffer. Then they were incubated either without (for second antibody control) or with 1 g/tube of bioreactive supernatants of mouse MUC16 monoclonals for 30 minutes on ice. For surface FACS staining, cells were incubated either without (for second antibody control) or with 1 g/tube of bioreactive supernatants of MUC16 monoclonals (9B11.20.16, 9C9.21.5.13 and 4H11.2.5), Mouse anti-human OC125 (M3519), Mouse anti-human M I(M3520) (DakoCytomation, Dako North America Inc., Carpinteria, CA) or VK8 (kindly provided by Dr. Beatrice Yin and Dr. Ken Lloyd, MSKCC, New York, NY) for 30 minutes on ice. Cells in Eppendorf tubes were also surface stained with 1 g/tube of non-specific isotype matched control mouse antibodies (13C4 for IgG1 and 4E11 for IgG2b monoclonals obtained from MSKCC Monoclonal Core Facility) and incubated on ice for 30 minutes. All cells were washed three times with FACS buffer. Cells were incubated with 1 g/tube of second antibody Goat anti-mouse IgGl-PE or IgG2b-PE for 30 minutes on ice and then washed three times with FACS buffer. The cells were analyzed by a FACS Calibur machine at the MSKCC Flow Cytometry Core Facility.

Western Blot Analysis: Stable cell lines were cultured in 10 cm dishes in their respective culture media and incubated with 5% CO2 at 37°C for 3 days. They were washed twice with ice cold PBS to remove the serum-containing media. Adherent cells were scraped with 1-2 ml of ice cold PBS, and the cells were spun down in an Eppendorf tube at 4°C in an Eppendorf centrifuge. Supernatant was discarded, and the cells were lysed with 0.2 ml of modified Ripa lysis buffer (20 mM Tris-HCL; pH 7.4; 150 mM NaCl; 1% NP-40; 1 mM Na3VO4; 1 mM PMSF; 1 mM DTT; 10pg/ml leupeptin; and 10 pg/ml aprotinin) for 30 minutes on ice and spun at 4C for 10 minutes. The soluble solution was separated into a tube and the debris pellet was discarded. Protein concentration was measured using the Bio-Rad Protein Assay (BioRaD Laboratories, Hercules, CA). Equal amounts of proteins (GST-MUIC16-CD-fusion protein or stable cell line extracts) were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membrane using a BioRad transfer apparatus in a cold room at 4°C. The membranes were blocked with 3% bovine serum albumin (BSA) in PBS with 0.1% Tween-20 (PBST) at 4°C overnight. Membranes were probed with primary antibody (1:1000 dilution) for 1 hr at room temperature and then washed three times with PBST. Then the membranes were stained with corresponding second antibody, anti-Mouse IgG Horse Radish Peroxidase (HRP) linked whole antibody from sheep (GE Healthcare, UK) (1:5000 dilution), for 1 hr at room temperature. Membranes were washed three times with PBST and developed with a Western Lightning* chemiluminescence reagent (ECL, Perkin Elmer, Waltham, MA) for 1-5 minutes at room temperature, and the signals were developed on Kodak BioMax Film. Binding and internalization studies with monoclonal antibodies and OVCAR3 and SKOV3 stable transfectants: Purified monoclonal antibodies were labeled with 131 using the iodogen method and purified by size exclusion chromatography (22). Saturation binding studies were performed with radiolabeled antibodies using substrates of intact OVCAR-3 cells. Briefly, 10 test solutions were prepared (in triplicate) and they contained increasing amounts of the radioiodinated antibodies, 3 500 000 cells in a total volume of 500 pL of PBS (0.2 % BSA; pH 7.4). The cells were isolated by rapid filtration through a glass fiber membrane and washed with ice cold tris buffered saline. Cells were counted in a gamma counter with standards of total activity added. For each concentration of radiolabeled antibody, non-specific binding was determined in the presence of 100 nM of the unmodified antibody. The data were analyzed with a least squares regression method (Origin, Microcal, Software Inc., Northampton, MA) to determine the IQ and Bmax values, and a Scatchard transformation was performed. 1 1-4H11 and1 3 I-OC125 Antibody cell internalization studies were performed with monoclonal antibodies and SKOV3-phrGFP-AMUC16 3 34 stable transfected cells. Briefly, radiolabeled antibody (370 MBq/mg, 100 kcpm) in 2 mL of medium was added to SKOV3 cells plated in a 6-well plate. The plates were incubated at 37C for up to 24 hours. At various time points, the medium was removed from three wells and the cells washed with 2 x 2 mL PBS. Cell surface bound activity was then stripped and collected with 2 x 2 mL of an ice cold acid wash (100 mM acetic acid 100 miM glycine; pH 3.0). The cells were then dissolved with 2 x 1 ml 1 M NaOH and collected. At the end of the study all samples were counted with a gamma counter together with standards, representing the initial amount of radioactivity added. All the media samples were analyzed by ITLC-SG with mobile phases of 5% TCA to determine unbound 1.

Tissue microarray (TMA): Tissue microarrays were either constructed within our institution or bought from a commercial laboratory if not available internally. Briefly, core-needle biopsies of pre-existing paraffin-embedded tissue were obtained from the so-called donor blocks and then relocated into a recipient paraffin-arrayed "master" block by using the techniques by Kononen et al. and subsequently modified by Hedvat et al (23-24). A manually operated Tissue Arrayer MTA-1 from o Beecher Instruments Inc. (Sun Prairie, WI) was used to produce sample circular spots (cores) that measured 0.6 to 1.0 mmin diameter. The cores were arrayed 0.3 to 0.4 mm apart from each other. A layer of control tissues was strategically laid around the actual tissue microarrays in order to avoid edging effects. The specific composition of each tissue microarray is delineated below. Slides of tissue microarrays for ovarian cancer, prostate cancer, adenocarcinoma of the lung, mucinous neoplasms of the pancreas, and invasive ductal and invasive lobular breast carcinoma were prepared by cutting 4 um sections from formalin-fixed paraffin-embedded tissue. Normal adult and fetal tissue microarrays were obtained from a commercial source (Biomax, US). OVCAR3 cells were used as positive controls.

Immunohistochemistry: Immunohistochemistry was performed on the tissue microarrays with both standard OC125 (Ventana, Tuscon, AZ) and the novel monoclonal antibodies. Sections of the tissue microarrays were cut at 4 microns, placed on Superfrost/Plus microscope slides (Fisher brand) and baked in a 600 oven for at least 60 minutes. The slides were then deparaffinized and hydrated to distilled water, soaked in citrate buffer at pH 6.00 for 30 minutes at 97 C, washed in running water for 2-5 minutes, incubated for 5 minutes in 3% hydrogen peroxide diluted in distilled water. Slides were washed in distilled water for 1 minute, transferred to a bath of phosphate buffered saline (PBS), pH 7.2, for two changes of 5 minutes each and placed in 0.05% BSA diluted in PBS for a minimum of 1 minute. After drying around tissue sections, normal serum was applied at a 1:20 dilution in 2% BSA/PBS and incubated for a minimum of 10 minutes at room temperature in a humidity chamber. The serum was then suctioned off without allowing the sections to dry, and approximately 150 lambda of novel antibody at a dilution of 1:1000 was placed on the tissue. The slide was incubated overnight (approximately 15-18 hours) at 4° C in a humidity chamber. Primary antibody was washed off using three changes of PBS for 10 minutes each. Secondary antibody, biotinylated a mouse from Vector laboratories (Burlingame, Ca), was applied at 1:500 dilution in 1% BSA/PBS and incubated for 45-60 minutes at room temperature in humidity chamber. The antibody was washed off again using three changes of PBS as above. Slides were then transferred to a bath of diaminobenzidine (DAB), diluted in PBS for 5-15 minutes. The slides were then washed in tap water for 1 minute, counterstained using Harris modified hematoxylin (Fisher), decolorized with 1% acid alcohol and blue in ammonia water, dehydrated with 3 changes each of 95% ethanol, 100% ethanol and xylene for 2 minutes each and coverslipped with permanent mounting medium.

Immunohistochemistry scoring: D Commercially available antibodies, such as OC125 and M1, target complex glycosylation dependent epitopes. Our hypothesis is that glycosylation may be tissue specific; therefore, it was important to examine the utility of the peptide-directed antibodies in paraffin-fixed tissues and survey the prevalence of MUC16 expression. The three candidate antibodies, 4H11, 9C9 and 4A5, were characterized using OVCAR3 cell line pellets. Of the three, the 4H11 antibody showed the strongest, most diffuse and consistent staining pattern at multiple dilutions, with the least amount of background staining and, therefore, was optimized for use in human tissues in the pathology core facility. Using 4H11, the inventors stained and scored positivity using tissue microarrays from high stage, high-grade ovarian serous carcinomas (Figure 2), these tumors being the most common type of ovarian cancer, representing approximately 80-85% of all ovarian carcinomas in Western industrialized nations (25). To test the specificity of the novel antibody, the inventors also stained tissue microarrays of cancers of the prostate, lung, breast, and pancreas and compared their staining intensities with that of OC125 monoclonal antibody (Figure 6A-D). To determine whether there would be any cross-reactivity with normal human tissues, the antibodies were also tested on normal human adult and fetal TMAs. All of the stained sections were reviewed by a reference pathologist (KJP). A subset of cores for which there was equivocal staining was also independently scored by a second pathologist (RAS) to ensure consistency in scoring methods. Only cytoplasmic and/or membranous staining was considered positive. If a portion of the cell showed membranous staining, that was considered partial staining. A scoring system was devised to provide a semiquantitative assessment of staining distribution and intensity in individual cores. At the same time, it was designed to be useful for comparing the staining distribution and intensity between OC125 and the novel antibodies. The score incorporated the percentage of cells, the intensity and pattern of the staining according to the following standards: score 0: no staining; score 1: <5% strong or weak; score 2: 5-50% strong or weak; score 3: 51-75% strong or 51-100% weak; score 4: 76-99% strong; and score 5: 100% strong staining (Figure 3). The pathologist first reviewed all tissue microarrays stained with OC125 and scored each core. Then the same cores stained with the novel antibodies were scored 1 to several days after OC125 without reference to the previous results. Direct comparison of the scoring between the stains for each core was made only after all of the scoring was completed. The same process was used for all non-ovarian tissue microarrays. After comparison, core staining was determined to be concordant, equivocal, or discordant based on the point differentials. Concordant cores differed by 0 to 1 point, equivocal cores differed by 2 points, and discordant cores differed by 3 to 5 points. The one exception to this rule was when the difference of1 point was between a score of 0 and 1, in which case, the differences were considered equivocal. This was in order to truly separate negative cases from even focally positive ones.

EXAMPLE2 Generation and characterization of anti-MUC16 monoclonal antibodies MUC16-directed monoclonal antibodies were isolated by ELISA-based screening using both the individual peptides and recombinant GST-AMUC16° protein followed by sequential subeloning for single cell clones.

Tables1A andIB: MUC6-carboxyterinus monoclonal antibodies showing their reactivity to GST-AMUC16.. western, FACS analysis on OVCAR3 wild type cells

TableI1A

Peptide I _ ___Peptide 2 Peptide 3

ELISA GST- ELISA GST- ELISA (1:10) GSTI Hybridomn MucCD (1:1) Hybrido MucC (1:1) Hybridomn MucCO (1:1) a Sups Western OVCAR3 ma Sups Western OVCAR3 a Sups Western OVCAR3 (1) +- FACSIl- Isotype (1:1) +1- FACS+I- Isotype (1) +I- FACS +I- Isotype 10OA2 + I gG,igM 13HI Weak -IgGI 22E10 + - IgG2b 23D4 missing 28F8 + + lgGlIgM_ 22F11I Weak - gm 2F4 Weak - igGi,igm 11 B6 -g I 1g 904 Weak - IgGl,IgM 01li Weak +- IgGI 4C7 + IgGI 31A3 Weak_ IgGI 23D3 Weak + lgGl,IgG2b 28F7 + + IgGI 4C2 + - IgG1,IgM

30B1 IgGI 9C7 + + IgG1 27G4 + - gm 31B2 + - 1M 9C9 + + lgGl,IgG2b_ 1901 + - IgG2b ______4H11 + + IgG2b, IgM 22F1 + - gG2b,IgM 4A2 - -IgGI 4D7 + IG 4A5 + + IgG1 9A5 __- gM 2909 + -IgGI 318 - - IgG2b 5C2 + + IgGI 6H2 Weak: - IgGl,igM 23012 - gG1,lgG2a 10F6 - IgGI 2504 IgGl,IgM 3H8 + - IgGl,IgM 26132 + + lgG1,IgG2bIgm_ 24012 - - gGl,gM 25H3, -gGl,IgM _ _ _ _ _ _ ____ _ _ _

Table lB__ _ _ _ _ _ _ _ ___ _ _ _ ____ _____ _ _

[___T Peptide I -_______- Peptide 2 -Peptide 3 ___

OVCAR3 soyeOVCAR3 OVAR ________FACS +f- FACS +yp OVCAR+I- yp

9B11.2016J+I- igGi 9C9.21.5.13 + IgG2b 31 A3.5.1 ig 4H1 1.2.5 j + IgG2b

9C7.6 + IgGI 5C2.17 4A5.37 28F7.181O j+ +

+ IgGI IgGI IgGi

Table 2: Antibodies specific for exemplary portions of MUC16

1. Muc16 Polypeptide 1:

14394 14410 (MUC16 sequence) NFSPLARRVDRVAIYEE (SEQ ID NO:01) 17 aa

Mouse monoclonals which are specific to this peptide are: 9B11.20.16 (IgGI) o 10A2 (IgG1, 1gM) 2F4 (IgG1, IgM) 23D3 (IgGI, IgG2b) 30B1 (IgGI) 31B2 (IgM)

2. Muc16 Polypeptide 2:

14425 14442 (MUC16 sequence) TLDRSSVLVDGYSPNRNE (SEQ ID NO:02) 18 aa

Mouse monoclonals which are specific to this peptide are: 4H11.2.5 (IgG2b) 13H1 (IgGI) 29G9 (IgGI) 9C9.21.5.13 (IgG2b) 28F8 (IgG1, IgM) 23G12 (IgG1, IgG2a) 9C7.6 (IgGI) 11B6 (IgM) 25G4 (IgG1, IgM) 5C2.17 (IgGI) 4C7 (IgGI) 26B2 (IgG1, IgG2b, IgM) 4A5.37 (IgGI) 4A2 (IgGI) 25H3 (IgG1, IgM) 28F7.18.10 (IgGI)

3. Muc16 Polypeptide 3 (SEQ ID NO:03)

14472 14492 (MUC16 sequence) CGVLVTTRRRKKEGEYNVQQQ 21 aa

Mouse monoclonals which are specific to this peptide are: 31A3.5.1 (IgGI) 19D1 (IgG2b) 10F6 (IgGI) 22E10 (IgG2b) 22F1 (IgG2b, IgM) 3H8 (IgG1, IgM) 22F11 (IgM) 4D7 (IgG3) 24G12 (IgG1, IgM) 19G4 (IgG1, IgM) 9A5 (IgM) 4C2 (IgG1, IgM) 31C8 (IgG2b) 27G4 (IgM) 6H2 (IgG1, IgM)

14452 14475 FWAVILIGLAGLLGLITCLICGVL (SEQ ID NO:14) is Transmembrane region 24 aa

4. Muc16 Polypeptide 4 (SEQ ID NO:15) containing a cysteine loop polypeptide (SEQ ID NO:19):

14367 14398 (MUC16 sequence) KSYFSDCQVSTFRSVPNRHHTGVDSLCNFSPL (SEQ ID NO:15) 32 aa I___ _s- s_

Mouse monoclonals which are specific to this peptide are: 24B3 (IgM) 9C7 (IgM)

4F12 IgM kappa 6H6 lgM kappa 25C2 IgM kappa 6E8 IgM kappa 2A3 IgM, IgG1, IgG2b, kappa 2G4 IgM, IgG1, kappa 4C8 IgM, kappa 2A6 IgG1 kappa 24G12 IgG1 kappa 15D5 IgG1 kappa 6E2 IgM, IgG1, IgG3, IgG2a, kappa 7E6 IgM, kappa, lambda 7G11 IgM kappa 20C3 IgG1, IgG2b 9A3 IgM kappa 15B6 IgM kappa 19D3 IgM kappa 5H-18 IgM, IgG1, IgG2b, kappa 24A12 IggM kappa

2D10 IgG3, IgM kappa 5B2 IgM,I IgG3, IgG2b, IgG2a, IgG1, kappa 8B6 IgG2a,IgG3, kappa 5A11 IgM,kappa

7D11 light kappa only 9F10 IgM, kappa

15D10 IgM, kappa 18D2 IgM, kappa

13A11 IgM, kappa

1A9 IgM, kappa

3B2 IgM, kappa

24F6 IgM, kappa

24E4 IgM, kappa

5A1 IgG2a, IgM, kappa

7B9 IgM, kappa

22F4 IgM, kappa

The identified monoclonal antibodies are listed in Table 1A and Table 2. Each of the selected monoclonal antibodies was reactive against GST-AMUC1614. The commercial MUC16 directed antibodies (OC125, M11, or VK8) did not bind to GST-AMUC16c° 4 in ELISA or Western blotting. The clones were tested in FACS against OVCAR3 ovarian cancer cells and in Western blot analysis against GST-AMUC16114 (Table IB), and selected purified monoclonal antibodies were isolated. The inventors used the OVCAR3 wild type and the SKOV3 cells transduced with phrGFP AMUC16c"4 to characterize the selected antibodies by FACS analysis. All of the selected monoclonal antibodies bound to both cell lines while commercial VK8, Ml1 and OC125 antibodies bound to the OVCAR3 cells but not to the SKOV3-phrGFP-AMUC16°14 cell line. The antibodies against Polypeptide 3 required permeabilization since it is an internal epitope (Figure 7). Western blot analysis using the GST-AMUC16"14 purified protein showed strong binding with 4H11 and 9C9 antibodies (Figure 4A), while the other selected antibodies showed less binding. The SKOV3-phrGFP-AMUC16°14 transfectant was also positive by Western blot analysis using 4H11 and 9C9 antibodies (Figure 4B). As before, the commercial antibodies did not interact with the GST-AMUC16c"4 purified protein or cell lysates of the SKOV3-phrGFP-AMUC16°4 cell line. The binding of six monoclonal antibodies against OVCAR3 MUC16 were examined in affinity binding studies. Three antibodies-9C7, 5C2 and 28F7-showed only modest levels of binding compared to the nonspecific binding of these antibodies to the OVCAR3 cells, which carry large numbers of MUC16 binding sites. In contrast, 4H11, 9C9, and 4A5 monoclonal antibodies showed highly specific binding affinity, as shown in Figure 5A, with binding affinities of 6.8-8.6 nM4 against the cell surface epitopes of OVCAR3 cells. The inventors also examined the internalization of antibody bound to cell surface MUC16 protein. The inventors examined internalization in the transfected SKOV3-phrGFP-AMUC16°4 cell line which bears the carboxy terminus of MUC16, including the 4H11 epitope and a single degenerate tandem repeat sequence to interact with the OC125 antibody. The commercial antibodies OC125, M11, and VK8 all bind to the cell surface of this transduced cell line. The mI-labeled 4H11 showed rapid internalization at a high level, whereas 3. 1 I-labeled OC125 antibody was internalized at a much lower rate (Figure 5B).

EXAMPLE3 Immunohistochemistry results: Given their highly specific binding affinities, the antibodies 9C9, 4A5, and 4H11 were characterized for utility in immunohistochemistry using OVCAR3 cell lines. Of the three, the 4H11 antibody was selected to be optimized for use in human tissues based on its robust, sensitive and specific staining pattern as compared to the other two antibodies.

A. Ovary Two high-stage, high-grade ovarian serous carcinoma tissue microarray slides composed of 419 cores, representing primary, metastatic and recurrent tumors from 40 patients were stained with both OC125 and 4H11 monoclonal antibodies (Figure 2). The OC125 tissue microarrays showed 279 (66%) cores with 3-5 staining, 99 (24%) with 1-2 staining, and 41 (10%) with no staining. The 4H11 tissue microarrays showed 236 (56%) with 3-5 staining, 91 (22%) with 1-2 staining, and 92 (22%) with no staining. The two antibodies were concordant in 233 (56%) cores, equivocal in 161 (38%), and discordant in 25 (6%). Of the 25 discordant cores, 12 (48% of discordant cases, 3% of all cases) showed greater 4H11 positivity than OC125. Nine were discordant by a difference of 4 points, and 3 were discordant by a difference of 5 points. There was a total of 186 discordant and equivocal cores together, 48 (26%) of which showed greater staining with 4H11 than OC125. The staining pattern of both 4H11 and OC125 was cytoplasmic and membranous, although the membranous pattern of OC125 was stronger and better defined than 4H11 in the majority of cases. Discordant cases demonstrated higher levels of 4H11 than other cases.

B. Breast Cancer A variety of other tissues were also examined for 4H11 staining to test the antibody's specificity. Of the 50 cores of invasive ductal carcinomas of the breast (number of patients unavailable), only 2 (4%) showed a score of 4 or greater 4H11 staining and none had scores of 3-5 for OC125 staining. The staining pattern with OC125 was mostly apical/luminal with some granular cytoplasmic staining. Some tumors with intracytoplasmic lumina also picked up the OC125 stain. 4H11 showed a more diffuse cytoplasmic blush without membranous accentuation.

In contrast, the invasive lobular breast carcinoma tissue microarray (composed of 179 cores with viable tumor, number of patients unavailable) had frequent MUC16 staining with 4H11. In this tissue microarray, 168 cores (94%) showed no staining for OC125, 5 (3%) showed 1-2 staining, and only 6 (3%) showed a staining intensity of 3. 4H11 staining was different in its distribution pattern, with 49 (27%) showing no staining, 81 (45%) showing 1-2 staining, and 49 (27%) showing 3-4 staining. Neither OC125 nor 4H11 had cores with a staining intensity of 5. The staining pattern was of cytoplasmic, luminal/membranous, or intraluminal for both OC125 and 4H11. The intraluminal pattern was strong and intense for both stains and highlighted the intracytoplasmic lumen that is commonly present in lobular carcinomas. The concordance rates were 34% concordant, 43% equivocal, and 23% discordant. Of the equivocal and discordant cases, there was none in which the OC125 was greater than the 4H11. All 42 discordant cases and 76 of 77 equivocal cases had 4H1I greater than OC125. There was also focal luminal staining with 4H11 in benign breast ducts and lobular carcinoma in situ.

C. Lung, pancreatic and prostatic adenocarcinomas Tumors from other organs were not reactive with either antibody. The lung adenocarcinoma TMA had 237 cores from 86 patients containing viable tumor. In the pancreatic TMA there were 92 cores from 21 patients containing pancreatic mucinous tumors, including intraductal papillary mucinous neoplasms (IPMN) and invasive ductal carcinomas. In the prostate cancer TMA there were 169 cores (number of patients not available). None of these cancer tissue microarrays had significant binding to either OC125 or 4H11. This information is summarized in Table 3.

Table 3. Staining intensity of OC125 as compared to 4H11 in tissue microarrays

OC125 vs. 4H11 staining intensity score(%) Site 0 1-2 3-5 OC125 4H11 OC125 4H11 OC125 4H11 Ovary high grade serous 10 28 24 22 66 56 Breast invasive ductal 68 78 32 18 0 4 Breast invasive lobular 94 27 3 45 3 27 Lung adenocarcinoma 63 77 24 18 13 5 Pancreas mucinous neoplasms 98 88 2 10 0 2 Prostate adenocarcinoma 0 0 0 0 0 0 Score 0: 0% staining; 1: <5% strong or weak; 2: 5-50% strong or weak; 3: 51-75% strong or 51-100% weak; 4: 76-99% strong; 5: 100% strong

D. Normal Tissues There was no staining with OC125 or 4H11 in normal adult colon, rectum, ectoccrvix, small intestine, ovary, liver, pancreatic ducts, spleen, kidney, and skin. OC125 and 4H11 both stained endocervical glands (OC125 luminal, 4H11 weak cytoplasmic), esophageal glands (luminal), bronchial epithelium (OC125 luminal, 4H11 intracytoplasmic granules), and thymic corpuscles (cytoplasmic). 41111 demonstrated weak to moderate staining of the gastric glands, particularly at the crypts, with an intracytoplasmic granular pattern. Other organs that showed punctuate intracytoplasmic staining with 41111 only were prostate, seminiferous tubules of the testes, and the islet cells of the pancreas. The staining in the pancreatic islets cells was particularly strong and D consistent. There was also nonspecific staining of liver, kidney and brain with 4H11. There were no cases that stained with OC125 and not 41111. Similarly, there was no staining with either OC125 or 4H11 in fetal heart, gallbladder, colon, small intestine, liver, rectum, adrenal, thyroid, spleen, skin, bone, epididymis, brain, lung, muscle, smooth muscle, kidney, eye, umbilical cord, and placenta. OC125 only stained thymic corpuscles in a pattern similar to that in adult tissue. 41111 stained both fetal pancreatic endocrine cells and endocervical glands in a similar pattern to that of their adult counterparts. Islet cells showed a granular cytoplasmic pattern, and endocervical glands showed a linear luminal pattern, which was more similar to the OC125 pattern in the adult tissue.

EXAMPLE4 Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Purpose: Most patients diagnosed with ovarian cancer will ultimately die from their disease. For this reason, novel approaches to the treatment of this malignancy are needed. Adoptive transfer of a patients own T cells, genetically modified ex vivo through the introduction of a gene encoding an chimeric antigen receptor (CAR), an artificial T cell receptor, targeted to a tumor associated antigen, is a novel and promising approach to cancer therapy applicable to the treatment of ovarian cancer. Experimental design: We have generated several CARs targeted to the retained extracellular domain of MUC16, termed MUC-CD, an antigen highly expressed on a majority of ovarian carcinomas. We investigate the in vitro biology of human T cells retrovirally transduced to express these CARs by co-culture assays on artificial antigen presenting cells (AAPCs) generated from NIH3T3 fibroblasts genetically modified to express the target MUC-CD antigen, as well as by cytotoxicity assays utilizing the human OV-CAR3(MUC-CD) ovarian tumor cell line and primary patient tumor cells. Finally, we assess the in vivo anti-tumor efficacy of MUC-CD targeted T cells in a SCID-Beige orthotopic, xenogeneic OV-CAR3(MUC-CD) murine tumor model. Exemplary sequences used in this work are in Figure 17-19. Results: CAR modified MUC-CD targeted T cells derived from both healthy donors and ovarian cancer patients exhibited efficient in vitro cytolytic activity against both human ovarian cell lines as well as primary ovarian carcinoma cells. MUC-CD targeted T cells maybe further expanded ex vivo through multiple cycles of co-culture on 3T3(MUC-CD/B7.1) AAPCs. Expanded MUC-CD targeted T cells infused into SCID-Beige mice bearing intraperitoneal human OV CAR3(MUC-CD) tumors either delayed progression or fully eradicated tumor even in the setting of advanced disease. Conclusion: These promising pre-clinical studies justify further investigation of MUC-CD targeted T cells as a potential therapeutic approach in the clinical setting treating patients with high risk MUC-16+ ovarian carcinomas.

INTRODUCTION Ovarian cancer is the sixth most common cancer worldwide and the seventh leading cause of cancer-related deaths in women (1, 2). Despite multimodality therapy with surgery and chemotherapy, most patients with ovarian carcinomas have a poor prognosis. For this reason, alternative approaches to treating this disease are urgently needed. Infusion of a patient's own T cells genetically targeted ex vivo to antigens expressed on the surface of tumor cells is a promising novel approach to the adoptive immunotherapy of cancer, and one which has only recently been explored in earnest in the clinical setting. T cells may be genetically modified to target tumor associated antigens through the retroviral introduction of genes encoding artificial T cell receptors termed chimeric antigen receptors (CARs). Genetic engineering of T cells to express artificial T cell receptors that direct cytotoxicity toward a tumor cell presents a means to enhance immune recognition and elimination of cancer cells. CARs are most commonly composed of a single chain fragment length antibody (scFv), derived from a marine monoclonal antibody targeting a given tumor associated antigen, fused to a transmembrane domain (typically CD8, CD28, OX-40, and 4-1BB), fused to the TCR ( chain cytoplasmic signaling domain (3-13). When used to reprogram T-cell specificity, these fusion receptors permit recognition of native antigen. When expressed by the T cells, the resulting construct, upon engagement with the targeted antigen, induces T cell activation, proliferation, and lysis of targeted cells. These fusion receptors transduce a functional antigen-dependent co-stimulatory signal in primary T cells, permitting sustained T-cell proliferation when both endogenous TCR and a chimeric receptor for stimulatory signaling are engaged. To date, preclinical studies utilizing CAR-modified T cells have demonstrated promising results in a wide variety of malignancies (3, 4, 11, 14-18). More recently this approach been investigated clinically in the form of phase I trials (6, 19-21). These genetic approaches offer a means to enhance immune recognition and elimination of cancer cells. Ovarian carcinomas appear to be relatively immunogenic tumors capable of inducing an endogenous immune response based on the fact that long-term prognosis of patients is markedly influenced by the degree and quality of the endogenous immune response to the tumor. Specifically, it has been well documented that the presence of endogenous effector T cells within the ovarian cancer tumor microenvironment directly correlates to prolonged patient survival (22 3 25). In contrast, increasing numbers of immune suppressive CD4+ CD25 regulatory T cells (Tregs) within the tumor, which in turn presumably abrogate the anti-tumor activity of infiltrating effector T cells, correlates with shorter patient survival (26-29). In fact, it appears that it is the ratio of Tregs to effector T cells within the tumor microenvironment which ultimately dictates whether the endogenous immune response to the cancer is of benefit or detriment to the patient (24, 28). In this setting, the ability to generate and subsequently expand a population of tumor targeted effector T cells ex vivo which are subsequently infused back into the patient, may in turn skew the Treg to effector T cell ratio to one more favorable to eradicating the disease. Mucins are important biomolecules for cellular homeostasis and protection of epithelial surfaces. Changes to expression of mucins in ovarian cancer might be exploited in diagnosis, prognosis and treatment (1). MUC16 is one such mucin which is over expressed on most ovarian carcinomas and is an established surrogate serum marker (CA-125) for the detection and progression of ovarian cancers (30-33). MUC16 is a high-glycosylated mucin composed of a large cleaved and released domain, termed CA-125, consisting of multiple repeat sequences, and a retained domain (MUC-CD) which includes a residual non-repeating extracellular fragment, a transmembrane domain, and a cytoplasmic tail (34). Since the antigen is otherwise only expressed at low levels in the uterus, endometrium, fallopian tubes, ovaries, and serosa of the abdominal and thoracic cavities, MUC16 is a potentially attractive target for immune-based therapies. However, the fact that most of the extracellular domain of MUC16 is cleaved and secreted limits the utility of MUC16 as a target antigen on ovarian carcinomas. In fact, to date, all reported MAbs to MUC16 bind to epitopes present on the large secreted CA-125 fraction of the glycoprotein, with none known to bind to the retained extra-cellular fraction (MUC-CD) of the antigen (35-37). Since the MUC-CD fraction of the antigen is retained on cell surface, generating T cells specific to this portion of MUC16 may largely overcome the limitation of MUC16 as a target for adoptive cellular immunotherapy. To this end, we have previously generated a series of murine

MAbs specific to the retained MIUC-CD extracellular domain (38). Utilizing a hybridoma which expresses one such MAb, 4H11, we have successfully constructed several CARs specific to the MUC-CD antigen. This invention provides a nucleic acid encoding a chimeric T cell receptor, composed of, at least a zeta chain, a signaling region and a binding element that specifically interacts with a selected target as well as the chimeric T cell receptor comprising a zeta chain portion, a signaling region and a binding element. In this report, we demonstrate highly efficient retroviral transduction of theseMIUC-CD targeted CARs into human T cells with resulting T cells able to specifically target and lyseIUC CD+ tumor cells in vitro. Furthermore, we demonstrate efficient MUC-CD targeted T cell D expansion in vitro through repeated co-culture on NIH (3T3) fibroblasts genetically modified to express MUC-CD and the co-stimulatory ligand B7.1 (CD80). Successful expansion of modified T cells allowed us to subsequently generate sufficient T cell numbers to conduct in vivo studies in immune compromised SCID-Beige mice bearing established intraperitoneal MUC-CD human ovarian tumors. Significantly, in these studies we demonstrate marked anti-tumor efficacy of MUC-CD targeted T cells, both following direct intraperitoneal as well as intravenous injection when compared to either untreated mice, or mice treated with T cells bearing a CAR targeted to an irrelevant antigen. In addition, we demonstrate significant cytotoxicity of 4H11-28z- patient's T cells and healthy donor's T cells targeting primary ascites-derived ovarian carcinoma cells from cancer patients. To our knowledge this is the first report wherein T cells genetically targeted to the MUC16 antigen demonstrate marked anti-tumor efficacy against MUC16+ tumors either in vitro or in vivo. These data serve as a rationale for proposing future clinical trials utilizing this approach in patients with high risk ovarian carcinomas.

MATERIALS AND METHODS Cell lines and T cells The OV-CAR3 tumor cell line was cultured in RPMI 1640 (Invitrogen, Grand Island, NY) supplemented with 10% heat-inactivated FBS, nonessential amino acids, HEPES buffer, pyruvate, and BME (Invitrogen). The PG13 and gpg29 retroviral producer cell lines were cultured in DMEM (Invitrogen) supplemented with 10% FCS, and NIH-3T3 artificial antigen-presenting cells (AAPC), described previously (3), were cultured in DMEM supplemented with 10% heat-inactivated donor calf serum. T cells were obtained from peripheral blood of healthy donors under IRB approved protocol #95-054, in BD Vacutainer CPT tubes (Becton Dickinson, Franklin Lakes, NJ) as per the manufacturers instructions. All media were supplemented with 2 mmol/L L-glutamine (Invitrogen),

100 units/mL penicillin, and 100 ptg/mL streptomycin (Invitrogen). T cells were cultured RPMI 1640 media as above supplemented with 20 IU/ml IL-2 (Novartis Pharmaceuticals, East Hanover, NJ) and where indicated, medium was supplemented with 10 ng/mL interleukin 15 (R&D Systems, Minneapolis, MN).

Isolation ofpatients ascites-derivedcancer cells Primary human ascites-derived cancer cells were obtained from ovarian cancer patients undergoing surgery for newly diagnosed advanced serous ovarian carcinoma under IRB approved protocol #97-134. The tumor cells were isolated from ascitic fluid of patients by centrifugation at 600g for 10 min at room temperature. Cells were washed once with 1x PBS and cultured in RPMI 1640 media supplemented with 10% FBS for future analysis.

Generation of the MUC-CD targeted4H11z and 4H11-28z CARs The heavy and light chain variable regions of the 4H11 monoclonal antibody were derived from the hybridoma cell line 4H11. Utilizing cDNA generated from 4H11 RNA we isolated the VH coding region by RACE PCR utilizing modified primers as described elsewhere (39, 40). The VL chain variable region was cloned by standard PCR utilizing modified primers as described by Orlandi et al (41, 42). The resulting VH and VL fragments were subeloned into the TopoTA PCR 2.1 cloning vector (Invitrogen) and sequenced. The VH and VL fragments were subsequently ligated to a (Gly4Ser) 3 spacer domain, generating the 4H11 scFv and fused to the human CD8 leader peptide (CD8L) by overlapping PCR (9, 41). In order to construct the MUC-CD targeted 4H11 CARs, the coding region of the CD8L-4H11 scFv was fused to the human CD8 hinge and transmembrane domains (to generate the 4H11z CAR), or alternatively to the CD28 transmembrane and cytoplasmic signaling domains (to generate the 4H11-28z CAR), fused to the T cell receptor CD3(-signaling domain (3, 9, 43). The resulting CAR constructs were subsequently sub-cloned into the modified MMLV retroviral vector SFG (44). VSV-G preudotyped retroviral supernatants derived from transduced gpg29 fibroblasts were used to construct stable PG13 gibbon ape leukemia virus (GaLV) envelope-pseudotyped retroviral producing cell lines (41).

Retroviralgene transfer Isolated healthy donor peripheral blood mononuclear cells (PBMCs) were activated with phytohemagglutinin (PHA) at 2pg/ml (Sigma. St. Louis, MO) and retrovirally transduced on retronectin coated non-tissue culture plates (45). Briefly, six-well non-tissue culture plates (BD Biosciences, San Jose, CA) were coated with RetroNectin (RN) (Takara Biomedicals, Otsu, Japan) as per manufacturer's instructions. Forty-eight hours after PHA activation, aliquots of 1x106 T cells in 1 ml of supplemented RPMI medium were placed in each well of the RN-coated plates, along with 1 ml of SFG retroviral supernatant. T cells were centrifuged daily for 3 consecutive days with fresh retroviral supernatant added daily at 2000g at 30°C for lhr (45). Gene transfer was assessed on day 7 by FACS. In order to generate the relevant NIH-3T3 murine fibroblast artificial antigen presenting cells, a MUC-CD construct encoding the retained extracellular, transmembrane and cytoplasmic domains of the MUC-16 antigen was initially subeloned into SFG retroviral vector, SFG(MUC CD). 3T3(MUC-CD) AAPCs were generated by retroviral transduction of SFG(MUC-CD) into D wild-type NIH-3T3 fibroblasts, while 3T3(MUC-CD/B7.1) AAPCs were generated by retroviral transduction of previously established 3T3(B7.1) fibroblasts (41, 46). Highly enriched cell lines were isolated by FACS. To generate the OV-CAR3(MIUC-CD) and OV-CAR3(MUC-CD/GFP-FFLue) cell lines, we retrovirally transduced the WT OV-CAR3 human ovarian cancer cell line with SFG(GFP FFLuc) as described previously (47) and/or SFG(MUC-CD) VSV-G pseudotyped retroviral supernatants derived from gpg29 fibroblasts as described elsewhere (44). Resulting tumor cells were sorted by FACS for either MUC-CD expression alone for the OVCAR3(MUC-CD) cell line, or dual MUC-CD and GFP expression for the OVCAR3(MUC-CD/GFP-FFLue) cell line. MUC CD expression by FACS was assessed using the 4H11 MAb.

In vitro analyses of CAR+ human T cells To assess in vitro expansion and cytokine release upon stimulation, transduced T cells were co-cultured for 7 days after retroviral transduction in 6-well tissue culture plates (BD Biosciences) on confluent NIH 3T3 AAPCs in RPMI medium supplemented with 10% FBS in the absence of supplemented cytokines. In order to generate sufficient numbers of CAR-modified T cells for in vivo studies, transduced T cells were co-cultured on B7.1+ AAPCs (3T3(MUC-CD/B7.1)) in RPMI medium supplemented with 20 IU IL-2/mL and 10 ng/mL IL-15 as described previously (3, 43). Patients T cells were activated and expanded with human CD3/CD28 beads (DYNAL@, Invitrogen, Carlsbad, CA) following manufacturer's recommendations.

Western Blot analysis of CAR expression Western blot analysis of T-cell lysates under reducing conditions with 0.1 mol/L DTT (Sigma) was performed as previously described (46). Briefly, transduced T cells were washed in PBS and resuspended in radioimmunoprecipitation assay (RIPA) buffer (Boston BioProducts,

Worcester, MA) with mini complete protease inhibitor as per the manufacturer's instructions (Roche Diagnostics, Indianapolis, IN). Resulting proteins were separated on 12% SDS-PAGE mini gels (Bio-Rad, Hercules, CA) after the addition of 6X reducing loading buffer (Boston BioProducts, Worcester, MA) and heating at 100°C for 10 min. Separated proteins were

subsequently transferred to Immobilon membranes and probed using an anti-human CD3( chain monoclonal antibody (BD Biosciences). Antibody binding was detected by probing the blot with goat anti-mouse horse radish peroxidase-conjugated antibody followed by luminescent detection using Western Lighting Chemiluminescence Reagent Plus (Perkin-Elmer Life Sciences, Boston, MA) as per the manufacturer's instructions. D Cytotoxicity assays In vitro modified T cell cytotoxicity was assessed using the DELFIA@ EuTDA assay (PerkinElmer LAS, Inc, Boston, MA) following manufacturer's recommendations. Cytotoxocity was assessed at 2 hours at effector T cell to target OV-CAR3(MUC-CD) or primary tumor cells (E:T) at indicated ratios. Effector T cells in these assays represent the number of CD8* CAR+ T cells.

Cytokine detection assays Cytokine assays were performed as per manufacturer's specifications using a multiplex Human Cytokine Detection assay to detect IL-2 and IFN (Millipore Corporation, Billerica, MA) utilizing the Luminex IS100 system. Cytokine concentrations were assessed using IS 2.3 software (Luminex Corp., Austin, TX).

In vivo SCID-Beige mouse tumor models In all in vivo studies, 8-12 week-old FOX CHASE C.B.-17 (SCID-Beige mice) (Taconic, Hudson, NY) were initially injected ip with either 3 x 106 OV-CAR3(MUC-CD), or for bioluminescent imaging (BLI) studies 3 x 106 OV-CAR3(MUC-CD/GFP-FFLuc) tumor cells. Subsequently, 3x107 CAR+ T cells were injected ip or iv on day 1 or 7 following tumor injection as indicated. Mice were monitored for distress as assessed by increasing abdominal girth, ruffled fur, and decreased response to stimuli. Distressed mice were euthanized. All murine studies were done in context of an Institutional Animal Care and Use Committee-approved protocol (#00-05-065).

Bioluminescent imaging (BLI) ofOVCAR3(MUC-CD/GFP-FFLuc)tumor cells in SCID Beige mice

BLI was performed using Xenogen IVIS imaging system with Living Image software (Xenogen; Alameda, CA). Briefly, OVCAR3(MUC-CD/GFP-FFLuc) tumor bearing mice were injected by ip with D-luciferin (150 mg/kg; Xenogen) suspended in 200 1 PBS and imaged under 2% isoflurane anesthesia after 10 min. Image acquisition was done on a 25-cm field of view at medium binning level for 0.5-min exposure time (3, 43).

Flow cytometry All flow cytometric analyses of T cells and tumor cells was performed using a FACScan cytometer with Cellquest software (BD Biosciences). T cells were analyzed using CAR-specific D polyclonal goat Alexa Fluor 647 antibody (Molecular probes, Eugene, OR) phycoerythrin-labeled anti-human CD4, CD8, B7.1 (Caltag Laboratories, Burlingame, CA), B7.2 (Invitrogen, Camarillo, CA), 4-1BBL, and OX40 antibodies (Ancell Corporation, Bayport, MN). 3T3(MUC-CD) and OV CAR3(MUC-CD) cells were stained with Alexa Fluor 647 labeled 4H11 antibody (generated and labeled in the MSKCC monoclonal antibody core facility).

CFSE labelingof CAR+ T cells CAR T cells were stained with CFSE using the CellTrace CFSF cell proliferation kit following manufacturer's recommendations (Molecular Probes, Eugene, OR). Proliferation of CFSE labeled T cells was analyzed by FACS. For detection of CFSE labeling T cells in vivo, ovarian tumors were macerated through 40 pm cell strainer (BD Falcon, Franklin Lakes, NJ) and washed twice with 2% FBS/PBS before antibody staining and FACS analysis.

Statistics Survival data assessed by log-rank analysis using GraphPad Prism software (GraphPad Prism software, San Diego, CA). Cytokine data were analyzed by Student's one-tailed t-test.

RESULTS We have constructed SFG retroviral vectors encoding first (4H1lz) and second generation (4H11-28z) CARs targeted to the MUC-CD antigen using the 4H11 hybridoma which generates a MAb specific to the MUC-CD antigen (Figure 11A). We confirmed expression of appropriately sized CAR proteins by Western blot analysis of resulting PG-13 retroviral producer cells (SFG 4H1lz and SFG-4H11-28z) probed with a (-chain specific antibody (data not shown). In order to assess the function of the first generation 4H11z CAR, healthy donor T cells isolated from peripheral blood were retrovirally transduced to express the 4H11z and control 19z1

CARs (Figure 1IB). Function of the 4H1lz CAR was assessed by proliferation of 4H11z transduced T cells following co-culture on 3T3(MUC-CD/B7.1) AAPCs. Results demonstrate specific proliferation of 4H1lz transduced T cells, when compared to 19z1 modified T cells (Figure 11C). These data are consistent 4H11z CAR mediated specific binding to theMIJC-CD antigen and subsequent T cell activation. Since most malignancies fail to express co-stimulatory ligands, we further modified the 4H11z CAR to express the CD28 transmembrane and cytoplasmic co-stimulatory signaling domains, constructing the second generation 4H11-28z CAR (Figure 11A). To assess whether the 4H11-28z CAR, when expressed by human T cells, was capable of generating both a primary activating signal termedd "signal 1") through the ( chain, as well as a co-stimulatory signal (termed "signal 2") through the CD28 cytoplasmic domain, which in turn allows for efficient T cell proliferation in the absence of exogenous co-stimulatory ligands, we compared T cell proliferation following co-culture on either 3T3(MUC-CD) or 3T3(MUC-CD/B7.1) AAPCs in the absence of exogenous cytokines. As expected, the second generation 4H11-28z+ T cells markedly expanded when compared to 4H11z+ T cells upon co-culture with 3T3(MUC-CD) AAPCs. In contrast, both 4H11z +and 4H11-28z+ T cells expanded similarly on 3T3(MUC-CD/B7.1) AAPCs (Figure 12A). Co-stimulation mediated by the 4H11-28z CAR was further verified by analysis of day 2 tissue culture supernatants from co-culture experiments on 3T3(MUC-CD) AAPCs demonstrating enhanced IL-2 secretion, a cytokine typically secreted in the context of T cell co-stimulation, when compared to control 19zl +and 19-28z+ T cells and first generation 4H11z+ T cells (Figure 12B). Secretion of IFNy was comparable between 4H11z +and 4H11-28z+ activated T cells. We next assessed the ability of MUC-CD targeted T cells to expand following weekly re stimulations through co-culture on 3T3(MUC-CD/B7.1) AAPCs in the context of exogenous IL-2 andIL-15(3). Both 4H1lz+ and 4H11-28z* T cells expanded greater than 2 logs over 3 weeks (Figure 12C). T cells transduced with the 4H11-28z were further analyzed by FACS for CAR expression 7 days after initial activation on AAPCs and following two subsequent co-stimulations on AAPCs demonstrating an expected enrichment of the CAR- T cell fraction (Figure 12D). Similar data was generated with expanded 4H11z T cells (data not shown).

In vitro cytotoxicity andproliferationofMUC-CD targeted T cellsfollowing co-culture with OV-CAR3(MUC-CD) andfreshly isolatedascites derived ovarian tumor cells. In order to assess the ability of 4H11z+ and 4H11-28z+ T cells to target and lyse human ovarian carcinoma tumors, we utilized the human OV-CAR3 cell line which was genetically modified to express the MUC-CD antigen thereby better reflecting the majority of clinical ovarian tumor samples which express the 4H11-targeted MUC-CD antigen (48). We initially verified specific lysis by MUC-CD targeted T cells demonstrating similar significant cytotoxic activity of 4H1lz and 4H11-28z CAR modified T cells targeting OV-CAR3(MUC-CD) tumor cells when compared control T cells expressing the irrelevant first and second generation CD19-targeted 19z and 1928z CARs (Figure 13A). Healthy donor T cells modified to express the 4H11-28z CAR similarly exhibited lysis of freshly isolated ascites derived MUC-CD t ovarian carcinoma cells when compared to 19-28z transduced T cells (Figure 13B). Moreover, patient's peripheral blood T cells modified to express the 4H11-28z CAR similarly lysed autologous primary MUC-CD+ tumor cells derived from the same ascites sample when compared to T cells modified to express the D control 19-28z CAR (Figure 13C). We further assessed the ability of 4H11z+ and 4H11-28z+ T cells from healthy donors to proliferate following co-culture on OV-CAR3(MUC-CD) as assessed by FACS of CFSE labeled T cells, as well as absolute T cells numbers over 7 days following co-culture with tumor (Figures 13D andE). Surprisingly, we found that both 4H1lz+ and 4H11-28z+ T cells expanded equally well following co-culture with OV-CAR3(MUC-CD) tumor cells suggesting the ability of this tumor cell line to co-stimulate T cells through expression of a co-stimulatory ligand. To address this possibility, we conducted further FACS analyses of OV-CAR3(MUC-CD) tumor cells demonstrating expression of the co-stimulatory 4-1BBL ligand (Figure 13F), but not the B7.1, B7.2, or OX-40L co-stimulatory ligands (data not shown).

In vivo anti-tumor activity ofMUC-CD targetedT cells in SCID-Beige mice. To assess the in vivo anti-tumor activity of 4H ll z* and 4H11-28z* T cells, we next generated an orthotopic xenotransplant ovarian cancer tumor model by ip injection of OV CAR3(MUC-CD) tumor cells into SCID-Beige mice. If left untreated, these mice developed marked ascites and multiple nodular peritoneal tumors by 3 weeks following tumor cell injection (Figure 14A). All untreated tumor bearing mice had to be euthanized by 7 weeks following tumor cell injection due to evidence of distress. To assess the in vivo anti-tumor efficacy of MUC-CD-targeted T cells, SCID-Beige mice were injected ip with OV-CAR3(MUC-CD/GFP-FFLue) tumor cells on day 1 followed by ip injection of 4H11z or 4H11-28z+ T cells on day 2. For negative controls, tumor bearing mice were either untreated or treated with T cells modified to express the irrelevant CD19-targeted CAR. Collectively, we found that 27% of all mice treated with MUC-CD targeted T cells (3/11 mice) remained alive without clinical evidence of disease 120 days out from tumor injection with no statistically significant difference in survival when comparing the 4H11z* and 4H1-28z+ T cell treated cohorts (Figure 14B). In contrast, both MUC-CD-targeted T cell treated cohorts demonstrated statistically significant enhanced survival when compared to untreated and 19zl T cell treated control cohorts. To assess whether systemically infused MUC-CD-targeted T cells successfully traffic to ip tumors, we next compared ip to iv infusion of 4H11-28z+ T cells in SCID-Beige mice bearing ip OV-CAR3(MUC-CD/GFP-FFLuc) tumors. Both ip and iv 4H11-28z+ T cell treated mice exhibited statistically enhanced survival when compared to untreated or 19-28z+ T cell treated control cohorts as assessed by overall survival (Figure 15A) as well as by BLI of tumor progression (Figure 15B). Furthermore, we found overall survival between the ip and iv treated groups to be statistically D equivalent by log rank analysis. These data imply successful trafficking of iv infused 4H11-28z* T cells to peritoneal tumors. We further confirmed trafficking of iv infused CFSE labeled 4H11-28z+ T cells to the peritoneum by FACS analysis of single cell suspensions of macerated OV CAR3(MUC-CD) tumors (Figure 15C).

In vivo anti-tumor activity ofMUC-CD targetedT cells in SCID-Beige mice bearing well establishedOV-CAR3(MUC-CD/GFP-FFLuc)tumors. To further assess whether 4H11-28z+ T cells were able to eradicate more clinically relevant tumor burdens, we next treated SCID-Beige mice bearing well established ip OV-CAR3(MUC CD/GFP-FFLuc) tumor injected 7 days prior to adoptive T cell therapy. Once more, we found that therapy with MUC-CD targeted T cells markedly eradicated BLI evident disease in all treated mice (Figure 16A) with 5 of 8 treated mice eventually developing relapsed progressive disease, and 3 mice remaining disease free as assessed by BLI imaging (not shown) out to 120 days post-tumor cell infusion (Figure 16B). These data demonstrate potent in vivo anti-tumor activity mediated by MUC-CD targeted T cells even in the setting of advanced disease.

DISCUSSION Based on extensive analyses of patient tumor samples, ovarian carcinomas appear to be relatively immunogenic tumors. Specifically, researchers have found there to be a direct correlation between prognosis following surgery and chemotherapy and the quantity of tumor infiltrating effector T cells (TILs) in pretreatment tumor samples (25, 49, 50). Furthermore, others have described an inverse correlation between prognosis following therapy and pre-treatment levels of Tregs within the tumor, which in turn presumably inhibit the anti-tumor function of tumor specific effector TILs (26, 28, 51). Both of these findings imply a role for an endogenous effector T cell response to tumor in controlling disease progression both prior to and following initial therapy and strongly support the contention that ovarian carcinomas may be susceptible to killing by adoptive infusion of autologous T cells targeted to ovarian tumor cell antigens. While endogenous effector TILs are one source for presumably tumor specific T cells, an alternative approach to adoptive T cell therapy is to isolate autologous peripheral blood T cells which in turn may be genetically modified ex vivo to target tumor cell antigens. One such genetic approach is to retrovirally transduce patient T cells with CARs targeted to surface exposed antigens either unique to or over-expressed by the tumor. To this end, promising preclinical studies utilizing this approach in other malignancies have recently been translated into the clinical setting (6, 16, 19, 52). Similarly, we have previously generated CARs targeted to the CD19 antigen expressed on normal B cells as well as most B cell malignancies and are currently conducting clinical trials treating patients with relapsed B cell chronic lymphocytic leukemia and acute lymphoblastic leukemias with autologous T cell modified to express a CD19 specific CAR (53). Application of this approach to ovarian carcinomas requires the identification to suitable target antigens expressed on the tumor cell surface. Significantly, other investigators have studied this approach in both the pre-clinical and clinical setting (4, 11, 54-57). Specifically, several groups have demonstrated significant anti-tumor responses to subcutaneous human ovarian carcinoma cell line tumors in immune compromised mice following intratumoral and/or intravenous infusion of T cells expressing CARs specific to the mesothelin and Lewis-Y antigens overexpressed on these tumor cell lines (56, 58, 59). Furthermore, Kershaw et al recently published the results of a phase I clinical trial treating patients with relapsed ovarian carcinomas with autologous T cells modified to express a CAR specific to the alpha-folate receptor (6). The authors of this study found that therapy with targeted T cells was well tolerated, but noted a lack of anti-tumor response in these studies related to poor persistence of modified T cells over time as well as a yet undefined T cell inhibitory factor in the serum of several treated patients. Z5 In our studies, we have chosen to target theMUC-16 glycoprotein which is over-expressed on a majority of ovarian carcinomas (1, 30, 32, 33). The utility of MUC-16 as a target antigen for adoptive T cell therapy is compromised by the fact that most of the extracellular portion of this molecule is cleaved by the tumor cell, secreted, and may be detected in the serum as the CA-125 tumormarker. However, following cleavage of this secreted fraction of MUC-16, there remains a residual extracellular fraction of the glycoprotein, termed MUC-CD, which is retained on the tumor surface and is therefore an attractive target for immune-based therapies. To this end, we utilized a series of murine hybridomas generated to the MUC-CD antigen to construct CARs specific to MUC-CD. Of these CARs, we identified a CAR generated from the 4H11 murine hybridoma termed 4H11lz, which, when expressed in human T cells, following co-culture on 3T3(MUC

CD/B7.1) AAPCs, resulted in rapid destruction of AAPC monolayers as well as marked modified T cell expansion. Significantly, the antigen to the 4H11 antibody is highly expressed on a majority of pre-treatment ovarian carcinoma surgical tumor samples obtained from patients treated at our institution as assessed by immuno-histochemistry (48). Optimal T cell activation requires both a primary T cell receptor mediated signal, "signal 1," along with a co-stimulatory "signal 2." Classically, this co-stimulatory signal may be provided by ligation of either B7.1 (CD80) or B7.2 (CD86) on the target cell with the T cell co-stimulatory receptorCD28. Alternatively, co-stimulation maybe generated by ligation of 4-BBL or OX-40L on the target cell with the respective 4-1BB or OX40 co-stimulatory receptors on the T cell (12, 60, 61). Since most tumor cells fail to express co-stimulatory ligands, we and others have previously demonstrated that second generation CARs further incorporating the cytoplasmic signaling domains the co-stimulatory receptors CD28, 4-1BB, and/or OX40 resulted in CARs capable of providing both signal 1 and signal 2 to the T cell upon binding to cognate antigen in the absence of exogenous co-stimulatory ligands (7-10, 12, 13, 15, 16, 62-65). To this end, we constructed a second generation CAR from the 4H11z CAR incorporating the transmembrane and cytoplasmic signaling domain of CD28 as described elsewhere (3, 9, 43). Consistent with previous studies, we found that T cells transduced to express the resulting 4H11-28z CAR, but not the first generation 4H11z CAR, efficiently expanded upon co-culture with 3T3(MUC-CD) fibroblasts in the absence of exogenous co-stimulation consistent with the ability of the 4H11-28z CAR to deliver both signal 1 and signal 2 to the T cell. This conclusion is further supported by the finding that 4H11-28z T cells secreted significantly higher levels of IL-2, a cytokine indicative of T cell co-stimulation, upon co-culture on 3T3(MC-CD) fibroblasts when compared to T cells transduced to express the first generation 4H11z CAR. We next assessed the ability of 4H11z+ and 4H11-28z+ T cells to target and lyse human ovarian carcinoma tumor cells. To this end, we initially utilized the OV-CAR3 human ovarian cancer cell line. Since the OV-CAR3 tumor cell line binds the 4H11 antibody weakly, we further genetically modified the cell line to express MUC-CD (OV-CAR3(MUC-CD)) to better mimic the clinical setting wherein a majority of clinical ovarian carcinoma tumor specimens highly express the 4H11 MUC-CD antigen (48). We demonstrated that human T cells modified to express either 4H11z or 4H11-28z eradicated OV-CAR3(MVUC-CD) tumor cells in vitro, and surprisingly observed that both 4H11Iz and 4H111-28z+ T cells expanded following co-culture with tumor in vitro. To define the etiology of this unanticipated 4H11iz T cell expansion, we further assessed whether OV-CAR3(MUC-CD) tumor cells expressed co-stimulatory ligands, and found that this tumor cell line expressed 4-1BBL, consistent with our experimental findings as well as with previously published reports demonstrating 4-1BBL expression by a variety of carcinoma cell lines (66-68). In order to further validate the clinical relevance of these findings, we subsequently demonstrated specific in vitro lysis of primary ascites-derived tumor cells isolated from untreated ovarian carcinoma patients by both healthy donor allogeneic 4H11-28z+ T cells as well as more significantly autologous 4H11-28z* patient peripheral blood T cells. These data strongly support the contention that treatment with autologous 4H11-based CAR+ T cells have promise in future clinical applications. In order to assess the in vivo relevance of our in vitro findings, we next generated a murine orthotopic OV-CAR3(MUC-CD) tumor model in SCID-Beige mice. We injected mice i.p. with D OV-CAR3(MUC-CD) tumor cells and the following day infused 4H11z+, 4H11-28z+, and control 19zl+ T cells i.p. This treatment approach resulted in a significant but similar delay to tumor progression and long-term survival in both the 4H11z+ and 4H11-28z+ T cell treated cohorts when compared to untreated mice or mice treated with control T cells targeted to the irrelevant CD19 antigen. We next compared ip to iv treatment with 4H11-28z+ T cells of orthotopic OV CAR3(MUC-CD/GFP-FFLuc) bearing mice, and found similar statistically significant survivals of mice over time with either direct ip infusion of T cells or systemic iv infusion of targeted T cells. Significantly, iv treated mice by day 1 following treatment, exhibited successful trafficking of targeted T cells to the peritoneum. These data suggests that adoptive therapy with targeted T cells may be equally efficacious following either a direct infusion into the peritoneum or through systemic iv infusion. These findings further support the future clinical potential of this approach in treating patients both with local relapse of disease as well as metastatic relapse to sites outside of the peritoneum. Finally, we assessed the ability of 4H11-28z T cells to eradicate more established disease by delaying modified T cell ip infusion by 7 days, when mice had greater established tumor burdens as assessed by bioluminescent imaging. This experimental setting better reflects the initial clinical setting wherein this adoptive T cell approach would be utilized. Significantly, despite the setting of markedly established disease, 4H11-28z+ T cells retained the ability to lyse larger tumor burdens, delay relapse of tumor, and in a significant percentage of mice, fully eradicate disease. In the studies presented here, we have consistently utilized mixed populations of CD4+ and CD8 +CAR+ T cells to assess both in vitro and in vivo anti-tumor activity. To this end, ongoing studies will address the role of isolated CD4+ and CD8+ CAR+ T cell subsets in the successful eradication of disease in this SCID-Beige OV-CAR3(MUC-CD) tumor model. The results of these studies may have implications to translating this therapeutic approach to the clinical setting. Furthermore, we acknowledge the limitations associated with the presented SCID-Beige tumor model. Namely, this is a xenotransplant model in an immune compromised mouse. To this end, ongoing studies in or laboratory are focused on generating a more clinically relevant syngeneic immune competent tumor model to better define the biology and anti-tumor efficacy of MUC-CD targeted CAR-modified T cells in the context of an intact immune system. In conclusion, herein we present the first published data demonstrating the feasibility of targeting MUC-16, an antigen over-expressed on a majority of ovarian carcinomas, through adoptive therapy with genetically modified T cells targeted to the retained MUC-CD portion of the MUC-16 antigen. Further, this report is the first to demonstrate efficient targeting of T cells in an orthotopic, clinically relevant, murine model of ovarian cancer, demonstrating efficacy both by ip 3 and iv infusion of modified T cells. Finally, these data support the further translation of this approach to the clinical setting in the form of a phase I clinical trial in patients with persistent or relapsed ovarian carcinomas following initial therapy with surgery and chemotherapy. n]

EXAMPLE 5 Raising Mouse MUC16 monoclonal antibodies in mice and hamsters. We selected 3 different regions of mouse MUC16 genome for which monoclonal antibodies were generated in mouse and hamster. The selected regions of the mouse MUC16 are Peptide 1 (SEQ ID NO:21, ecto region of cytoplasmic domain), Peptide 2 (SEQ ID NO:22, first cysteine loop) and Peptide 3 (SEQ ID NO:23, second cysteine loop) (Figure 20A) and its comparison with human MUC16 is shown in Figure 20B. A cysteine was added to the peptide sequence at the N terminus of Peptide 1 (SEQ ID NO:21) and Peptide 3 (SEQ ID NO:23) for better conjugation with KLH. Individual peptides were conjugated to KLH using Promega kit. These 3 conjugated peptides were pooled and immunized into 5 mice and 4 hamsters. 5 immunizations with a 3 week interval for each immunization were administered. Sera from these animals were tested by ELISA for their specific reactivity with individual peptides (SEQ ID NO:21, 22 and 23). Positive selected animals were allowed to rest for a month and then i.v. boosted with pooled peptides immunogen (SEQ ID NO:21, 22 and 23) and harvested the spleens after 4 days. Splenocytes were mixed with hybridoma partners and plated into microtiter plates at various clonal densities. Plates were cultured at 37C 5% CO 2 for 10 days and then selected the clones. Supernatants from these selected clones were tested by ELISA for their specific reactivity with individual peptides (SEQ ID NO:21, 22 and 23). Positive clonal sups were tested by FACS, western blot and imaging using 2 mouse cell lines (ID8 and BR5-FVB1) and a human cell line (OVCAR-3).

Table 4 shows the summary of mouse and hamster monoclonal antibodies against mouse MUC16 peptide antigens Peptide 1 (SEQ ID NO:21), Peptide 2 (SEQ ID NO:22), and Peptide 3 (SEQ ID NO:23). A very strong antigenic response was seen with Peptide 1 (SEQ ID NO:21).

Table 4 Mouse Mouse MUC16 mAbs Frozen Mouse mAb 16 (3-IgGI; 8-IgG2b; 1 Peptide 1 46 IgM; 4-Unkown isotype) Animals not iv boosted with Peptide 2 0 0 peptide 2 Peptide 3 6 6 (4-IgGI; 2-IgM)

Peptide 1,2,3 0 0 Peptide 1,2 0 0 Peptide 2,3 0 0

No Peptide 0 0

Mouse Hamster MUC16 mAbs Frozen Hamster mAb Peptide 1 69 21 Peptide 2 6 6 Peptide 3 7 7

Peptide 1,2,3 2 1 Peptide 1,2 1 1 Peptide 2,3 1 0

No Peptide 10 2

Details of mouse and hamster mAbs against Peptide 1 (SEQ ID NO:21), Peptide 2 (SEQ ID NO:22), and Peptide 3 (SEQ ID NO:23 are listed in Table 5 and Table 6 respectively.

Table 5:

isotype i Fusion Cloned Clones Well

- 1 ODO1 - 1 09F07

IgG1 1 16A09 no success - 1 21A07 - 1 24G10 IgG 1 10C04 yes 10C4-3H5 10C4-1F2 10C4-2H8 10C4-1G7 IgG 1 17F02 yes 17F2-3G5 17F2-3F6 17F2-2F9 17F2-1E11 IgG 2b 1 01A08 IgG 2b 1 01F08 IgG 1 12B10 yes 12B1O-3F7 12B10-3G10 12B10-2F6 12B10-2F10 IgG 2b 1 17H10 IgG 2b 1 18D05 IgG 2b 1 23B12

b 1 25E09 25E9-3 25E9-5 25E9-13 25E9-16 IgM 1 16F12 IgG I 04A06 no success 05D01 success IgG1 21B08 yes 21B8-IHII 21B8-3G6 21B8-3H9 21B8-1G8 IgG 21E01 yes 21El-1E3 21El-1G9 21El-2G7 21E1-3G12 08A02 17313 1E05

Table 6: Hamster -mAb --I-,- Peptide Cloned OIH03 02F02 1 0l4 04G07 1 (14,1101 3 411b2E1 4111-2E3 4H1-3E1 4H1-3H3 06A08 1 06F02 1 07F08 3 0711,05 2

09E1t 3 09F08 1

01110 1

1A8 I 15A8- 1A-E 15A8- 15A8-3D2 2E2 1A2E0 2E11 151108 3 19B05 1 211104 3 ~22B5 2 22B5- 22B5-3G9 22B5- 22B5-3F11 1F6 2G8 ___________

22DII 3 23G12 1 25E 8 1 271109 3 28B12 1&2&3 28C1 2 2 301102 1I_____ ____________

31AI1 2 31C01 2 331106 1&2 34FIO 1 34110 5 1 36COI 1 36C11 36E 4 1 37LE10 1 101111 1I ____________________________

Hamster antibody 22B05 recognizes mouse (SEQ ID NO:22) and also the corresponding human sequence (SEQ ID NO:15). Western blot analysis using mouse ID8 and BR5-FVB1 cell extracts were also performed for all the selected monoclonal antibodies as shown in Figure 21 and Figure 22 respectively. Among the mouse MUC16 monoclonal antibodies, we selected 12B10-3G10 subelone mouse mAb for further screening. Similarly, hamster monoclonal antibodies, 15A8-2E10, 22B5 2G8 and 4H1-2E1 subclones were selected for further screening. Immunohistochemical analysis was performed with paraffin and cryosections of ID8 (mouse), OVCAR-3 (human), BR5-FVB1 (mouse) cell lines and 13.5 days of Embryo. Paraffin or cryosections were probed with mouse 12B10 mAb, hamster 15A8, hamster 22B5 and hamster 4E1 mAbs to see the early development of mouse MUC16 (Figure 23) 12B10-3G10 sub clone were further analyzed for single chain Fv fragments. Figure24 shows 12B10-3G10 VH and VL DNA and Amino Acids sequences. Bioreactive supernatants and purified 12B10-3G10 were generated for animal studies and other characterization studies. FACS analysis was performed with purified 12B10-3G10 on ID8, OVCAR3 and BR5-FVB1 cells showing over 90% positivity to both mouse and human MUC16 ecto-domain fragment (Figure 25).

REFERENCES CITED IN THE SPECIFICATION AND EXAMPLES 1-3 1. Bast RC, Jr., Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68(5):1331-7. 2. Bast RC, Jr., Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309(15):883-7. 3. Rustin GJ, Bast RC, Jr., Kelloff GJ, Barrett JC, Carter SK, Nisen PD, et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 2004;10(l1):3919-26. 4. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005;99(2):267 77. 5. Bast RC, Jr., Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005;15 Suppl 3:274-81. 6. Moore RG, Maclaughlan S, Bast RC, Jr. Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecol Oncol 2009.

7. Nustad K, Lebedin Y, Lloyd KO, Shigemasa K, de Bruijn HW, Jansson B, et al. Epitopes on CA 125 from cervical mucus and ascites fluid and characterization of six new antibodies. Third report from the ISOBM TD- workshop. Tumour Biol 2002;23(5):303-14. 8. Fendrick JL, Konishi I, Geary SM, Parmley TH, Quirk JG, Jr., O'Brien TJ. CA125 phosphorylation is associated with its secretion from the WISH human amnion cell line. Tumour Biol 1997;18(5):278-89. 9. Fendrick JL, Staley KA, Gee MK, McDougald SR, Quirk JG, Jr., O'Brien TJ. Characterization of CA 125 synthesized by the human epithelial amnion WISH cell line. Tumour Biol 1993;14(5):310-8. 10. O'Brien TJ, Beard JB, Underwood LJ, Shigemasa K. The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumour Biol 2002;23(3):154-69. 11. Yin BW, Dnistrian A, Lloyd KO. Ovarian cancer antigen CAl25 is encoded by the MUC16 mucin gene. Int J Cancer 2002;98(5):737-40. 12. Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001;276(29):27371-5. 13. Hollingsworth M, Swanson B. Mucins in Cancer: protection and control of the cell surface. Nature Rviews: Cancer 2004;4(1):45-60. 14. Huang L, Ren J, Chen D, Li Y, Kharbanda S, Kufe D. MUC cytoplasmic domain coactivates Wnt target gene transcription and confers transformation. Cancer Biol Ther 2003;2(6):702-6. 15. Li Q, Ren J, Kufe D. Interaction of human MUC1 and beta-catenin is regulated by Lck and ZAP-70 in activated Jurkat T cells. Biochem Biophys Res Commun 2004;315(2):471-6. 16. Ren J, Agata N, Chen D, Li Y, Yu WH, Huang L, et al. Human MUC carcinoma associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 2004;5(2):163-75. 17. Ren J, Bharti A, Raina D, Chen W, Ahmad R, Kufe D. MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90. Oncogene 2006;25(1):20-31. 18. Ramsauer VP, Pino V, Farooq A, Carothers Carraway CA, Salas PJ, Carraway KL. Muc4 ErbB2 Complex Formation and Signaling in Polarized CACO-2 Epithelial Cells Indicate That Muc4 Acts as an Unorthodox Ligand for ErbB2. Mol Biol Cell 2006. 19. Bafna S, Singh AP, Moniaux N, Eudy JD, Meza JL, Batra SK. MUC4, a multifunctional transmembrane glycoprotein, induces oncogenic transformation of NIH3T3 mouse fibroblast cells. Cancer Res 2008;68(22):9231-8.

20. Ponnusamy MP, Singh AP, Jain M, Chakraborty S, Moniaux N, Batra SK. MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cells. Br J Cancer 2008;99(3):520-6. 21. Nap M, Vitali A, Nustad K, Bast RC, Jr., O'Brien TJ, Nilsson 0, et al. Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2nd report from the ISOBM TD-1 Workshop. Tumour Biol 1996;17(6):325-31. 22. Markwell MA, Fox CF. Surface - specific iodination of membrane proteins of viruses and eucarytic cells using 1,3,4, 6-tetrachloro-3alpha,6alpha-diphenylglycouril. Biochemistry 1978;17:4807-4817. 23. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4(7):844 7. 24. Hedvat CV, Hegde A, Chaganti RS, Chen B, Qin J, Filippa DA, et al. Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol 2002;33(10):968-74. 25. Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol 2008;27(2):161-74. 26. O'Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biol 2001;22(6):348-66. 27. Harris M, Howell A, Chrissohou M, Swindell RI, Hudson M, Sellwood RA. A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. Br J Cancer 1984;50(1):23-30. 28. Kaneko 0, Gong L, Zhang J, Hansen JK, Hassan R, Lee B, et al. A binding domain on mesothelin for CA125/MUC16. J Biol Chem 2009;284(6):3739-49.

REFERENCES CITED IN EXAMPLE 4

1. Singh AP, Senapati S, Ponnusamy MP, et al. Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. Lancet Oncol 2008;9(11):1076-85. 2. Sun CC, Ramirez PT, Bodurka DC. Quality of life for patients with epithelial ovarian cancer. Nat Clin Pract Oncol 2007;4(1):18-29. 3. Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 2003;9(3):279-86.

4. Hwu P, Yang JC, Cowherd R, et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 1995;55(15):3369-73. 5. Imai C, Mihara K, Andreansky M, et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004;18(4):676-84. 6. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006;12(20 Pt 1):6106-15. 7. Kochenderfer JN, Feldman SA, Zhao Y, et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother 2009;32(7):689-702. 8. Loskog A, Giandomenico V, Rossig C, Pule M, Dotti G, Brenner MK. Addition of the D CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 2006;20(10):1819-28. 9. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol 2002;20(1):70-5. 10. Moeller M, Haynes NM, Trapani JA, et al. A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells. Cancer Gene Ther 2004;11(5):371-9. 11. Parker LL, Do MT, Westwood JA, et al. Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. Hum Gene Ther 2000;11(17):2377-87. 12. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009;21(2):215-23. 13. Stephan MT, Ponomarev V, Brentjens RJ, et al. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med 2007;13(12):1440-9. 14. Daly T, Royal RE, Kershaw MH, et al. Recognition of human colon cancer by T cells transduced with a chimeric receptor gene. Cancer Gene Ther 2000;7(2):284-91. 15. Jensen MC, Cooper LJ, Wu AM, Forman SJ, Raubitschek A. Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. Cytotherapy 2003;5(2):131-8. 16. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008;14(11):1264-70. 17. Savoldo B, Rooney CM, Di Stasi A, et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood 2007;110(7):2620-30.

18. Wang G, Chopra RK, Royal RE, Yang JC, Rosenberg SA, Hwu P. A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc gamma chain chimeric receptor gene recognizing a human ovarian cancer antigen. Nat Med 1998;4(2):168-72. 19. Hollyman D, Stefanski J, Przybylowski M, et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother 2009;32(2):169-80. 20. Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006;24(13):e20-2. 21. Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008;112(6):2261-71. 22. Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007;104(9):3360-5. 23. Leffers N, Gooden MJ, de Jong RA, et al. Prognostic significance of tumor-infiltrating T lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother 2009;58(3):449-59. 24. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102(51):18538-43. 25. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348(3):203-13. 26. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10(9):942-9. 27. Leffers N, Lambeck AJ, de Graeff P, et al. Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation. Gynecol Oncol 2008;110(3):365-73. 28. Nelson BH. The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev 2008;222:101-16. 29. Wolf D, Wolf AM, Rumpold H, et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005;11(23):8326-31.

30. Badgwell D, Bast RC, Jr. Early detection of ovarian cancer. Dis Markers 2007;23(5-6):397 410. 31. Bast RC, Jr., Badgwell D, Lu Z, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005;15 Suppl 3:274-81. 32. Fritsche HA, Bast RC. CA 125 in ovarian cancer: advances and controversy. Clin Chem 1998;44(7):1379-80. 33. Krivak TC, Tian C, Rose GS, Armstrong DK, Maxwell GL. A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled D in GOG 172. Gynecol Oncol 2009;115(1):81-5. 34. O'Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biol 2001;22(6):348-66. 35. Bellone S, Anfossi S, O'Brien TJ, et al. Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer. Am J Obstet Gynecol 2009;200(1):75 el-10. 36. Berek JS. Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab. Expert Opin Biol Ther 2004;4(7):1159-65. 37. O'Brien TJ, Tanimoto H, Konishi I, Gee M. More than 15 years of CA 125: what is known about the antigen, its structure and its function. Int J Biol Markers 1998;13(4):188-95. D 38. Rao TD, Park KJ, Smith-Jones P, et al. Novel monoclonal antibodies against proximal (carboxy-terminal) portions of MUC16 (submitted to Applied Immunohistochemistry and Molecular Morphometry). 39. Wang Z, Raifu M, Howard M, et al. Universal PCR amplification of mouse immunoglobulin gene variable regions: the design of degenerate primers and an assessment of the effect of DNA polymerase 3'to 5'exonuclease activity. J Immunol Methods 2000;233(1-2):167-77. 40. Doenecke A, Winnacker EL, Hallek M. Rapid amplification of cDNA ends (RACE) improves the PCR-based isolation of immunoglobulin variable region genes from murine and human lymphoma cells and cell lines. Leukemia 1997;11(10):1787-92. 41. Gong MC, Latouche JB, Krause A, Heston WD, Bander NH, Sadelain M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1999;1(2):123-7. 42. Orlandi R, Gussow DH, Jones PT, Winter G. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc Natl Acad Sci U S A 1989;86(10):3833-7.

43. Brentjens RJ, Santos E, Nikhamin Y, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 2007;13(18 Pt 1):5426-35. 44. Riviere I, Brose K, Mulligan RC. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci U S A 1995;92(15):6733-7. 45. Quintas-Cardama A, Yeh RK, Hollyman D, et al. Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application. Hum Gene Ther 2007;18(12):1253-60. 46. Latouche JB, Sadelain M. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat Biotechnol 2000;18(4):405-9. 47. Santos EB, Yeh R, Lee J, et al. Sensitive in vivo imaging of T cells using a membrane bound Gaussia princeps luciferase. Nat Med 2009;15(3):338-44. 48. Park KJ, Soslow R, Linkov I, Rao TD, D S. The extracellular portion of the MUC16 cytoplasmic domain is detectable in ovarian carcinomas using novel monoclonal antibody, 4H11. Mod Pathol, 2008; 21(1s):217A-218A. 49. Raspollini MR, Castiglione F, Rossi Degl'innocenti D, et al. Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann Oncol 2005;16(4):590-6. 50. Tomsova M, Melichar B, Sedlakova I, Steiner I. Prognostic significance of CD3+ tumor infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol 2008;108(2):415-20. 51. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61(12):4766-72. 52. Lamers CH, Langeveld SC, Groot-van Ruijven CM, Debets R, Sleijfer S, Gratama JW. Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo. Cancer Immunol Immunother 2007;56(12):1875-83. 53. Brentjens R, Hollyman D, Weiss M, et al. A Phase I trial for the treatment of chemo refractory chronic lymphocytic leukemia with CD19-targeted autologous T cells. Molecular Therapy 2008;16:S15. 54. Barber A, Zhang T, DeMars LR, Conejo-Garcia J, Roby KF, Sentman CL. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer Res 2007;67(10):5003-8.

55. Barber A, Zhang T, Sentman CL. Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer. J Immunol 2008;180(l):72-8. 56. Carpenito C, Milone MC, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CDl37 domains. Proc Natl Acad Sci U S A 2009;106(9):3360-5. 57. Kershaw MH, Westwood JA, Hwu P. Dual-specific T cells combine proliferation and antitumor activity. Nat Biotechnol 2002;20(12):1221-7. 58. Hung CF, Wu TC, Monie A, Roden R. Antigen-specific immunotherapy of cervical and 3 ovarian cancer. Immunol Rev 2008;222:43-69. 59. Westwood JA, Smyth MJ, Teng MW, et al. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci U S A 2005;102(52):19051-6. 60. Habib-Agahi M, Jaberipour M, Searle PF. 4-1BBL costimulation retrieves CD28 expression in activated T cells. CellImmunol 2009;256(1-2):39-46. 61. Habib-Agahi M, Phan TT, Searle PF. Co-stimulation with 4-BB ligand allows extended T cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells. Int Immunol 2007;19(12):1383-94. 62. Brentjens RJ, Sadelain M. Somatic cell engineering and the immunotherapy of leukemias D and lymphomas. Adv Pharmacol 2004;51:347-70. 63. Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 2004;172(1):104-13. 64. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T !5 lymphocytes. Nat Rev Cancer 2003;3(l):35-45. 65. Wilkie S, Picco G, Foster J, et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol 2008;180(7):4901-9. 66. Li Q, Ai J, Song Z, Liu J, Shan B. 4-1BB (CD137) ligand enhanced anti-tumor immune response against mouse forestomach carcinoma in vivo. Cell Mol Immunol 2008;5(5):379-84. 67. Salih HR, Kosowski SG, Haluska VF, et al. Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells. J Immunol 2000;165(5):2903-10. 68. Wan YL, Zheng SS, Zhao ZC, Li MW, Jia CK, Zhang H. Expression of co-stimulator 4 1BB molecule in hepatocellular carcinoma and adjacent non-tumor liver tissue, and its possible role in tumor immunity. World J Gastroenterol 2004;10(2):195-9.

Each and every publication and patent mentioned in the above specification is herein incorporated by reference in its entirety for all purposes. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific embodiments, the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in the art and in fields related thereto are intended to be within the scope of the following claims.

In the present specification and claims, the word 'comprising' and its derivatives .0 including 'comprises' and 'comprise' include each of the stated integers but does not exclude the inclusion of one or more further integers. The reference to any prior art in this specification is not, and should not be taken as an acknowledgement or any form of suggestion that the prior art forms part of the common general knowledge. .5 Definitions of the specific embodiments of the invention as claimed herein follow. According to a first embodiment of the invention, there is provided an isolated antibody, or an antigen-binding fragment thereof, that specifically binds to a MUC16 polypeptide or to an antigenic portion thereof, wherein the MUC16 polypeptide is TLDRSSVLVDGYSPNRNE (SEQ ID NO:02), and '0 wherein the antibody comprises a variable heavy ("VH") chain encoded by SEQ ID NO:04 and a variable light ("VL") chain encoded by SEQ ID NO:05. According to a second embodiment of the invention, there is provided a humanized antibody or antigen-binding fragment thereof made by substituting the complementarity determining regions of a first antibody into a human framework domain, wherein the humanized antibody or antigen-binding fragment thereof specifically binds to a MUC16 polypeptide or to an antigenic portion thereof, wherein the first antibody specifically binds to the MUC16 polypeptide or the antigenic portion thereof, wherein the MUC16 polypeptide is TLDRSSVLVDGYSPNRNE (SEQ ID NO:02), and wherein the first antibody comprises a VH chain encoded by SEQ ID NO:04 and a VL chain encoded by SEQ ID NO:05. According to a third embodiment of the invention, there is provided a composition comprising (a) the antibody or antigen-binding fragment of the first or second embodiment, and (b) a pharmaceutically acceptable carrier.

According to a fourth embodiment of the invention, there is provided a hybridoma cell that produces a monoclonal antibody, or an antigen-binding fragment thereof, that specifically binds to a MUC16 polypeptide or to an antigenic portion thereof, wherein the MUC16 polypeptide is TLDRSSVLVDGYSPNRNE (SEQ ID NO:02), and wherein the antibody comprises a variable heavy ("VH") chain encoded by SEQ ID NO:04 and a variable light ("VL") chain encoded by SEQ ID NO:05. According to a fifth embodiment of the invention, there is provided a method for identifying a subject as having a cancer in which MUC16 is expressed, wherein said method .0 comprises administering the antibody of the first or second embodiment to the subject, and determining the presence and location of the antibody in the subject, wherein said antibody is labeled. According to a sixth embodiment of the invention, there is provided an ex vivo method for identifying a subject as having a cancer in which MUC16 is expressed, wherein said method .5 comprises: (a) obtaining a first sample from a first subject; (b) contacting the first sample with the antibody of the first or second embodiment; and (c) determining whether the antibody has an increased level of binding to the first sample as compared to a control sample lacking the cancer. .0 According to a seventh embodiment of the invention, there is provided a single chain variable fragment (scFv) comprising a VH chain sequence encoded by SEQ ID NO:04 and a VL chain sequence encoded by SEQ ID NO:05. According to an eighth embodiment of the invention, there is provided a single chain variable fragment (scFv) comprising a VH chain sequence and a VL chain sequence of the humanized antibody or antigen-binding fragment of the second embodiment. According to a ninth embodiment of the invention, there is provided a chimeric antigen receptor (CAR) comprising the scFv of the seventh or eighth embodiment. According to a tenth embodiment of the invention, there is provided a CAR comprising the scFv of the ninth embodiment fused to a transmembrane domain. According to an eleventh embodiment of the invention, there is provided a T cell expressing the CAR of the ninth or tenth embodiment. According to a twelfth embodiment of the invention, there is provided a method for treating a cancer in which MUC16 is expressed, comprising administering to a subject a therapeutically effective amount of the antibody or antigen-binding fragment of the first or second embodiment. According to a thirteenth embodiment of the invention, there is provided a method for treating a cancer in which MUC16 is expressed, comprising administering to a subject the T cell of the eleventh embodiment. According to a fourteenth embodiment of the invention, there is provided a chimeric antibody, comprising the antibody of the first embodiment. According to a fifteenth embodiment of the invention, there is provided a humanized antibody that is the antibody of the second embodiment. .0 According to a sixteenth embodiment of the invention, there is provided a method for treating a cancer in which MUC16 is expressed, comprising administering to a subject the antibody of the fourteenth embodiment. According to a seventeenth embodiment of the invention, there is provided a method for treating a cancer in which MUC16 is expressed, comprising administering to a subject the .5 antibody of the fifteenth embodiment. According to an eighteenth embodiment of the invention, there is provided use of a therapeutically effective amount of the antibody or antigen-binding fragment of the first or second embodiment in the preparation of a medicament for treating a cancer in which MUC16 is expressed. .0 According to a nineteenth embodiment of the invention, there is provided use of the T cell of the eleventh embodiment in the preparation of a medicament for treating a cancer in which MUC16 is expressed. According to a twentieth embodiment of the invention, there is provided use of the antibody of the fourteenth embodiment in the preparation of a medicament for treating a cancer in which MUC16 is expressed. According to a twenty-first embodiment of the invention, there is provided use of the antibody of the fifteenth embodiment in the preparation of a medicament for treating a cancer in which MUC16 is expressed. Further embodiments of the invention are described in the Paragraphs below.

1. An isolated antibody, or an antigen-binding fragment thereof, that specifically binds to a MUC16 polypeptide or to an antigenic portion thereof, wherein the MUC16 polypeptide is selected from the group consisting of a) TLDRKSVFVDGYSQNRDD (SEQ ID NO:21), b) KSYFSDCQVLAFRSVSNNNNHTGVDSLCNFSPL (SEQ ID NO:22), and c) SLYSNCRLASLRPKKNGTATGVNAICSYHQN (SEQ ID NO:23).

2. The antibody of Paragraph 1, wherein the antibody is selected from the group consisting of a monoclonal antibody, a chimeric antibody, a recombinant antibody, an antigen-binding fragment of a recombinant antibody, a humanized antibody, and an antibody displayed upon the surface of a phage.

3. The antibody of Paragraph 2, wherein the antibody is a monoclonal antibody.

4. The antibody of Paragraph 3, wherein the monoclonal antibody is produced by hybridoma .0 cells selected from the group consisting of 12B10-3G10, 10C4-3H5, 10C4-1F2, 10C4-2H8, 10C4-1G7, 17F2-3G5, 17F2-3F6, 17F2-2F9, 17F2-1E11, 12B10-3F7, 12B10-2F6, 12B10 2F10, 25E9-3, 25E9-5, 25E9-1, 25E9-16, 21B8-1H11, 21B8-3G6, 21B8-3H9, 21B8-1G8, 21El-1E3,21El-1G9,21El-2G7,21El-3G12,4H1-2E1, 4H1-2E3, 4H1-3E1, 4H1-3H3, 15A8-2E2, 15A8-2E10, 15A8-2E11, 15A8-3D2, 22B5-1F6, 22B5-3G9, 22B5-2G8, and .5 22B5-3F11.

5. The antibody of Paragraph 1, wherein the MUC16 polypeptide is TLDRKSVFVDGYSQNRDD (SEQ ID NO:21).

6. The antibody of Paragraph 5, wherein the antibody comprises a variable heavy (VH) chain sequence SEQ ID NO:27, and a variable light (VL) chain sequence SEQ ID NO:29.

7. The antibody of Paragraph 6, wherein the antibody is a monoclonal antibody produced by hybridoma cell 12B10-3G10.

8. The antibody of Paragraph 1, wherein the antigen-binding fragment is selected from the group consisting of a Fab fragment, a F(ab')2 fragment, and a Fv fragment.

9. The antibody of Paragraph 1, wherein the antibody, or antigen-binding fragment thereof, is covalently linked to a cytotoxic agent or a prodrug of a cytotoxic agent.

10. The antibody of Paragraph 1, wherein the antibody specifically binds to human MUC16 (SEQ ID NO:25).

11. The antibody of Paragraph 1, wherein the antibody internalizes into a cell.

12. The antibody of Paragraph 1, wherein the antibody lacks specific binding to a glycosylated MUC16 extracellular domain.

13. A composition comprising (a) the antibody, or antigen-binding fragment thereof, of Paragraph 1, and (b) a pharmaceutically acceptable carrier.

14. A hybridoma cell that produces an antibody, or an antigen-binding fragment thereof, that specifically binds to a MUC16 polypeptide or to an antigenic portion thereof, wherein the .0 MUC16 polypeptide is selected from the group consisting of

a) TLDRKSVFVDGYSQNRDD (SEQ ID NO:21),

b) KSYFSDCQVLAFRSVSNNNNHTGVDSLCNFSPL (SEQ ID NO:22), and

c) SLYSNCRLASLRPKKNGTATGVNAICSYHQN (SEQ TD NO:23).

15. An isolated nucleotide sequence comprising a polynucleotide that encodes at least one of .5 a variable heavy (VH) chain sequence and the variable light (VL) chain sequence of an antibody that specifically binds to a MUC16 polypeptide, wherein the MUC16 polypeptide is selected from the group consisting of

a) TLDRKSVFVDGYSQNRDD (SEQ ID NO:21),

b) KSYFSDCQVLAFRSVSNNNNHTGVDSLCNFSPL (SEQ ID NO:22), and

c) SLYSNCRLASLRPKKNGTATGVNAICSYHQN (SEQ ID NO:23).

16. The nucleotide sequence of Paragraph 15, wherein the MUC16 polypeptide is

TLDRKSVFVDGYSQNRDD (SEQ ID NO:21).

17. The nucleotide sequence of Paragraph 16, wherein the polynucleotide encoding the variable heavy (VH) chain sequence comprises SEQ ID NO:26, and wherein the polynucleotide encoding the variable light (VL) chain sequence comprises SEQ ID NO:28.

18. A method for producing an antibody that specifically binds to a MUC16 polypeptide or to an antigenic portion thereof, comprising administering to a subject an immunologically effective amount of a MUC16 polypeptide selected from the group consisting of

a) TLDRKS VFVDGYS QNRDD (SEQ ID NO:21),

b) KSYFSDCQVLAFRSVSNN NHTGVDSLCNFSPL (SEQ ID NO:22), and

c) SLYSNCRLASLRPKKNGTATGVNAICSYHQN (SEQ ID NO:23).

.0 19. A method for identifying a subject as having disease, comprising determining the level, in a sample from the subject, of specific binding of the antibody of Paragraph 1 with the MUC16 polypeptide or with the antigenic portion thereof, wherein detecting an altered level of the specific binding relative to a control sample identifies the subject as having disease.

20. The method of Paragraph 19, wherein the disease is cancer.

.5 21. The method of Paragraph 20, wherein the cancer is selected from the group consisting of ovarian cancer and breast cancer.

22. The method of Paragraph 19, further comprising detecting an altered level of binding of the antibody to the sample compared to a control sample.

23. The method of Paragraph 19, wherein the detecting is selected from the group consisting of immunohistochemistry, enzyme-linked immunosorbent assay (ELISA), fluorescence activated cell sorting (FACS), Western blot, immunoprecipitation, and radiographic imaging.

24. A method for reducing one or more symptoms of disease comprising administering to a subject in need thereof a therapeutically effective amount of the antibody of Paragraph 1.

25. The method of Paragraph 24, wherein the disease is cancer.

26. The method of Paragraph 25, wherein the cancer is selected from the group consisting of ovarian cancer and breast cancer.

27. The method of Paragraph 24, further comprising detecting a reduction in one or more symptoms of the disease after the administration.

6847536_1 17 Sep 2019

SEQUENCE LISTING

<110> MEMORIAL SLOAN-KETTERING CANCER CENTER Spriggs, David Thapi, Dharmarao

<120> Antibodies to MUC16 and Methods of Use Thereof

<130> SLOAN-17044

<140> PCT/US11/30025 <141> 2011-03-25 2019232796

<150> US 61/317,964 <151> 2010-03-26

<160> 31

<170> PatentIn version 3.5

<210> 1 <211> 17 <212> PRT <213> Artificial Sequence

<220> <223> Synthetic

<400> 1

Asn Phe Ser Pro Leu Ala Arg Arg Val Asp Arg Val Ala Ile Tyr Glu 1 5 10 15

Glu

<210> 2 <211> 18 <212> PRT <213> Artificial Sequence

<220> <223> Synthetic

<400> 2

Thr Leu Asp Arg Ser Ser Val Leu Val Asp Gly Tyr Ser Pro Asn Arg 1 5 10 15

Asn Glu

<210> 3 <211> 21 <212> PRT <213> Artificial Sequence

<220> <223> Synthetic

<400> 3

Cys Gly Val Leu Val Thr Thr Arg Arg Arg Lys Lys Glu Gly Glu Tyr 1 5 10 15

Page 1

6847536_1 17 Sep 2019

Asn Val Gln Gln Gln 20

<210> 4 <211> 366 <212> DNA <213> Artificial Sequence

<220> <223> Synthetic 2019232796

<400> 4 gtgaagctgg aggagtcagg gggaggcttc gtgaagcctg gagggtccct caaaatctcc 60

tgtgcagcct ctggattcac tttcagaaac tatgccatgt cctgggttcg cctgagtccg 120

gagatgaggc tggagtgggt cgcaaccatt agcagtgctg gtggttacat cttctattct 180

gacagtgtgc agggacgatt caccatttcc agagacaatg ccaagaacac cctccacttg 240

caaatgggca gtctgaggtc tggggacacg gccatgtatt actgtgcaag gcagggattt 300

ggtaactacg gtgattacta tgctatggac tactggggcc aagggaccac ggtcaccgtc 360

tcctca 366

<210> 5 <211> 339 <212> DNA <213> Artificial Sequence

<220> <223> Synthetic

<400> 5 gacattgagc tcacccagtc tccatcctcc ctggctgtgt cagcaggaga gaaggtcact 60

atgagctgca aatccagtca gagtctgctc aacagtagaa cccgaaagaa ccagttggct 120

tggtaccagc aaaaaacagg acagtctcct gaactgctga tctactgggc atccactcgg 180

caatctgggg tccctgatcg cttcacaggc agtggatctg ggacagattt cactctcacc 240

atcagcagtg tgcaggctga agacctggca gtttattact gccagcaatc ttataatcta 300

ctcacgttcg gtcctgggac caagctggag atcaaacgg 339

<210> 6 <211> 366 <212> DNA <213> Artificial Sequence

<220> <223> Synthetic

<400> 6 gtgaagctgc aggagtcagg gggaggcttc gtgaagcctg gagggtccct caaagtctcc 60

tgtgcagcct ctggattcac tttcagtagc tatgccatgt cctgggttcg cctgagtccg 120

gagatgaggc tggagtgggt cgcaaccatt agcagtgctg gtggttacat cttctattct 180

gacagtgtgc agggacgatt caccatttcc agagacaatg ccaagaacac cctgcacctg 240

caaatgggca gtctgaggtc tggggacacg gccatgtatt actgtgcaag gcagggattt 300 Page 2

6847536_1 17 Sep 2019

ggtaactacg gtgattacta tgctatggac tactggggcc aagggaccac ggtcaccgtc 360

tcctca 366

<210> 7 <211> 339 <212> DNA <213> Artificial Sequence

<220> <223> Synthetic 2019232796

<400> 7 gacattgagc tcacccagtc tccatcctcc ctggctgtgt cagcaggaga gaaggtcact 60

atgagctgca aatccagtca gagtctgctc aacagtagaa cccgaaagaa ccagttggct 120

tggtaccagc aaaaaccagg acagtctcct gaactgctga tctactgggc atccactagg 180

caatctggag tccctgatcg cttcacaggc agtggatctg ggacagattt cactctcacc 240

atcagcagtg tgcaggctga agacctggca gtttattact gccagcaatc ttataatcta 300

ctcacgttcg gtcctgggac caagctggag gtcaaacgg 339

<210> 8 <211> 348 <212> DNA <213> Artificial Sequence

<220> <223> Synthetic

<400> 8 gtgaagctgg aggagtcagg gggagacttg gtgaagcctg gagggtccct gaaactctcc 60

tgtgcagtct ctggattcac tttcagtagc cattccatgt cttggattcg tcagactcca 120

gagaagaggc tagagtgggt cgcatccgtg agtagtggtg gtaggatcta ctattcggac 180

agtgtgaagg gccgattcac cgtcaccaga gaaaatgaca ggaacaccct gtatttgtta 240

atgagtagtc tgaggtctga ggacacggcc atgtattatt gtggaagagg acaggtattt 300

tatgctttgg acaattgggg ccaagggacc acggtcaccg tctcctca 348

<210> 9 <211> 339 <212> DNA <213> Artificial Sequence

<220> <223> Synthetic

<400> 9 gacattgagc tcacccagtc tccatcctcc ctggctgtgt cagcaggaga gaaggtcact 60

atgagctgca aatccagtca gagtctgctc aacagtagaa cccgaaagaa ccagttggct 120

tggtaccagc aaaaaccagg acagtctcct gaactgctga tctactgggc atccactagg 180

caatctggag tccctgatcg cttcacaggc agtggatctg ggacagattt cactctcacc 240

atcagcagtg tgcaggctga agacctggca gtttattact gccagcaatc ttataatcta 300

Page 3

6847536_1 17 Sep 2019

ctcacgttcg gtcctgggac caagctggag gtcaaacgg 339

<210> 10 <211> 216 <212> DNA <213> Artificial Sequence

<220> <223> Synthetic

<400> 10 gacattgagc tcacccagtc tccaaagctc ctgatctaca aggtttccaa ccgattttct 60 2019232796

ggggtcccag acaggttcag tggcagtgga tcagggacag atttcacact caagatcagc 120

agagtggagg ctgaggatct gggagtttat tactgctttc aaggttcaca tgttccgtgg 180

acgttcggtg gagggaccaa gctggagatc aaacgg 216

<210> 11 <211> 354 <212> DNA <213> Artificial Sequence

<220> <223> Synthetic

<400> 11 gaggtgaagc tggaggagtc aggacctgaa ctggtgaagc ctggggcttc agtgaagata 60

tcctgcaagg cttctggtta ctcatttact ggctacttta tgaactgggt gaagcagacc 120

catggaaaga gccttgagtg gattggacgt attaatcctt acaatggtgc tactttctac 180

aatcagaagt tcacgggcaa ggccacaatg actgtagaca aatcctctac cacagcccac 240

atggagctcc tgagcctgac atctgaggac tctgcagtct attattgtgg aaaggggaat 300

tactacggcc cctttgatta ctggggccaa gggaccacgg tcaccgtctc ctca 354

<210> 12 <211> 333 <212> DNA <213> Artificial Sequence

<220> <223> Synthetic

<400> 12 gacattgagc tcacccagtc tccatcttat cttgctgcat ctcctgaaga aaccattact 60

attaattgca gggcaagtaa gagcattagc aaatatttag cctggtatca aaagaaacct 120

gggaaaacta ataagcttct tatctactct ggatccactt tgcaatctgg aattccatca 180

aggttcagtg gcagtggatc tggtacagat ttcactctca ccatcagtag cctggagcct 240

gaagattttg caatgtatta ctgtcaacag cataatgaat acccgtggac gttcggtgga 300

gggaccaagc tggagatcaa acgggcggcc gca 333

<210> 13 <211> 14507 <212> PRT <213> Homo sapiens Page 4

6847536_1 17 Sep 2019

<400> 13

Met Leu Lys Pro Ser Gly Leu Pro Gly Ser Ser Ser Pro Thr Arg Ser 1 5 10 15

Leu Met Thr Gly Ser Arg Ser Thr Lys Ala Thr Pro Glu Met Asp Ser 20 25 30

Gly Leu Thr Gly Ala Thr Leu Ser Pro Lys Thr Ser Thr Gly Ala Ile 35 40 45 2019232796

Val Val Thr Glu His Thr Leu Pro Phe Thr Ser Pro Asp Lys Thr Leu 50 55 60

Ala Ser Pro Thr Ser Ser Val Val Gly Arg Thr Thr Gln Ser Leu Gly 65 70 75 80

Val Met Ser Ser Ala Leu Pro Glu Ser Thr Ser Arg Gly Met Thr His 85 90 95

Ser Glu Gln Arg Thr Ser Pro Ser Leu Ser Pro Gln Val Asn Gly Thr 100 105 110

Pro Ser Arg Asn Tyr Pro Ala Thr Ser Met Val Ser Gly Leu Ser Ser 115 120 125

Pro Arg Thr Arg Thr Ser Ser Thr Glu Gly Asn Phe Thr Lys Glu Ala 130 135 140

Ser Thr Tyr Thr Leu Thr Val Glu Thr Thr Ser Gly Pro Val Thr Glu 145 150 155 160

Lys Tyr Thr Val Pro Thr Glu Thr Ser Thr Thr Glu Gly Asp Ser Thr 165 170 175

Glu Thr Pro Trp Asp Thr Arg Tyr Ile Pro Val Lys Ile Thr Ser Pro 180 185 190

Met Lys Thr Phe Ala Asp Ser Thr Ala Ser Lys Glu Asn Ala Pro Val 195 200 205

Ser Met Thr Pro Ala Glu Thr Thr Val Thr Asp Ser His Thr Pro Gly 210 215 220

Arg Thr Asn Pro Ser Phe Gly Thr Leu Tyr Ser Ser Phe Leu Asp Leu 225 230 235 240

Ser Pro Lys Gly Thr Pro Asn Ser Arg Gly Glu Thr Ser Leu Glu Leu 245 250 255

Ile Leu Ser Thr Thr Gly Tyr Pro Phe Ser Ser Pro Glu Pro Gly Ser 260 265 270 Page 5

6847536_1 17 Sep 2019

Ala Gly His Ser Arg Ile Ser Thr Ser Ala Pro Leu Ser Ser Ser Ala 275 280 285

Ser Val Leu Asp Asn Lys Ile Ser Glu Thr Ser Ile Phe Ser Gly Gln 290 295 300

Ser Leu Thr Ser Pro Leu Ser Pro Gly Val Pro Glu Ala Arg Ala Ser 305 310 315 320 2019232796

Thr Met Pro Asn Ser Ala Ile Pro Phe Ser Met Thr Leu Ser Asn Ala 325 330 335

Glu Thr Ser Ala Glu Arg Val Arg Ser Thr Ile Ser Ser Leu Gly Thr 340 345 350

Pro Ser Ile Ser Thr Lys Gln Thr Ala Glu Thr Ile Leu Thr Phe His 355 360 365

Ala Phe Ala Glu Thr Met Asp Ile Pro Ser Thr His Ile Ala Lys Thr 370 375 380

Leu Ala Ser Glu Trp Leu Gly Ser Pro Gly Thr Leu Gly Gly Thr Ser 385 390 395 400

Thr Ser Ala Leu Thr Thr Thr Ser Pro Ser Thr Thr Leu Val Ser Glu 405 410 415

Glu Thr Asn Thr His His Ser Thr Ser Gly Lys Glu Thr Glu Gly Thr 420 425 430

Leu Asn Thr Ser Met Thr Pro Leu Glu Thr Ser Ala Pro Gly Glu Glu 435 440 445

Ser Glu Met Thr Ala Thr Leu Val Pro Thr Leu Gly Phe Thr Thr Leu 450 455 460

Asp Ser Lys Ile Arg Ser Pro Ser Gln Val Ser Ser Ser His Pro Thr 465 470 475 480

Arg Glu Leu Arg Thr Thr Gly Ser Thr Ser Gly Arg Gln Ser Ser Ser 485 490 495

Thr Ala Ala His Gly Ser Ser Asp Ile Leu Arg Ala Thr Thr Ser Ser 500 505 510

Thr Ser Lys Ala Ser Ser Trp Thr Ser Glu Ser Thr Ala Gln Gln Phe 515 520 525

Ser Glu Pro Gln His Thr Gln Trp Val Glu Thr Ser Pro Ser Met Lys 530 535 540

Page 6

6847536_1 17 Sep 2019

Thr Glu Arg Pro Pro Ala Ser Thr Ser Val Ala Ala Pro Ile Thr Thr 545 550 555 560

Ser Val Pro Ser Val Val Ser Gly Phe Thr Thr Leu Lys Thr Ser Ser 565 570 575

Thr Lys Gly Ile Trp Leu Glu Glu Thr Ser Ala Asp Thr Leu Ile Gly 580 585 590 2019232796

Glu Ser Thr Ala Gly Pro Thr Thr His Gln Phe Ala Val Pro Thr Gly 595 600 605

Ile Ser Met Thr Gly Gly Ser Ser Thr Arg Gly Ser Gln Gly Thr Thr 610 615 620

His Leu Leu Thr Arg Ala Thr Ala Ser Ser Glu Thr Ser Ala Asp Leu 625 630 635 640

Thr Leu Ala Thr Asn Gly Val Pro Val Ser Val Ser Pro Ala Val Ser 645 650 655

Lys Thr Ala Ala Gly Ser Ser Pro Pro Gly Gly Thr Lys Pro Ser Tyr 660 665 670

Thr Met Val Ser Ser Val Ile Pro Glu Thr Ser Ser Leu Gln Ser Ser 675 680 685

Ala Phe Arg Glu Gly Thr Ser Leu Gly Leu Thr Pro Leu Asn Thr Arg 690 695 700

His Pro Phe Ser Ser Pro Glu Pro Asp Ser Ala Gly His Thr Lys Ile 705 710 715 720

Ser Thr Ser Ile Pro Leu Leu Ser Ser Ala Ser Val Leu Glu Asp Lys 725 730 735

Val Ser Ala Thr Ser Thr Phe Ser His His Lys Ala Thr Ser Ser Ile 740 745 750

Thr Thr Gly Thr Pro Glu Ile Ser Thr Lys Thr Lys Pro Ser Ser Ala 755 760 765

Val Leu Ser Ser Met Thr Leu Ser Asn Ala Ala Thr Ser Pro Glu Arg 770 775 780

Val Arg Asn Ala Thr Ser Pro Leu Thr His Pro Ser Pro Ser Gly Glu 785 790 795 800

Glu Thr Ala Gly Ser Val Leu Thr Leu Ser Thr Ser Ala Glu Thr Thr 805 810 815

Page 7

6847536_1 17 Sep 2019

Asp Ser Pro Asn Ile His Pro Thr Gly Thr Leu Thr Ser Glu Ser Ser 820 825 830

Glu Ser Pro Ser Thr Leu Ser Leu Pro Ser Val Ser Gly Val Lys Thr 835 840 845

Thr Phe Ser Ser Ser Thr Pro Ser Thr His Leu Phe Thr Ser Gly Glu 850 855 860

Glu Thr Glu Glu Thr Ser Asn Pro Ser Val Ser Gln Pro Glu Thr Ser 2019232796

865 870 875 880

Val Ser Arg Val Arg Thr Thr Leu Ala Ser Thr Ser Val Pro Thr Pro 885 890 895

Val Phe Pro Thr Met Asp Thr Trp Pro Thr Arg Ser Ala Gln Phe Ser 900 905 910

Ser Ser His Leu Val Ser Glu Leu Arg Ala Thr Ser Ser Thr Ser Val 915 920 925

Thr Asn Ser Thr Gly Ser Ala Leu Pro Lys Ile Ser His Leu Thr Gly 930 935 940

Thr Ala Thr Met Ser Gln Thr Asn Arg Asp Thr Phe Asn Asp Ser Ala 945 950 955 960

Ala Pro Gln Ser Thr Thr Trp Pro Glu Thr Ser Pro Arg Phe Lys Thr 965 970 975

Gly Leu Pro Ser Ala Thr Thr Thr Val Ser Thr Ser Ala Thr Ser Leu 980 985 990

Ser Ala Thr Val Met Val Ser Lys Phe Thr Ser Pro Ala Thr Ser Ser 995 1000 1005

Met Glu Ala Thr Ser Ile Arg Glu Pro Ser Thr Thr Ile Leu Thr 1010 1015 1020

Thr Glu Thr Thr Asn Gly Pro Gly Ser Met Ala Val Ala Ser Thr 1025 1030 1035

Asn Ile Pro Ile Gly Lys Gly Tyr Ile Thr Glu Gly Arg Leu Asp 1040 1045 1050

Thr Ser His Leu Pro Ile Gly Thr Thr Ala Ser Ser Glu Thr Ser 1055 1060 1065

Met Asp Phe Thr Met Ala Lys Glu Ser Val Ser Met Ser Val Ser 1070 1075 1080

Pro Ser Gln Ser Met Asp Ala Ala Gly Ser Ser Thr Pro Gly Arg Page 8

6847536_1 17 Sep 2019

1085 1090 1095

Thr Ser Gln Phe Val Asp Thr Phe Ser Asp Asp Val Tyr His Leu 1100 1105 1110

Thr Ser Arg Glu Ile Thr Ile Pro Arg Asp Gly Thr Ser Ser Ala 1115 1120 1125

Leu Thr Pro Gln Met Thr Ala Thr His Pro Pro Ser Pro Asp Pro 1130 1135 1140 2019232796

Gly Ser Ala Arg Ser Thr Trp Leu Gly Ile Leu Ser Ser Ser Pro 1145 1150 1155

Ser Ser Pro Thr Pro Lys Val Thr Met Ser Ser Thr Phe Ser Thr 1160 1165 1170

Gln Arg Val Thr Thr Ser Met Ile Met Asp Thr Val Glu Thr Ser 1175 1180 1185

Arg Trp Asn Met Pro Asn Leu Pro Ser Thr Thr Ser Leu Thr Pro 1190 1195 1200

Ser Asn Ile Pro Thr Ser Gly Ala Ile Gly Lys Ser Thr Leu Val 1205 1210 1215

Pro Leu Asp Thr Pro Ser Pro Ala Thr Ser Leu Glu Ala Ser Glu 1220 1225 1230

Gly Gly Leu Pro Thr Leu Ser Thr Tyr Pro Glu Ser Thr Asn Thr 1235 1240 1245

Pro Ser Ile His Leu Gly Ala His Ala Ser Ser Glu Ser Pro Ser 1250 1255 1260

Thr Ile Lys Leu Thr Met Ala Ser Val Val Lys Pro Gly Ser Tyr 1265 1270 1275

Thr Pro Leu Thr Phe Pro Ser Ile Glu Thr His Ile His Val Ser 1280 1285 1290

Thr Ala Arg Met Ala Tyr Ser Ser Gly Ser Ser Pro Glu Met Thr 1295 1300 1305

Ala Pro Gly Glu Thr Asn Thr Gly Ser Thr Trp Asp Pro Thr Thr 1310 1315 1320

Tyr Ile Thr Thr Thr Asp Pro Lys Asp Thr Ser Ser Ala Gln Val 1325 1330 1335

Ser Thr Pro His Ser Val Arg Thr Leu Arg Thr Thr Glu Asn His 1340 1345 1350 Page 9

6847536_1 17 Sep 2019

Pro Lys Thr Glu Ser Ala Thr Pro Ala Ala Tyr Ser Gly Ser Pro 1355 1360 1365

Lys Ile Ser Ser Ser Pro Asn Leu Thr Ser Pro Ala Thr Lys Ala 1370 1375 1380

Trp Thr Ile Thr Asp Thr Thr Glu His Ser Thr Gln Leu His Tyr 1385 1390 1395 2019232796

Thr Lys Leu Ala Glu Lys Ser Ser Gly Phe Glu Thr Gln Ser Ala 1400 1405 1410

Pro Gly Pro Val Ser Val Val Ile Pro Thr Ser Pro Thr Ile Gly 1415 1420 1425

Ser Ser Thr Leu Glu Leu Thr Ser Asp Val Pro Gly Glu Pro Leu 1430 1435 1440

Val Leu Ala Pro Ser Glu Gln Thr Thr Ile Thr Leu Pro Met Ala 1445 1450 1455

Thr Trp Leu Ser Thr Ser Leu Thr Glu Glu Met Ala Ser Thr Asp 1460 1465 1470

Leu Asp Ile Ser Ser Pro Ser Ser Pro Met Ser Thr Phe Ala Ile 1475 1480 1485

Phe Pro Pro Met Ser Thr Pro Ser His Glu Leu Ser Lys Ser Glu 1490 1495 1500

Ala Asp Thr Ser Ala Ile Arg Asn Thr Asp Ser Thr Thr Leu Asp 1505 1510 1515

Gln His Leu Gly Ile Arg Ser Leu Gly Arg Thr Gly Asp Leu Thr 1520 1525 1530

Thr Val Pro Ile Thr Pro Leu Thr Thr Thr Trp Thr Ser Val Ile 1535 1540 1545

Glu His Ser Thr Gln Ala Gln Asp Thr Leu Ser Ala Thr Met Ser 1550 1555 1560

Pro Thr His Val Thr Gln Ser Leu Lys Asp Gln Thr Ser Ile Pro 1565 1570 1575

Ala Ser Ala Ser Pro Ser His Leu Thr Glu Val Tyr Pro Glu Leu 1580 1585 1590

Gly Thr Gln Gly Arg Ser Ser Ser Glu Ala Thr Thr Phe Trp Lys 1595 1600 1605

Page 10

6847536_1 17 Sep 2019

Pro Ser Thr Asp Thr Leu Ser Arg Glu Ile Glu Thr Gly Pro Thr 1610 1615 1620

Asn Ile Gln Ser Thr Pro Pro Met Asp Asn Thr Thr Thr Gly Ser 1625 1630 1635

Ser Ser Ser Gly Val Thr Leu Gly Ile Ala His Leu Pro Ile Gly 1640 1645 1650 2019232796

Thr Ser Ser Pro Ala Glu Thr Ser Thr Asn Met Ala Leu Glu Arg 1655 1660 1665

Arg Ser Ser Thr Ala Thr Val Ser Met Ala Gly Thr Met Gly Leu 1670 1675 1680

Leu Val Thr Ser Ala Pro Gly Arg Ser Ile Ser Gln Ser Leu Gly 1685 1690 1695

Arg Val Ser Ser Val Leu Ser Glu Ser Thr Thr Glu Gly Val Thr 1700 1705 1710

Asp Ser Ser Lys Gly Ser Ser Pro Arg Leu Asn Thr Gln Gly Asn 1715 1720 1725

Thr Ala Leu Ser Ser Ser Leu Glu Pro Ser Tyr Ala Glu Gly Ser 1730 1735 1740

Gln Met Ser Thr Ser Ile Pro Leu Thr Ser Ser Pro Thr Thr Pro 1745 1750 1755

Asp Val Glu Phe Ile Gly Gly Ser Thr Phe Trp Thr Lys Glu Val 1760 1765 1770

Thr Thr Val Met Thr Ser Asp Ile Ser Lys Ser Ser Ala Arg Thr 1775 1780 1785

Glu Ser Ser Ser Ala Thr Leu Met Ser Thr Ala Leu Gly Ser Thr 1790 1795 1800

Glu Asn Thr Gly Lys Glu Lys Leu Arg Thr Ala Ser Met Asp Leu 1805 1810 1815

Pro Ser Pro Thr Pro Ser Met Glu Val Thr Pro Trp Ile Ser Leu 1820 1825 1830

Thr Leu Ser Asn Ala Pro Asn Thr Thr Asp Ser Leu Asp Leu Ser 1835 1840 1845

His Gly Val His Thr Ser Ser Ala Gly Thr Leu Ala Thr Asp Arg 1850 1855 1860

Page 11

6847536_1 17 Sep 2019

Ser Leu Asn Thr Gly Val Thr Arg Ala Ser Arg Leu Glu Asn Gly 1865 1870 1875

Ser Asp Thr Ser Ser Lys Ser Leu Ser Met Gly Asn Ser Thr His 1880 1885 1890

Thr Ser Met Thr Tyr Thr Glu Lys Ser Glu Val Ser Ser Ser Ile 1895 1900 1905

His Pro Arg Pro Glu Thr Ser Ala Pro Gly Ala Glu Thr Thr Leu 2019232796

1910 1915 1920

Thr Ser Thr Pro Gly Asn Arg Ala Ile Ser Leu Thr Leu Pro Phe 1925 1930 1935

Ser Ser Ile Pro Val Glu Glu Val Ile Ser Thr Gly Ile Thr Ser 1940 1945 1950

Gly Pro Asp Ile Asn Ser Ala Pro Met Thr His Ser Pro Ile Thr 1955 1960 1965

Pro Pro Thr Ile Val Trp Thr Ser Thr Gly Thr Ile Glu Gln Ser 1970 1975 1980

Thr Gln Pro Leu His Ala Val Ser Ser Glu Lys Val Ser Val Gln 1985 1990 1995

Thr Gln Ser Thr Pro Tyr Val Asn Ser Val Ala Val Ser Ala Ser 2000 2005 2010

Pro Thr His Glu Asn Ser Val Ser Ser Gly Ser Ser Thr Ser Ser 2015 2020 2025

Pro Tyr Ser Ser Ala Ser Leu Glu Ser Leu Asp Ser Thr Ile Ser 2030 2035 2040

Arg Arg Asn Ala Ile Thr Ser Trp Leu Trp Asp Leu Thr Thr Ser 2045 2050 2055

Leu Pro Thr Thr Thr Trp Pro Ser Thr Ser Leu Ser Glu Ala Leu 2060 2065 2070

Ser Ser Gly His Ser Gly Val Ser Asn Pro Ser Ser Thr Thr Thr 2075 2080 2085

Glu Phe Pro Leu Phe Ser Ala Ala Ser Thr Ser Ala Ala Lys Gln 2090 2095 2100

Arg Asn Pro Glu Thr Glu Thr His Gly Pro Gln Asn Thr Ala Ala 2105 2110 2115

Ser Thr Leu Asn Thr Asp Ala Ser Ser Val Thr Gly Leu Ser Glu Page 12

6847536_1 17 Sep 2019

2120 2125 2130

Thr Pro Val Gly Ala Ser Ile Ser Ser Glu Val Pro Leu Pro Met 2135 2140 2145

Ala Ile Thr Ser Arg Ser Asp Val Ser Gly Leu Thr Ser Glu Ser 2150 2155 2160

Thr Ala Asn Pro Ser Leu Gly Thr Ala Ser Ser Ala Gly Thr Lys 2165 2170 2175 2019232796

Leu Thr Arg Thr Ile Ser Leu Pro Thr Ser Glu Ser Leu Val Ser 2180 2185 2190

Phe Arg Met Asn Lys Asp Pro Trp Thr Val Ser Ile Pro Leu Gly 2195 2200 2205

Ser His Pro Thr Thr Asn Thr Glu Thr Ser Ile Pro Val Asn Ser 2210 2215 2220

Ala Gly Pro Pro Gly Leu Ser Thr Val Ala Ser Asp Val Ile Asp 2225 2230 2235

Thr Pro Ser Asp Gly Ala Glu Ser Ile Pro Thr Val Ser Phe Ser 2240 2245 2250

Pro Ser Pro Asp Thr Glu Val Thr Thr Ile Ser His Phe Pro Glu 2255 2260 2265

Lys Thr Thr His Ser Phe Arg Thr Ile Ser Ser Leu Thr His Glu 2270 2275 2280

Leu Thr Ser Arg Val Thr Pro Ile Pro Gly Asp Trp Met Ser Ser 2285 2290 2295

Ala Met Ser Thr Lys Pro Thr Gly Ala Ser Pro Ser Ile Thr Leu 2300 2305 2310

Gly Glu Arg Arg Thr Ile Thr Ser Ala Ala Pro Thr Thr Ser Pro 2315 2320 2325

Ile Val Leu Thr Ala Ser Phe Thr Glu Thr Ser Thr Val Ser Leu 2330 2335 2340

Asp Asn Glu Thr Thr Val Lys Thr Ser Asp Ile Leu Asp Ala Arg 2345 2350 2355

Lys Thr Asn Glu Leu Pro Ser Asp Ser Ser Ser Ser Ser Asp Leu 2360 2365 2370

Ile Asn Thr Ser Ile Ala Ser Ser Thr Met Asp Val Thr Lys Thr 2375 2380 2385 Page 13

6847536_1 17 Sep 2019

Ala Ser Ile Ser Pro Thr Ser Ile Ser Gly Met Thr Ala Ser Ser 2390 2395 2400

Ser Pro Ser Leu Phe Ser Ser Asp Arg Pro Gln Val Pro Thr Ser 2405 2410 2415

Thr Thr Glu Thr Asn Thr Ala Thr Ser Pro Ser Val Ser Ser Asn 2420 2425 2430 2019232796

Thr Tyr Ser Leu Asp Gly Gly Ser Asn Val Gly Gly Thr Pro Ser 2435 2440 2445

Thr Leu Pro Pro Phe Thr Ile Thr His Pro Val Glu Thr Ser Ser 2450 2455 2460

Ala Leu Leu Ala Trp Ser Arg Pro Val Arg Thr Phe Ser Thr Met 2465 2470 2475

Val Ser Thr Asp Thr Ala Ser Gly Glu Asn Pro Thr Ser Ser Asn 2480 2485 2490

Ser Val Val Thr Ser Val Pro Ala Pro Gly Thr Trp Thr Ser Val 2495 2500 2505

Gly Ser Thr Thr Asp Leu Pro Ala Met Gly Phe Leu Lys Thr Ser 2510 2515 2520

Pro Ala Gly Glu Ala His Ser Leu Leu Ala Ser Thr Ile Glu Pro 2525 2530 2535

Ala Thr Ala Phe Thr Pro His Leu Ser Ala Ala Val Val Thr Gly 2540 2545 2550

Ser Ser Ala Thr Ser Glu Ala Ser Leu Leu Thr Thr Ser Glu Ser 2555 2560 2565

Lys Ala Ile His Ser Ser Pro Gln Thr Pro Thr Thr Pro Thr Ser 2570 2575 2580

Gly Ala Asn Trp Glu Thr Ser Ala Thr Pro Glu Ser Leu Leu Val 2585 2590 2595

Val Thr Glu Thr Ser Asp Thr Thr Leu Thr Ser Lys Ile Leu Val 2600 2605 2610

Thr Asp Thr Ile Leu Phe Ser Thr Val Ser Thr Pro Pro Ser Lys 2615 2620 2625

Phe Pro Ser Thr Gly Thr Leu Ser Gly Ala Ser Phe Pro Thr Leu 2630 2635 2640

Page 14

6847536_1 17 Sep 2019

Leu Pro Asp Thr Pro Ala Ile Pro Leu Thr Ala Thr Glu Pro Thr 2645 2650 2655

Ser Ser Leu Ala Thr Ser Phe Asp Ser Thr Pro Leu Val Thr Ile 2660 2665 2670

Ala Ser Asp Ser Leu Gly Thr Val Pro Glu Thr Thr Leu Thr Met 2675 2680 2685 2019232796

Ser Glu Thr Ser Asn Gly Asp Ala Leu Val Leu Lys Thr Val Ser 2690 2695 2700

Asn Pro Asp Arg Ser Ile Pro Gly Ile Thr Ile Gln Gly Val Thr 2705 2710 2715

Glu Ser Pro Leu His Pro Ser Ser Thr Ser Pro Ser Lys Ile Val 2720 2725 2730

Ala Pro Arg Asn Thr Thr Tyr Glu Gly Ser Ile Thr Val Ala Leu 2735 2740 2745

Ser Thr Leu Pro Ala Gly Thr Thr Gly Ser Leu Val Phe Ser Gln 2750 2755 2760

Ser Ser Glu Asn Ser Glu Thr Thr Ala Leu Val Asp Ser Ser Ala 2765 2770 2775

Gly Leu Glu Arg Ala Ser Val Met Pro Leu Thr Thr Gly Ser Gln 2780 2785 2790

Gly Met Ala Ser Ser Gly Gly Ile Arg Ser Gly Ser Thr His Ser 2795 2800 2805

Thr Gly Thr Lys Thr Phe Ser Ser Leu Pro Leu Thr Met Asn Pro 2810 2815 2820

Gly Glu Val Thr Ala Met Ser Glu Ile Thr Thr Asn Arg Leu Thr 2825 2830 2835

Ala Thr Gln Ser Thr Ala Pro Lys Gly Ile Pro Val Lys Pro Thr 2840 2845 2850

Ser Ala Glu Ser Gly Leu Leu Thr Pro Val Ser Ala Ser Ser Ser 2855 2860 2865

Pro Ser Lys Ala Phe Ala Ser Leu Thr Thr Ala Pro Pro Thr Trp 2870 2875 2880

Gly Ile Pro Gln Ser Thr Leu Thr Phe Glu Phe Ser Glu Val Pro 2885 2890 2895

Page 15

6847536_1 17 Sep 2019

Ser Leu Asp Thr Lys Ser Ala Ser Leu Pro Thr Pro Gly Gln Ser 2900 2905 2910

Leu Asn Thr Ile Pro Asp Ser Asp Ala Ser Thr Ala Ser Ser Ser 2915 2920 2925

Leu Ser Lys Ser Pro Glu Lys Asn Pro Arg Ala Arg Met Met Thr 2930 2935 2940

Ser Thr Lys Ala Ile Ser Ala Ser Ser Phe Gln Ser Thr Gly Phe 2019232796

2945 2950 2955

Thr Glu Thr Pro Glu Gly Ser Ala Ser Pro Ser Met Ala Gly His 2960 2965 2970

Glu Pro Arg Val Pro Thr Ser Gly Thr Gly Asp Pro Arg Tyr Ala 2975 2980 2985

Ser Glu Ser Met Ser Tyr Pro Asp Pro Ser Lys Ala Ser Ser Ala 2990 2995 3000

Met Thr Ser Thr Ser Leu Ala Ser Lys Leu Thr Thr Leu Phe Ser 3005 3010 3015

Thr Gly Gln Ala Ala Arg Ser Gly Ser Ser Ser Ser Pro Ile Ser 3020 3025 3030

Leu Ser Thr Glu Lys Glu Thr Ser Phe Leu Ser Pro Thr Ala Ser 3035 3040 3045

Thr Ser Arg Lys Thr Ser Leu Phe Leu Gly Pro Ser Met Ala Arg 3050 3055 3060

Gln Pro Asn Ile Leu Val His Leu Gln Thr Ser Ala Leu Thr Leu 3065 3070 3075

Ser Pro Thr Ser Thr Leu Asn Met Ser Gln Glu Glu Pro Pro Glu 3080 3085 3090

Leu Thr Ser Ser Gln Thr Ile Ala Glu Glu Glu Gly Thr Thr Ala 3095 3100 3105

Glu Thr Gln Thr Leu Thr Phe Thr Pro Ser Glu Thr Pro Thr Ser 3110 3115 3120

Leu Leu Pro Val Ser Ser Pro Thr Glu Pro Thr Ala Arg Arg Lys 3125 3130 3135

Ser Ser Pro Glu Thr Trp Ala Ser Ser Ile Ser Val Pro Ala Lys 3140 3145 3150

Thr Ser Leu Val Glu Thr Thr Asp Gly Thr Leu Val Thr Thr Ile Page 16

6847536_1 17 Sep 2019

3155 3160 3165

Lys Met Ser Ser Gln Ala Ala Gln Gly Asn Ser Thr Trp Pro Ala 3170 3175 3180

Pro Ala Glu Glu Thr Gly Ser Ser Pro Ala Gly Thr Ser Pro Gly 3185 3190 3195

Ser Pro Glu Met Ser Thr Thr Leu Lys Ile Met Ser Ser Lys Glu 3200 3205 3210 2019232796

Pro Ser Ile Ser Pro Glu Ile Arg Ser Thr Val Arg Asn Ser Pro 3215 3220 3225

Trp Lys Thr Pro Glu Thr Thr Val Pro Met Glu Thr Thr Val Glu 3230 3235 3240

Pro Val Thr Leu Gln Ser Thr Ala Leu Gly Ser Gly Ser Thr Ser 3245 3250 3255

Ile Ser His Leu Pro Thr Gly Thr Thr Ser Pro Thr Lys Ser Pro 3260 3265 3270

Thr Glu Asn Met Leu Ala Thr Glu Arg Val Ser Leu Ser Pro Ser 3275 3280 3285

Pro Pro Glu Ala Trp Thr Asn Leu Tyr Ser Gly Thr Pro Gly Gly 3290 3295 3300

Thr Arg Gln Ser Leu Ala Thr Met Ser Ser Val Ser Leu Glu Ser 3305 3310 3315

Pro Thr Ala Arg Ser Ile Thr Gly Thr Gly Gln Gln Ser Ser Pro 3320 3325 3330

Glu Leu Val Ser Lys Thr Thr Gly Met Glu Phe Ser Met Trp His 3335 3340 3345

Gly Ser Thr Gly Gly Thr Thr Gly Asp Thr His Val Ser Leu Ser 3350 3355 3360

Thr Ser Ser Asn Ile Leu Glu Asp Pro Val Thr Ser Pro Asn Ser 3365 3370 3375

Val Ser Ser Leu Thr Asp Lys Ser Lys His Lys Thr Glu Thr Trp 3380 3385 3390

Val Ser Thr Thr Ala Ile Pro Ser Thr Val Leu Asn Asn Lys Ile 3395 3400 3405

Met Ala Ala Glu Gln Gln Thr Ser Arg Ser Val Asp Glu Ala Tyr 3410 3415 3420 Page 17

6847536_1 17 Sep 2019

Ser Ser Thr Ser Ser Trp Ser Asp Gln Thr Ser Gly Ser Asp Ile 3425 3430 3435

Thr Leu Gly Ala Ser Pro Asp Val Thr Asn Thr Leu Tyr Ile Thr 3440 3445 3450

Ser Thr Ala Gln Thr Thr Ser Leu Val Ser Leu Pro Ser Gly Asp 3455 3460 3465 2019232796

Gln Gly Ile Thr Ser Leu Thr Asn Pro Ser Gly Gly Lys Thr Ser 3470 3475 3480

Ser Ala Ser Ser Val Thr Ser Pro Ser Ile Gly Leu Glu Thr Leu 3485 3490 3495

Arg Ala Asn Val Ser Ala Val Lys Ser Asp Ile Ala Pro Thr Ala 3500 3505 3510

Gly His Leu Ser Gln Thr Ser Ser Pro Ala Glu Val Ser Ile Leu 3515 3520 3525

Asp Val Thr Thr Ala Pro Thr Pro Gly Ile Ser Thr Thr Ile Thr 3530 3535 3540

Thr Met Gly Thr Asn Ser Ile Ser Thr Thr Thr Pro Asn Pro Glu 3545 3550 3555

Val Gly Met Ser Thr Met Asp Ser Thr Pro Ala Thr Glu Arg Arg 3560 3565 3570

Thr Thr Ser Thr Glu His Pro Ser Thr Trp Ser Ser Thr Ala Ala 3575 3580 3585

Ser Asp Ser Trp Thr Val Thr Asp Met Thr Ser Asn Leu Lys Val 3590 3595 3600

Ala Arg Ser Pro Gly Thr Ile Ser Thr Met His Thr Thr Ser Phe 3605 3610 3615

Leu Ala Ser Ser Thr Glu Leu Asp Ser Met Ser Thr Pro His Gly 3620 3625 3630

Arg Ile Thr Val Ile Gly Thr Ser Leu Val Thr Pro Ser Ser Asp 3635 3640 3645

Ala Ser Ala Val Lys Thr Glu Thr Ser Thr Ser Glu Arg Thr Leu 3650 3655 3660

Ser Pro Ser Asp Thr Thr Ala Ser Thr Pro Ile Ser Thr Phe Ser 3665 3670 3675

Page 18

6847536_1 17 Sep 2019

Arg Val Gln Arg Met Ser Ile Ser Val Pro Asp Ile Leu Ser Thr 3680 3685 3690

Ser Trp Thr Pro Ser Ser Thr Glu Ala Glu Asp Val Pro Val Ser 3695 3700 3705

Met Val Ser Thr Asp His Ala Ser Thr Lys Thr Asp Pro Asn Thr 3710 3715 3720 2019232796

Pro Leu Ser Thr Phe Leu Phe Asp Ser Leu Ser Thr Leu Asp Trp 3725 3730 3735

Asp Thr Gly Arg Ser Leu Ser Ser Ala Thr Ala Thr Thr Ser Ala 3740 3745 3750

Pro Gln Gly Ala Thr Thr Pro Gln Glu Leu Thr Leu Glu Thr Met 3755 3760 3765

Ile Ser Pro Ala Thr Ser Gln Leu Pro Phe Ser Ile Gly His Ile 3770 3775 3780

Thr Ser Ala Val Thr Pro Ala Ala Met Ala Arg Ser Ser Gly Val 3785 3790 3795

Thr Phe Ser Arg Pro Asp Pro Thr Ser Lys Lys Ala Glu Gln Thr 3800 3805 3810

Ser Thr Gln Leu Pro Thr Thr Thr Ser Ala His Pro Gly Gln Val 3815 3820 3825

Pro Arg Ser Ala Ala Thr Thr Leu Asp Val Ile Pro His Thr Ala 3830 3835 3840

Lys Thr Pro Asp Ala Thr Phe Gln Arg Gln Gly Gln Thr Ala Leu 3845 3850 3855

Thr Thr Glu Ala Arg Ala Thr Ser Asp Ser Trp Asn Glu Lys Glu 3860 3865 3870

Lys Ser Thr Pro Ser Ala Pro Trp Ile Thr Glu Met Met Asn Ser 3875 3880 3885

Val Ser Glu Asp Thr Ile Lys Glu Val Thr Ser Ser Ser Ser Val 3890 3895 3900

Leu Arg Thr Leu Asn Thr Leu Asp Ile Asn Leu Glu Ser Gly Thr 3905 3910 3915

Thr Ser Ser Pro Ser Trp Lys Ser Ser Pro Tyr Glu Arg Ile Ala 3920 3925 3930

Page 19

6847536_1 17 Sep 2019

Pro Ser Glu Ser Thr Thr Asp Lys Glu Ala Ile His Pro Ser Thr 3935 3940 3945

Asn Thr Val Glu Thr Thr Gly Trp Val Thr Ser Ser Glu His Ala 3950 3955 3960

Ser His Ser Thr Ile Pro Ala His Ser Ala Ser Ser Lys Leu Thr 3965 3970 3975

Ser Pro Val Val Thr Thr Ser Thr Arg Glu Gln Ala Ile Val Ser 2019232796

3980 3985 3990

Met Ser Thr Thr Thr Trp Pro Glu Ser Thr Arg Ala Arg Thr Glu 3995 4000 4005

Pro Asn Ser Phe Leu Thr Ile Glu Leu Arg Asp Val Ser Pro Tyr 4010 4015 4020

Met Asp Thr Ser Ser Thr Thr Gln Thr Ser Ile Ile Ser Ser Pro 4025 4030 4035

Gly Ser Thr Ala Ile Thr Lys Gly Pro Arg Thr Glu Ile Thr Ser 4040 4045 4050

Ser Lys Arg Ile Ser Ser Ser Phe Leu Ala Gln Ser Met Arg Ser 4055 4060 4065

Ser Asp Ser Pro Ser Glu Ala Ile Thr Arg Leu Ser Asn Phe Pro 4070 4075 4080

Ala Met Thr Glu Ser Gly Gly Met Ile Leu Ala Met Gln Thr Ser 4085 4090 4095

Pro Pro Gly Ala Thr Ser Leu Ser Ala Pro Thr Leu Asp Thr Ser 4100 4105 4110

Ala Thr Ala Ser Trp Thr Gly Thr Pro Leu Ala Thr Thr Gln Arg 4115 4120 4125

Phe Thr Tyr Ser Glu Lys Thr Thr Leu Phe Ser Lys Gly Pro Glu 4130 4135 4140

Asp Thr Ser Gln Pro Ser Pro Pro Ser Val Glu Glu Thr Ser Ser 4145 4150 4155

Ser Ser Ser Leu Val Pro Ile His Ala Thr Thr Ser Pro Ser Asn 4160 4165 4170

Ile Leu Leu Thr Ser Gln Gly His Ser Pro Ser Ser Thr Pro Pro 4175 4180 4185

Val Thr Ser Val Phe Leu Ser Glu Thr Ser Gly Leu Gly Lys Thr Page 20

6847536_1 17 Sep 2019

4190 4195 4200

Thr Asp Met Ser Arg Ile Ser Leu Glu Pro Gly Thr Ser Leu Pro 4205 4210 4215

Pro Asn Leu Ser Ser Thr Ala Gly Glu Ala Leu Ser Thr Tyr Glu 4220 4225 4230

Ala Ser Arg Asp Thr Lys Ala Ile His His Ser Ala Asp Thr Ala 4235 4240 4245 2019232796

Val Thr Asn Met Glu Ala Thr Ser Ser Glu Tyr Ser Pro Ile Pro 4250 4255 4260

Gly His Thr Lys Pro Ser Lys Ala Thr Ser Pro Leu Val Thr Ser 4265 4270 4275

His Ile Met Gly Asp Ile Thr Ser Ser Thr Ser Val Phe Gly Ser 4280 4285 4290

Ser Glu Thr Thr Glu Ile Glu Thr Val Ser Ser Val Asn Gln Gly 4295 4300 4305

Leu Gln Glu Arg Ser Thr Ser Gln Val Ala Ser Ser Ala Thr Glu 4310 4315 4320

Thr Ser Thr Val Ile Thr His Val Ser Ser Gly Asp Ala Thr Thr 4325 4330 4335

His Val Thr Lys Thr Gln Ala Thr Phe Ser Ser Gly Thr Ser Ile 4340 4345 4350

Ser Ser Pro His Gln Phe Ile Thr Ser Thr Asn Thr Phe Thr Asp 4355 4360 4365

Val Ser Thr Asn Pro Ser Thr Ser Leu Ile Met Thr Glu Ser Ser 4370 4375 4380

Gly Val Thr Ile Thr Thr Gln Thr Gly Pro Thr Gly Ala Ala Thr 4385 4390 4395

Gln Gly Pro Tyr Leu Leu Asp Thr Ser Thr Met Pro Tyr Leu Thr 4400 4405 4410

Glu Thr Pro Leu Ala Val Thr Pro Asp Phe Met Gln Ser Glu Lys 4415 4420 4425

Thr Thr Leu Ile Ser Lys Gly Pro Lys Asp Val Ser Trp Thr Ser 4430 4435 4440

Pro Pro Ser Val Ala Glu Thr Ser Tyr Pro Ser Ser Leu Thr Pro 4445 4450 4455 Page 21

6847536_1 17 Sep 2019

Phe Leu Val Thr Thr Ile Pro Pro Ala Thr Ser Thr Leu Gln Gly 4460 4465 4470

Gln His Thr Ser Ser Pro Val Ser Ala Thr Ser Val Leu Thr Ser 4475 4480 4485

Gly Leu Val Lys Thr Thr Asp Met Leu Asn Thr Ser Met Glu Pro 4490 4495 4500 2019232796

Val Thr Asn Ser Pro Gln Asn Leu Asn Asn Pro Ser Asn Glu Ile 4505 4510 4515

Leu Ala Thr Leu Ala Ala Thr Thr Asp Ile Glu Thr Ile His Pro 4520 4525 4530

Ser Ile Asn Lys Ala Val Thr Asn Met Gly Thr Ala Ser Ser Ala 4535 4540 4545

His Val Leu His Ser Thr Leu Pro Val Ser Ser Glu Pro Ser Thr 4550 4555 4560

Ala Thr Ser Pro Met Val Pro Ala Ser Ser Met Gly Asp Ala Leu 4565 4570 4575

Ala Ser Ile Ser Ile Pro Gly Ser Glu Thr Thr Asp Ile Glu Gly 4580 4585 4590

Glu Pro Thr Ser Ser Leu Thr Ala Gly Arg Lys Glu Asn Ser Thr 4595 4600 4605

Leu Gln Glu Met Asn Ser Thr Thr Glu Ser Asn Ile Ile Leu Ser 4610 4615 4620

Asn Val Ser Val Gly Ala Ile Thr Glu Ala Thr Lys Met Glu Val 4625 4630 4635

Pro Ser Phe Asp Ala Thr Phe Ile Pro Thr Pro Ala Gln Ser Thr 4640 4645 4650

Lys Phe Pro Asp Ile Phe Ser Val Ala Ser Ser Arg Leu Ser Asn 4655 4660 4665

Ser Pro Pro Met Thr Ile Ser Thr His Met Thr Thr Thr Gln Thr 4670 4675 4680

Gly Ser Ser Gly Ala Thr Ser Lys Ile Pro Leu Ala Leu Asp Thr 4685 4690 4695

Ser Thr Leu Glu Thr Ser Ala Gly Thr Pro Ser Val Val Thr Glu 4700 4705 4710

Page 22

6847536_1 17 Sep 2019

Gly Phe Ala His Ser Lys Ile Thr Thr Ala Met Asn Asn Asp Val 4715 4720 4725

Lys Asp Val Ser Gln Thr Asn Pro Pro Phe Gln Asp Glu Ala Ser 4730 4735 4740

Ser Pro Ser Ser Gln Ala Pro Val Leu Val Thr Thr Leu Pro Ser 4745 4750 4755 2019232796

Ser Val Ala Phe Thr Pro Gln Trp His Ser Thr Ser Ser Pro Val 4760 4765 4770

Ser Met Ser Ser Val Leu Thr Ser Ser Leu Val Lys Thr Ala Gly 4775 4780 4785

Lys Val Asp Thr Ser Leu Glu Thr Val Thr Ser Ser Pro Gln Ser 4790 4795 4800

Met Ser Asn Thr Leu Asp Asp Ile Ser Val Thr Ser Ala Ala Thr 4805 4810 4815

Thr Asp Ile Glu Thr Thr His Pro Ser Ile Asn Thr Val Val Thr 4820 4825 4830

Asn Val Gly Thr Thr Gly Ser Ala Phe Glu Ser His Ser Thr Val 4835 4840 4845

Ser Ala Tyr Pro Glu Pro Ser Lys Val Thr Ser Pro Asn Val Thr 4850 4855 4860

Thr Ser Thr Met Glu Asp Thr Thr Ile Ser Arg Ser Ile Pro Lys 4865 4870 4875

Ser Ser Lys Thr Thr Arg Thr Glu Thr Glu Thr Thr Ser Ser Leu 4880 4885 4890

Thr Pro Lys Leu Arg Glu Thr Ser Ile Ser Gln Glu Ile Thr Ser 4895 4900 4905

Ser Thr Glu Thr Ser Thr Val Pro Tyr Lys Glu Leu Thr Gly Ala 4910 4915 4920

Thr Thr Glu Val Ser Arg Thr Asp Val Thr Ser Ser Ser Ser Thr 4925 4930 4935

Ser Phe Pro Gly Pro Asp Gln Ser Thr Val Ser Leu Asp Ile Ser 4940 4945 4950

Thr Glu Thr Asn Thr Arg Leu Ser Thr Ser Pro Ile Met Thr Glu 4955 4960 4965

Page 23

6847536_1 17 Sep 2019

Ser Ala Glu Ile Thr Ile Thr Thr Gln Thr Gly Pro His Gly Ala 4970 4975 4980

Thr Ser Gln Asp Thr Phe Thr Met Asp Pro Ser Asn Thr Thr Pro 4985 4990 4995

Gln Ala Gly Ile His Ser Ala Met Thr His Gly Phe Ser Gln Leu 5000 5005 5010

Asp Val Thr Thr Leu Met Ser Arg Ile Pro Gln Asp Val Ser Trp 2019232796

5015 5020 5025

Thr Ser Pro Pro Ser Val Asp Lys Thr Ser Ser Pro Ser Ser Phe 5030 5035 5040

Leu Ser Ser Pro Ala Met Thr Thr Pro Ser Leu Ile Ser Ser Thr 5045 5050 5055

Leu Pro Glu Asp Lys Leu Ser Ser Pro Met Thr Ser Leu Leu Thr 5060 5065 5070

Ser Gly Leu Val Lys Ile Thr Asp Ile Leu Arg Thr Arg Leu Glu 5075 5080 5085

Pro Val Thr Ser Ser Leu Pro Asn Phe Ser Ser Thr Ser Asp Lys 5090 5095 5100

Ile Leu Ala Thr Ser Lys Asp Ser Lys Asp Thr Lys Glu Ile Phe 5105 5110 5115

Pro Ser Ile Asn Thr Glu Glu Thr Asn Val Lys Ala Asn Asn Ser 5120 5125 5130

Gly His Glu Ser His Ser Pro Ala Leu Ala Asp Ser Glu Thr Pro 5135 5140 5145

Lys Ala Thr Thr Gln Met Val Ile Thr Thr Thr Val Gly Asp Pro 5150 5155 5160

Ala Pro Ser Thr Ser Met Pro Val His Gly Ser Ser Glu Thr Thr 5165 5170 5175

Asn Ile Lys Arg Glu Pro Thr Tyr Phe Leu Thr Pro Arg Leu Arg 5180 5185 5190

Glu Thr Ser Thr Ser Gln Glu Ser Ser Phe Pro Thr Asp Thr Ser 5195 5200 5205

Phe Leu Leu Ser Lys Val Pro Thr Gly Thr Ile Thr Glu Val Ser 5210 5215 5220

Ser Thr Gly Val Asn Ser Ser Ser Lys Ile Ser Thr Pro Asp His Page 24

6847536_1 17 Sep 2019

5225 5230 5235

Asp Lys Ser Thr Val Pro Pro Asp Thr Phe Thr Gly Glu Ile Pro 5240 5245 5250

Arg Val Phe Thr Ser Ser Ile Lys Thr Lys Ser Ala Glu Met Thr 5255 5260 5265

Ile Thr Thr Gln Ala Ser Pro Pro Glu Ser Ala Ser His Ser Thr 5270 5275 5280 2019232796

Leu Pro Leu Asp Thr Ser Thr Thr Leu Ser Gln Gly Gly Thr His 5285 5290 5295

Ser Thr Val Thr Gln Gly Phe Pro Tyr Ser Glu Val Thr Thr Leu 5300 5305 5310

Met Gly Met Gly Pro Gly Asn Val Ser Trp Met Thr Thr Pro Pro 5315 5320 5325

Val Glu Glu Thr Ser Ser Val Ser Ser Leu Met Ser Ser Pro Ala 5330 5335 5340

Met Thr Ser Pro Ser Pro Val Ser Ser Thr Ser Pro Gln Ser Ile 5345 5350 5355

Pro Ser Ser Pro Leu Pro Val Thr Ala Leu Pro Thr Ser Val Leu 5360 5365 5370

Val Thr Thr Thr Asp Val Leu Gly Thr Thr Ser Pro Glu Ser Val 5375 5380 5385

Thr Ser Ser Pro Pro Asn Leu Ser Ser Ile Thr His Glu Arg Pro 5390 5395 5400

Ala Thr Tyr Lys Asp Thr Ala His Thr Glu Ala Ala Met His His 5405 5410 5415

Ser Thr Asn Thr Ala Val Thr Asn Val Gly Thr Ser Gly Ser Gly 5420 5425 5430

His Lys Ser Gln Ser Ser Val Leu Ala Asp Ser Glu Thr Ser Lys 5435 5440 5445

Ala Thr Pro Leu Met Ser Thr Thr Ser Thr Leu Gly Asp Thr Ser 5450 5455 5460

Val Ser Thr Ser Thr Pro Asn Ile Ser Gln Thr Asn Gln Ile Gln 5465 5470 5475

Thr Glu Pro Thr Ala Ser Leu Ser Pro Arg Leu Arg Glu Ser Ser 5480 5485 5490 Page 25

6847536_1 17 Sep 2019

Thr Ser Glu Lys Thr Ser Ser Thr Thr Glu Thr Asn Thr Ala Phe 5495 5500 5505

Ser Tyr Val Pro Thr Gly Ala Ile Thr Gln Ala Ser Arg Thr Glu 5510 5515 5520

Ile Ser Ser Ser Arg Thr Ser Ile Ser Asp Leu Asp Arg Pro Thr 5525 5530 5535 2019232796

Ile Ala Pro Asp Ile Ser Thr Gly Met Ile Thr Arg Leu Phe Thr 5540 5545 5550

Ser Pro Ile Met Thr Lys Ser Ala Glu Met Thr Val Thr Thr Gln 5555 5560 5565

Thr Thr Thr Pro Gly Ala Thr Ser Gln Gly Ile Leu Pro Trp Asp 5570 5575 5580

Thr Ser Thr Thr Leu Phe Gln Gly Gly Thr His Ser Thr Val Ser 5585 5590 5595

Gln Gly Phe Pro His Ser Glu Ile Thr Thr Leu Arg Ser Arg Thr 5600 5605 5610

Pro Gly Asp Val Ser Trp Met Thr Thr Pro Pro Val Glu Glu Thr 5615 5620 5625

Ser Ser Gly Phe Ser Leu Met Ser Pro Ser Met Thr Ser Pro Ser 5630 5635 5640

Pro Val Ser Ser Thr Ser Pro Glu Ser Ile Pro Ser Ser Pro Leu 5645 5650 5655

Pro Val Thr Ala Leu Leu Thr Ser Val Leu Val Thr Thr Thr Asn 5660 5665 5670

Val Leu Gly Thr Thr Ser Pro Glu Pro Val Thr Ser Ser Pro Pro 5675 5680 5685

Asn Leu Ser Ser Pro Thr Gln Glu Arg Leu Thr Thr Tyr Lys Asp 5690 5695 5700

Thr Ala His Thr Glu Ala Met His Ala Ser Met His Thr Asn Thr 5705 5710 5715

Ala Val Ala Asn Val Gly Thr Ser Ile Ser Gly His Glu Ser Gln 5720 5725 5730

Ser Ser Val Pro Ala Asp Ser His Thr Ser Lys Ala Thr Ser Pro 5735 5740 5745

Page 26

6847536_1 17 Sep 2019

Met Gly Ile Thr Phe Ala Met Gly Asp Thr Ser Val Ser Thr Ser 5750 5755 5760

Thr Pro Ala Phe Phe Glu Thr Arg Ile Gln Thr Glu Ser Thr Ser 5765 5770 5775

Ser Leu Ile Pro Gly Leu Arg Asp Thr Arg Thr Ser Glu Glu Ile 5780 5785 5790 2019232796

Asn Thr Val Thr Glu Thr Ser Thr Val Leu Ser Glu Val Pro Thr 5795 5800 5805

Thr Thr Thr Thr Glu Val Ser Arg Thr Glu Val Ile Thr Ser Ser 5810 5815 5820

Arg Thr Thr Ile Ser Gly Pro Asp His Ser Lys Met Ser Pro Tyr 5825 5830 5835

Ile Ser Thr Glu Thr Ile Thr Arg Leu Ser Thr Phe Pro Phe Val 5840 5845 5850

Thr Gly Ser Thr Glu Met Ala Ile Thr Asn Gln Thr Gly Pro Ile 5855 5860 5865

Gly Thr Ile Ser Gln Ala Thr Leu Thr Leu Asp Thr Ser Ser Thr 5870 5875 5880

Ala Ser Trp Glu Gly Thr His Ser Pro Val Thr Gln Arg Phe Pro 5885 5890 5895

His Ser Glu Glu Thr Thr Thr Met Ser Arg Ser Thr Lys Gly Val 5900 5905 5910

Ser Trp Gln Ser Pro Pro Ser Val Glu Glu Thr Ser Ser Pro Ser 5915 5920 5925

Ser Pro Val Pro Leu Pro Ala Ile Thr Ser His Ser Ser Leu Tyr 5930 5935 5940

Ser Ala Val Ser Gly Ser Ser Pro Thr Ser Ala Leu Pro Val Thr 5945 5950 5955

Ser Leu Leu Thr Ser Gly Arg Arg Lys Thr Ile Asp Met Leu Asp 5960 5965 5970

Thr His Ser Glu Leu Val Thr Ser Ser Leu Pro Ser Ala Ser Ser 5975 5980 5985

Phe Ser Gly Glu Ile Leu Thr Ser Glu Ala Ser Thr Asn Thr Glu 5990 5995 6000

Page 27

6847536_1 17 Sep 2019

Thr Ile His Phe Ser Glu Asn Thr Ala Glu Thr Asn Met Gly Thr 6005 6010 6015

Thr Asn Ser Met His Lys Leu His Ser Ser Val Ser Ile His Ser 6020 6025 6030

Gln Pro Ser Gly His Thr Pro Pro Lys Val Thr Gly Ser Met Met 6035 6040 6045

Glu Asp Ala Ile Val Ser Thr Ser Thr Pro Gly Ser Pro Glu Thr 2019232796

6050 6055 6060

Lys Asn Val Asp Arg Asp Ser Thr Ser Pro Leu Thr Pro Glu Leu 6065 6070 6075

Lys Glu Asp Ser Thr Ala Leu Val Met Asn Ser Thr Thr Glu Ser 6080 6085 6090

Asn Thr Val Phe Ser Ser Val Ser Leu Asp Ala Ala Thr Glu Val 6095 6100 6105

Ser Arg Ala Glu Val Thr Tyr Tyr Asp Pro Thr Phe Met Pro Ala 6110 6115 6120

Ser Ala Gln Ser Thr Lys Ser Pro Asp Ile Ser Pro Glu Ala Ser 6125 6130 6135

Ser Ser His Ser Asn Ser Pro Pro Leu Thr Ile Ser Thr His Lys 6140 6145 6150

Thr Ile Ala Thr Gln Thr Gly Pro Ser Gly Val Thr Ser Leu Gly 6155 6160 6165

Gln Leu Thr Leu Asp Thr Ser Thr Ile Ala Thr Ser Ala Gly Thr 6170 6175 6180

Pro Ser Ala Arg Thr Gln Asp Phe Val Asp Ser Glu Thr Thr Ser 6185 6190 6195

Val Met Asn Asn Asp Leu Asn Asp Val Leu Lys Thr Ser Pro Phe 6200 6205 6210

Ser Ala Glu Glu Ala Asn Ser Leu Ser Ser Gln Ala Pro Leu Leu 6215 6220 6225

Val Thr Thr Ser Pro Ser Pro Val Thr Ser Thr Leu Gln Glu His 6230 6235 6240

Ser Thr Ser Ser Leu Val Ser Val Thr Ser Val Pro Thr Pro Thr 6245 6250 6255

Leu Ala Lys Ile Thr Asp Met Asp Thr Asn Leu Glu Pro Val Thr Page 28

6847536_1 17 Sep 2019

6260 6265 6270

Arg Ser Pro Gln Asn Leu Arg Asn Thr Leu Ala Thr Ser Glu Ala 6275 6280 6285

Thr Thr Asp Thr His Thr Met His Pro Ser Ile Asn Thr Ala Val 6290 6295 6300

Ala Asn Val Gly Thr Thr Ser Ser Pro Asn Glu Phe Tyr Phe Thr 6305 6310 6315 2019232796

Val Ser Pro Asp Ser Asp Pro Tyr Lys Ala Thr Ser Ala Val Val 6320 6325 6330

Ile Thr Ser Thr Ser Gly Asp Ser Ile Val Ser Thr Ser Met Pro 6335 6340 6345

Arg Ser Ser Ala Met Lys Lys Ile Glu Ser Glu Thr Thr Phe Ser 6350 6355 6360

Leu Ile Phe Arg Leu Arg Glu Thr Ser Thr Ser Gln Lys Ile Gly 6365 6370 6375

Ser Ser Ser Asp Thr Ser Thr Val Phe Asp Lys Ala Phe Thr Ala 6380 6385 6390

Ala Thr Thr Glu Val Ser Arg Thr Glu Leu Thr Ser Ser Ser Arg 6395 6400 6405

Thr Ser Ile Gln Gly Thr Glu Lys Pro Thr Met Ser Pro Asp Thr 6410 6415 6420

Ser Thr Arg Ser Val Thr Met Leu Ser Thr Phe Ala Gly Leu Thr 6425 6430 6435

Lys Ser Glu Glu Arg Thr Ile Ala Thr Gln Thr Gly Pro His Arg 6440 6445 6450

Ala Thr Ser Gln Gly Thr Leu Thr Trp Asp Thr Ser Ile Thr Thr 6455 6460 6465

Ser Gln Ala Gly Thr His Ser Ala Met Thr His Gly Phe Ser Gln 6470 6475 6480

Leu Asp Leu Ser Thr Leu Thr Ser Arg Val Pro Glu Tyr Ile Ser 6485 6490 6495

Gly Thr Ser Pro Pro Ser Val Glu Lys Thr Ser Ser Ser Ser Ser 6500 6505 6510

Leu Leu Ser Leu Pro Ala Ile Thr Ser Pro Ser Pro Val Pro Thr 6515 6520 6525 Page 29

6847536_1 17 Sep 2019

Thr Leu Pro Glu Ser Arg Pro Ser Ser Pro Val His Leu Thr Ser 6530 6535 6540

Leu Pro Thr Ser Gly Leu Val Lys Thr Thr Asp Met Leu Ala Ser 6545 6550 6555

Val Ala Ser Leu Pro Pro Asn Leu Gly Ser Thr Ser His Lys Ile 6560 6565 6570 2019232796

Pro Thr Thr Ser Glu Asp Ile Lys Asp Thr Glu Lys Met Tyr Pro 6575 6580 6585

Ser Thr Asn Ile Ala Val Thr Asn Val Gly Thr Thr Thr Ser Glu 6590 6595 6600

Lys Glu Ser Tyr Ser Ser Val Pro Ala Tyr Ser Glu Pro Pro Lys 6605 6610 6615

Val Thr Ser Pro Met Val Thr Ser Phe Asn Ile Arg Asp Thr Ile 6620 6625 6630

Val Ser Thr Ser Met Pro Gly Ser Ser Glu Ile Thr Arg Ile Glu 6635 6640 6645

Met Glu Ser Thr Phe Ser Leu Ala His Gly Leu Lys Gly Thr Ser 6650 6655 6660

Thr Ser Gln Asp Pro Ile Val Ser Thr Glu Lys Ser Ala Val Leu 6665 6670 6675

His Lys Leu Thr Thr Gly Ala Thr Glu Thr Ser Arg Thr Glu Val 6680 6685 6690

Ala Ser Ser Arg Arg Thr Ser Ile Pro Gly Pro Asp His Ser Thr 6695 6700 6705

Glu Ser Pro Asp Ile Ser Thr Glu Val Ile Pro Ser Leu Pro Ile 6710 6715 6720

Ser Leu Gly Ile Thr Glu Ser Ser Asn Met Thr Ile Ile Thr Arg 6725 6730 6735

Thr Gly Pro Pro Leu Gly Ser Thr Ser Gln Gly Thr Phe Thr Leu 6740 6745 6750

Asp Thr Pro Thr Thr Ser Ser Arg Ala Gly Thr His Ser Met Ala 6755 6760 6765

Thr Gln Glu Phe Pro His Ser Glu Met Thr Thr Val Met Asn Lys 6770 6775 6780

Page 30

6847536_1 17 Sep 2019

Asp Pro Glu Ile Leu Ser Trp Thr Ile Pro Pro Ser Ile Glu Lys 6785 6790 6795

Thr Ser Phe Ser Ser Ser Leu Met Pro Ser Pro Ala Met Thr Ser 6800 6805 6810

Pro Pro Val Ser Ser Thr Leu Pro Lys Thr Ile His Thr Thr Pro 6815 6820 6825 2019232796

Ser Pro Met Thr Ser Leu Leu Thr Pro Ser Leu Val Met Thr Thr 6830 6835 6840

Asp Thr Leu Gly Thr Ser Pro Glu Pro Thr Thr Ser Ser Pro Pro 6845 6850 6855

Asn Leu Ser Ser Thr Ser His Glu Ile Leu Thr Thr Asp Glu Asp 6860 6865 6870

Thr Thr Ala Ile Glu Ala Met His Pro Ser Thr Ser Thr Ala Ala 6875 6880 6885

Thr Asn Val Glu Thr Thr Ser Ser Gly His Gly Ser Gln Ser Ser 6890 6895 6900

Val Leu Ala Asp Ser Glu Lys Thr Lys Ala Thr Ala Pro Met Asp 6905 6910 6915

Thr Thr Ser Thr Met Gly His Thr Thr Val Ser Thr Ser Met Ser 6920 6925 6930

Val Ser Ser Glu Thr Thr Lys Ile Lys Arg Glu Ser Thr Tyr Ser 6935 6940 6945

Leu Thr Pro Gly Leu Arg Glu Thr Ser Ile Ser Gln Asn Ala Ser 6950 6955 6960

Phe Ser Thr Asp Thr Ser Ile Val Leu Ser Glu Val Pro Thr Gly 6965 6970 6975

Thr Thr Ala Glu Val Ser Arg Thr Glu Val Thr Ser Ser Gly Arg 6980 6985 6990

Thr Ser Ile Pro Gly Pro Ser Gln Ser Thr Val Leu Pro Glu Ile 6995 7000 7005

Ser Thr Arg Thr Met Thr Arg Leu Phe Ala Ser Pro Thr Met Thr 7010 7015 7020

Glu Ser Ala Glu Met Thr Ile Pro Thr Gln Thr Gly Pro Ser Gly 7025 7030 7035

Page 31

6847536_1 17 Sep 2019

Ser Thr Ser Gln Asp Thr Leu Thr Leu Asp Thr Ser Thr Thr Lys 7040 7045 7050

Ser Gln Ala Lys Thr His Ser Thr Leu Thr Gln Arg Phe Pro His 7055 7060 7065

Ser Glu Met Thr Thr Leu Met Ser Arg Gly Pro Gly Asp Met Ser 7070 7075 7080

Trp Gln Ser Ser Pro Ser Leu Glu Asn Pro Ser Ser Leu Pro Ser 2019232796

7085 7090 7095

Leu Leu Ser Leu Pro Ala Thr Thr Ser Pro Pro Pro Ile Ser Ser 7100 7105 7110

Thr Leu Pro Val Thr Ile Ser Ser Ser Pro Leu Pro Val Thr Ser 7115 7120 7125

Leu Leu Thr Ser Ser Pro Val Thr Thr Thr Asp Met Leu His Thr 7130 7135 7140

Ser Pro Glu Leu Val Thr Ser Ser Pro Pro Lys Leu Ser His Thr 7145 7150 7155

Ser Asp Glu Arg Leu Thr Thr Gly Lys Asp Thr Thr Asn Thr Glu 7160 7165 7170

Ala Val His Pro Ser Thr Asn Thr Ala Ala Ser Asn Val Glu Ile 7175 7180 7185

Pro Ser Ser Gly His Glu Ser Pro Ser Ser Ala Leu Ala Asp Ser 7190 7195 7200

Glu Thr Ser Lys Ala Thr Ser Pro Met Phe Ile Thr Ser Thr Gln 7205 7210 7215

Glu Asp Thr Thr Val Ala Ile Ser Thr Pro His Phe Leu Glu Thr 7220 7225 7230

Ser Arg Ile Gln Lys Glu Ser Ile Ser Ser Leu Ser Pro Lys Leu 7235 7240 7245

Arg Glu Thr Gly Ser Ser Val Glu Thr Ser Ser Ala Ile Glu Thr 7250 7255 7260

Ser Ala Val Leu Ser Glu Val Ser Ile Gly Ala Thr Thr Glu Ile 7265 7270 7275

Ser Arg Thr Glu Val Thr Ser Ser Ser Arg Thr Ser Ile Ser Gly 7280 7285 7290

Ser Ala Glu Ser Thr Met Leu Pro Glu Ile Ser Thr Thr Arg Lys Page 32

6847536_1 17 Sep 2019

7295 7300 7305

Ile Ile Lys Phe Pro Thr Ser Pro Ile Leu Ala Glu Ser Ser Glu 7310 7315 7320

Met Thr Ile Lys Thr Gln Thr Ser Pro Pro Gly Ser Thr Ser Glu 7325 7330 7335

Ser Thr Phe Thr Leu Asp Thr Ser Thr Thr Pro Ser Leu Val Ile 7340 7345 7350 2019232796

Thr His Ser Thr Met Thr Gln Arg Leu Pro His Ser Glu Ile Thr 7355 7360 7365

Thr Leu Val Ser Arg Gly Ala Gly Asp Val Pro Arg Pro Ser Ser 7370 7375 7380

Leu Pro Val Glu Glu Thr Ser Pro Pro Ser Ser Gln Leu Ser Leu 7385 7390 7395

Ser Ala Met Ile Ser Pro Ser Pro Val Ser Ser Thr Leu Pro Ala 7400 7405 7410

Ser Ser His Ser Ser Ser Ala Ser Val Thr Ser Leu Leu Thr Pro 7415 7420 7425

Gly Gln Val Lys Thr Thr Glu Val Leu Asp Ala Ser Ala Glu Pro 7430 7435 7440

Glu Thr Ser Ser Pro Pro Ser Leu Ser Ser Thr Ser Val Glu Ile 7445 7450 7455

Leu Ala Thr Ser Glu Val Thr Thr Asp Thr Glu Lys Ile His Pro 7460 7465 7470

Phe Ser Asn Thr Ala Val Thr Lys Val Gly Thr Ser Ser Ser Gly 7475 7480 7485

His Glu Ser Pro Ser Ser Val Leu Pro Asp Ser Glu Thr Thr Lys 7490 7495 7500

Ala Thr Ser Ala Met Gly Thr Ile Ser Ile Met Gly Asp Thr Ser 7505 7510 7515

Val Ser Thr Leu Thr Pro Ala Leu Ser Asn Thr Arg Lys Ile Gln 7520 7525 7530

Ser Glu Pro Ala Ser Ser Leu Thr Thr Arg Leu Arg Glu Thr Ser 7535 7540 7545

Thr Ser Glu Glu Thr Ser Leu Ala Thr Glu Ala Asn Thr Val Leu 7550 7555 7560 Page 33

6847536_1 17 Sep 2019

Ser Lys Val Ser Thr Gly Ala Thr Thr Glu Val Ser Arg Thr Glu 7565 7570 7575

Ala Ile Ser Phe Ser Arg Thr Ser Met Ser Gly Pro Glu Gln Ser 7580 7585 7590

Thr Met Ser Gln Asp Ile Ser Ile Gly Thr Ile Pro Arg Ile Ser 7595 7600 7605 2019232796

Ala Ser Ser Val Leu Thr Glu Ser Ala Lys Met Thr Ile Thr Thr 7610 7615 7620

Gln Thr Gly Pro Ser Glu Ser Thr Leu Glu Ser Thr Leu Asn Leu 7625 7630 7635

Asn Thr Ala Thr Thr Pro Ser Trp Val Glu Thr His Ser Ile Val 7640 7645 7650

Ile Gln Gly Phe Pro His Pro Glu Met Thr Thr Ser Met Gly Arg 7655 7660 7665

Gly Pro Gly Gly Val Ser Trp Pro Ser Pro Pro Phe Val Lys Glu 7670 7675 7680

Thr Ser Pro Pro Ser Ser Pro Leu Ser Leu Pro Ala Val Thr Ser 7685 7690 7695

Pro His Pro Val Ser Thr Thr Phe Leu Ala His Ile Pro Pro Ser 7700 7705 7710

Pro Leu Pro Val Thr Ser Leu Leu Thr Ser Gly Pro Ala Thr Thr 7715 7720 7725

Thr Asp Ile Leu Gly Thr Ser Thr Glu Pro Gly Thr Ser Ser Ser 7730 7735 7740

Ser Ser Leu Ser Thr Thr Ser His Glu Arg Leu Thr Thr Tyr Lys 7745 7750 7755

Asp Thr Ala His Thr Glu Ala Val His Pro Ser Thr Asn Thr Gly 7760 7765 7770

Gly Thr Asn Val Ala Thr Thr Ser Ser Gly Tyr Lys Ser Gln Ser 7775 7780 7785

Ser Val Leu Ala Asp Ser Ser Pro Met Cys Thr Thr Ser Thr Met 7790 7795 7800

Gly Asp Thr Ser Val Leu Thr Ser Thr Pro Ala Phe Leu Glu Thr 7805 7810 7815

Page 34

6847536_1 17 Sep 2019

Arg Arg Ile Gln Thr Glu Leu Ala Ser Ser Leu Thr Pro Gly Leu 7820 7825 7830

Arg Glu Ser Ser Gly Ser Glu Gly Thr Ser Ser Gly Thr Lys Met 7835 7840 7845

Ser Thr Val Leu Ser Lys Val Pro Thr Gly Ala Thr Thr Glu Ile 7850 7855 7860 2019232796

Ser Lys Glu Asp Val Thr Ser Ile Pro Gly Pro Ala Gln Ser Thr 7865 7870 7875

Ile Ser Pro Asp Ile Ser Thr Arg Thr Val Ser Trp Phe Ser Thr 7880 7885 7890

Ser Pro Val Met Thr Glu Ser Ala Glu Ile Thr Met Asn Thr His 7895 7900 7905

Thr Ser Pro Leu Gly Ala Thr Thr Gln Gly Thr Ser Thr Leu Asp 7910 7915 7920

Thr Ser Ser Thr Thr Ser Leu Thr Met Thr His Ser Thr Ile Ser 7925 7930 7935

Gln Gly Phe Ser His Ser Gln Met Ser Thr Leu Met Arg Arg Gly 7940 7945 7950

Pro Glu Asp Val Ser Trp Met Ser Pro Pro Leu Leu Glu Lys Thr 7955 7960 7965

Arg Pro Ser Phe Ser Leu Met Ser Ser Pro Ala Thr Thr Ser Pro 7970 7975 7980

Ser Pro Val Ser Ser Thr Leu Pro Glu Ser Ile Ser Ser Ser Pro 7985 7990 7995

Leu Pro Val Thr Ser Leu Leu Thr Ser Gly Leu Ala Lys Thr Thr 8000 8005 8010

Asp Met Leu His Lys Ser Ser Glu Pro Val Thr Asn Ser Pro Ala 8015 8020 8025

Asn Leu Ser Ser Thr Ser Val Glu Ile Leu Ala Thr Ser Glu Val 8030 8035 8040

Thr Thr Asp Thr Glu Lys Thr His Pro Ser Ser Asn Arg Thr Val 8045 8050 8055

Thr Asp Val Gly Thr Ser Ser Ser Gly His Glu Ser Thr Ser Phe 8060 8065 8070

Page 35

6847536_1 17 Sep 2019

Val Leu Ala Asp Ser Gln Thr Ser Lys Val Thr Ser Pro Met Val 8075 8080 8085

Ile Thr Ser Thr Met Glu Asp Thr Ser Val Ser Thr Ser Thr Pro 8090 8095 8100

Gly Phe Phe Glu Thr Ser Arg Ile Gln Thr Glu Pro Thr Ser Ser 8105 8110 8115

Leu Thr Leu Gly Leu Arg Lys Thr Ser Ser Ser Glu Gly Thr Ser 2019232796

8120 8125 8130

Leu Ala Thr Glu Met Ser Thr Val Leu Ser Gly Val Pro Thr Gly 8135 8140 8145

Ala Thr Ala Glu Val Ser Arg Thr Glu Val Thr Ser Ser Ser Arg 8150 8155 8160

Thr Ser Ile Ser Gly Phe Ala Gln Leu Thr Val Ser Pro Glu Thr 8165 8170 8175

Ser Thr Glu Thr Ile Thr Arg Leu Pro Thr Ser Ser Ile Met Thr 8180 8185 8190

Glu Ser Ala Glu Met Met Ile Lys Thr Gln Thr Asp Pro Pro Gly 8195 8200 8205

Ser Thr Pro Glu Ser Thr His Thr Val Asp Ile Ser Thr Thr Pro 8210 8215 8220

Asn Trp Val Glu Thr His Ser Thr Val Thr Gln Arg Phe Ser His 8225 8230 8235

Ser Glu Met Thr Thr Leu Val Ser Arg Ser Pro Gly Asp Met Leu 8240 8245 8250

Trp Pro Ser Gln Ser Ser Val Glu Glu Thr Ser Ser Ala Ser Ser 8255 8260 8265

Leu Leu Ser Leu Pro Ala Thr Thr Ser Pro Ser Pro Val Ser Ser 8270 8275 8280

Thr Leu Val Glu Asp Phe Pro Ser Ala Ser Leu Pro Val Thr Ser 8285 8290 8295

Leu Leu Asn Pro Gly Leu Val Ile Thr Thr Asp Arg Met Gly Ile 8300 8305 8310

Ser Arg Glu Pro Gly Thr Ser Ser Thr Ser Asn Leu Ser Ser Thr 8315 8320 8325

Ser His Glu Arg Leu Thr Thr Leu Glu Asp Thr Val Asp Thr Glu Page 36

6847536_1 17 Sep 2019

8330 8335 8340

Asp Met Gln Pro Ser Thr His Thr Ala Val Thr Asn Val Arg Thr 8345 8350 8355

Ser Ile Ser Gly His Glu Ser Gln Ser Ser Val Leu Ser Asp Ser 8360 8365 8370

Glu Thr Pro Lys Ala Thr Ser Pro Met Gly Thr Thr Tyr Thr Met 8375 8380 8385 2019232796

Gly Glu Thr Ser Val Ser Ile Ser Thr Ser Asp Phe Phe Glu Thr 8390 8395 8400

Ser Arg Ile Gln Ile Glu Pro Thr Ser Ser Leu Thr Ser Gly Leu 8405 8410 8415

Arg Glu Thr Ser Ser Ser Glu Arg Ile Ser Ser Ala Thr Glu Gly 8420 8425 8430

Ser Thr Val Leu Ser Glu Val Pro Ser Gly Ala Thr Thr Glu Val 8435 8440 8445

Ser Arg Thr Glu Val Ile Ser Ser Arg Gly Thr Ser Met Ser Gly 8450 8455 8460

Pro Asp Gln Phe Thr Ile Ser Pro Asp Ile Ser Thr Glu Ala Ile 8465 8470 8475

Thr Arg Leu Ser Thr Ser Pro Ile Met Thr Glu Ser Ala Glu Ser 8480 8485 8490

Ala Ile Thr Ile Glu Thr Gly Ser Pro Gly Ala Thr Ser Glu Gly 8495 8500 8505

Thr Leu Thr Leu Asp Thr Ser Thr Thr Thr Phe Trp Ser Gly Thr 8510 8515 8520

His Ser Thr Ala Ser Pro Gly Phe Ser His Ser Glu Met Thr Thr 8525 8530 8535

Leu Met Ser Arg Thr Pro Gly Asp Val Pro Trp Pro Ser Leu Pro 8540 8545 8550

Ser Val Glu Glu Ala Ser Ser Val Ser Ser Ser Leu Ser Ser Pro 8555 8560 8565

Ala Met Thr Ser Thr Ser Phe Phe Ser Thr Leu Pro Glu Ser Ile 8570 8575 8580

Ser Ser Ser Pro His Pro Val Thr Ala Leu Leu Thr Leu Gly Pro 8585 8590 8595 Page 37

6847536_1 17 Sep 2019

Val Lys Thr Thr Asp Met Leu Arg Thr Ser Ser Glu Pro Glu Thr 8600 8605 8610

Ser Ser Pro Pro Asn Leu Ser Ser Thr Ser Ala Glu Ile Leu Ala 8615 8620 8625

Thr Ser Glu Val Thr Lys Asp Arg Glu Lys Ile His Pro Ser Ser 8630 8635 8640 2019232796

Asn Thr Pro Val Val Asn Val Gly Thr Val Ile Tyr Lys His Leu 8645 8650 8655

Ser Pro Ser Ser Val Leu Ala Asp Leu Val Thr Thr Lys Pro Thr 8660 8665 8670

Ser Pro Met Ala Thr Thr Ser Thr Leu Gly Asn Thr Ser Val Ser 8675 8680 8685

Thr Ser Thr Pro Ala Phe Pro Glu Thr Met Met Thr Gln Pro Thr 8690 8695 8700

Ser Ser Leu Thr Ser Gly Leu Arg Glu Ile Ser Thr Ser Gln Glu 8705 8710 8715

Thr Ser Ser Ala Thr Glu Arg Ser Ala Ser Leu Ser Gly Met Pro 8720 8725 8730

Thr Gly Ala Thr Thr Lys Val Ser Arg Thr Glu Ala Leu Ser Leu 8735 8740 8745

Gly Arg Thr Ser Thr Pro Gly Pro Ala Gln Ser Thr Ile Ser Pro 8750 8755 8760

Glu Ile Ser Thr Glu Thr Ile Thr Arg Ile Ser Thr Pro Leu Thr 8765 8770 8775

Thr Thr Gly Ser Ala Glu Met Thr Ile Thr Pro Lys Thr Gly His 8780 8785 8790

Ser Gly Ala Ser Ser Gln Gly Thr Phe Thr Leu Asp Thr Ser Ser 8795 8800 8805

Arg Ala Ser Trp Pro Gly Thr His Ser Ala Ala Thr His Arg Ser 8810 8815 8820

Pro His Ser Gly Met Thr Thr Pro Met Ser Arg Gly Pro Glu Asp 8825 8830 8835

Val Ser Trp Pro Ser Arg Pro Ser Val Glu Lys Thr Ser Pro Pro 8840 8845 8850

Page 38

6847536_1 17 Sep 2019

Ser Ser Leu Val Ser Leu Ser Ala Val Thr Ser Pro Ser Pro Leu 8855 8860 8865

Tyr Ser Thr Pro Ser Glu Ser Ser His Ser Ser Pro Leu Arg Val 8870 8875 8880

Thr Ser Leu Phe Thr Pro Val Met Met Lys Thr Thr Asp Met Leu 8885 8890 8895 2019232796

Asp Thr Ser Leu Glu Pro Val Thr Thr Ser Pro Pro Ser Met Asn 8900 8905 8910

Ile Thr Ser Asp Glu Ser Leu Ala Thr Ser Lys Ala Thr Met Glu 8915 8920 8925

Thr Glu Ala Ile Gln Leu Ser Glu Asn Thr Ala Val Thr Gln Met 8930 8935 8940

Gly Thr Ile Ser Ala Arg Gln Glu Phe Tyr Ser Ser Tyr Pro Gly 8945 8950 8955

Leu Pro Glu Pro Ser Lys Val Thr Ser Pro Val Val Thr Ser Ser 8960 8965 8970

Thr Ile Lys Asp Ile Val Ser Thr Thr Ile Pro Ala Ser Ser Glu 8975 8980 8985

Ile Thr Arg Ile Glu Met Glu Ser Thr Ser Thr Leu Thr Pro Thr 8990 8995 9000

Pro Arg Glu Thr Ser Thr Ser Gln Glu Ile His Ser Ala Thr Lys 9005 9010 9015

Pro Ser Thr Val Pro Tyr Lys Ala Leu Thr Ser Ala Thr Ile Glu 9020 9025 9030

Asp Ser Met Thr Gln Val Met Ser Ser Ser Arg Gly Pro Ser Pro 9035 9040 9045

Asp Gln Ser Thr Met Ser Gln Asp Ile Ser Thr Glu Val Ile Thr 9050 9055 9060

Arg Leu Ser Thr Ser Pro Ile Lys Thr Glu Ser Thr Glu Met Thr 9065 9070 9075

Ile Thr Thr Gln Thr Gly Ser Pro Gly Ala Thr Ser Arg Gly Thr 9080 9085 9090

Leu Thr Leu Asp Thr Ser Thr Thr Phe Met Ser Gly Thr His Ser 9095 9100 9105

Page 39

6847536_1 17 Sep 2019

Thr Ala Ser Gln Gly Phe Ser His Ser Gln Met Thr Ala Leu Met 9110 9115 9120

Ser Arg Thr Pro Gly Asp Val Pro Trp Leu Ser His Pro Ser Val 9125 9130 9135

Glu Glu Ala Ser Ser Ala Ser Phe Ser Leu Ser Ser Pro Val Met 9140 9145 9150

Thr Ser Ser Ser Pro Val Ser Ser Thr Leu Pro Asp Ser Ile His 2019232796

9155 9160 9165

Ser Ser Ser Leu Pro Val Thr Ser Leu Leu Thr Ser Gly Leu Val 9170 9175 9180

Lys Thr Thr Glu Leu Leu Gly Thr Ser Ser Glu Pro Glu Thr Ser 9185 9190 9195

Ser Pro Pro Asn Leu Ser Ser Thr Ser Ala Glu Ile Leu Ala Ile 9200 9205 9210

Thr Glu Val Thr Thr Asp Thr Glu Lys Leu Glu Met Thr Asn Val 9215 9220 9225

Val Thr Ser Gly Tyr Thr His Glu Ser Pro Ser Ser Val Leu Ala 9230 9235 9240

Asp Ser Val Thr Thr Lys Ala Thr Ser Ser Met Gly Ile Thr Tyr 9245 9250 9255

Pro Thr Gly Asp Thr Asn Val Leu Thr Ser Thr Pro Ala Phe Ser 9260 9265 9270

Asp Thr Ser Arg Ile Gln Thr Lys Ser Lys Leu Ser Leu Thr Pro 9275 9280 9285

Gly Leu Met Glu Thr Ser Ile Ser Glu Glu Thr Ser Ser Ala Thr 9290 9295 9300

Glu Lys Ser Thr Val Leu Ser Ser Val Pro Thr Gly Ala Thr Thr 9305 9310 9315

Glu Val Ser Arg Thr Glu Ala Ile Ser Ser Ser Arg Thr Ser Ile 9320 9325 9330

Pro Gly Pro Ala Gln Ser Thr Met Ser Ser Asp Thr Ser Met Glu 9335 9340 9345

Thr Ile Thr Arg Ile Ser Thr Pro Leu Thr Arg Lys Glu Ser Thr 9350 9355 9360

Asp Met Ala Ile Thr Pro Lys Thr Gly Pro Ser Gly Ala Thr Ser Page 40

6847536_1 17 Sep 2019

9365 9370 9375

Gln Gly Thr Phe Thr Leu Asp Ser Ser Ser Thr Ala Ser Trp Pro 9380 9385 9390

Gly Thr His Ser Ala Thr Thr Gln Arg Phe Pro Gln Ser Val Val 9395 9400 9405

Thr Thr Pro Met Ser Arg Gly Pro Glu Asp Val Ser Trp Pro Ser 9410 9415 9420 2019232796

Pro Leu Ser Val Glu Lys Asn Ser Pro Pro Ser Ser Leu Val Ser 9425 9430 9435

Ser Ser Ser Val Thr Ser Pro Ser Pro Leu Tyr Ser Thr Pro Ser 9440 9445 9450

Gly Ser Ser His Ser Ser Pro Val Pro Val Thr Ser Leu Phe Thr 9455 9460 9465

Ser Ile Met Met Lys Ala Thr Asp Met Leu Asp Ala Ser Leu Glu 9470 9475 9480

Pro Glu Thr Thr Ser Ala Pro Asn Met Asn Ile Thr Ser Asp Glu 9485 9490 9495

Ser Leu Ala Ala Ser Lys Ala Thr Thr Glu Thr Glu Ala Ile His 9500 9505 9510

Val Phe Glu Asn Thr Ala Ala Ser His Val Glu Thr Thr Ser Ala 9515 9520 9525

Thr Glu Glu Leu Tyr Ser Ser Ser Pro Gly Phe Ser Glu Pro Thr 9530 9535 9540

Lys Val Ile Ser Pro Val Val Thr Ser Ser Ser Ile Arg Asp Asn 9545 9550 9555

Met Val Ser Thr Thr Met Pro Gly Ser Ser Gly Ile Thr Arg Ile 9560 9565 9570

Glu Ile Glu Ser Met Ser Ser Leu Thr Pro Gly Leu Arg Glu Thr 9575 9580 9585

Arg Thr Ser Gln Asp Ile Thr Ser Ser Thr Glu Thr Ser Thr Val 9590 9595 9600

Leu Tyr Lys Met Pro Ser Gly Ala Thr Pro Glu Val Ser Arg Thr 9605 9610 9615

Glu Val Met Pro Ser Ser Arg Thr Ser Ile Pro Gly Pro Ala Gln 9620 9625 9630 Page 41

6847536_1 17 Sep 2019

Ser Thr Met Ser Leu Asp Ile Ser Asp Glu Val Val Thr Arg Leu 9635 9640 9645

Ser Thr Ser Pro Ile Met Thr Glu Ser Ala Glu Ile Thr Ile Thr 9650 9655 9660

Thr Gln Thr Gly Tyr Ser Leu Ala Thr Ser Gln Val Thr Leu Pro 9665 9670 9675 2019232796

Leu Gly Thr Ser Met Thr Phe Leu Ser Gly Thr His Ser Thr Met 9680 9685 9690

Ser Gln Gly Leu Ser His Ser Glu Met Thr Asn Leu Met Ser Arg 9695 9700 9705

Gly Pro Glu Ser Leu Ser Trp Thr Ser Pro Arg Phe Val Glu Thr 9710 9715 9720

Thr Arg Ser Ser Ser Ser Leu Thr Ser Leu Pro Leu Thr Thr Ser 9725 9730 9735

Leu Ser Pro Val Ser Ser Thr Leu Leu Asp Ser Ser Pro Ser Ser 9740 9745 9750

Pro Leu Pro Val Thr Ser Leu Ile Leu Pro Gly Leu Val Lys Thr 9755 9760 9765

Thr Glu Val Leu Asp Thr Ser Ser Glu Pro Lys Thr Ser Ser Ser 9770 9775 9780

Pro Asn Leu Ser Ser Thr Ser Val Glu Ile Pro Ala Thr Ser Glu 9785 9790 9795

Ile Met Thr Asp Thr Glu Lys Ile His Pro Ser Ser Asn Thr Ala 9800 9805 9810

Val Ala Lys Val Arg Thr Ser Ser Ser Val His Glu Ser His Ser 9815 9820 9825

Ser Val Leu Ala Asp Ser Glu Thr Thr Ile Thr Ile Pro Ser Met 9830 9835 9840

Gly Ile Thr Ser Ala Val Asp Asp Thr Thr Val Phe Thr Ser Asn 9845 9850 9855

Pro Ala Phe Ser Glu Thr Arg Arg Ile Pro Thr Glu Pro Thr Phe 9860 9865 9870

Ser Leu Thr Pro Gly Phe Arg Glu Thr Ser Thr Ser Glu Glu Thr 9875 9880 9885

Page 42

6847536_1 17 Sep 2019

Thr Ser Ile Thr Glu Thr Ser Ala Val Leu Tyr Gly Val Pro Thr 9890 9895 9900

Ser Ala Thr Thr Glu Val Ser Met Thr Glu Ile Met Ser Ser Asn 9905 9910 9915

Arg Ile His Ile Pro Asp Ser Asp Gln Ser Thr Met Ser Pro Asp 9920 9925 9930 2019232796

Ile Ile Thr Glu Val Ile Thr Arg Leu Ser Ser Ser Ser Met Met 9935 9940 9945

Ser Glu Ser Thr Gln Met Thr Ile Thr Thr Gln Lys Ser Ser Pro 9950 9955 9960

Gly Ala Thr Ala Gln Ser Thr Leu Thr Leu Ala Thr Thr Thr Ala 9965 9970 9975

Pro Leu Ala Arg Thr His Ser Thr Val Pro Pro Arg Phe Leu His 9980 9985 9990

Ser Glu Met Thr Thr Leu Met Ser Arg Ser Pro Glu Asn Pro Ser 9995 10000 10005

Trp Lys Ser Ser Leu Phe Val Glu Lys Thr Ser Ser Ser Ser Ser 10010 10015 10020

Leu Leu Ser Leu Pro Val Thr Thr Ser Pro Ser Val Ser Ser Thr 10025 10030 10035

Leu Pro Gln Ser Ile Pro Ser Ser Ser Phe Ser Val Thr Ser Leu 10040 10045 10050

Leu Thr Pro Gly Met Val Lys Thr Thr Asp Thr Ser Thr Glu Pro 10055 10060 10065

Gly Thr Ser Leu Ser Pro Asn Leu Ser Gly Thr Ser Val Glu Ile 10070 10075 10080

Leu Ala Ala Ser Glu Val Thr Thr Asp Thr Glu Lys Ile His Pro 10085 10090 10095

Ser Ser Ser Met Ala Val Thr Asn Val Gly Thr Thr Ser Ser Gly 10100 10105 10110

His Glu Leu Tyr Ser Ser Val Ser Ile His Ser Glu Pro Ser Lys 10115 10120 10125

Ala Thr Tyr Pro Val Gly Thr Pro Ser Ser Met Ala Glu Thr Ser 10130 10135 10140

Page 43

6847536_1 17 Sep 2019

Ile Ser Thr Ser Met Pro Ala Asn Phe Glu Thr Thr Gly Phe Glu 10145 10150 10155

Ala Glu Pro Phe Ser His Leu Thr Ser Gly Phe Arg Lys Thr Asn 10160 10165 10170

Met Ser Leu Asp Thr Ser Ser Val Thr Pro Thr Asn Thr Pro Ser 10175 10180 10185

Ser Pro Gly Ser Thr His Leu Leu Gln Ser Ser Lys Thr Asp Phe 2019232796

10190 10195 10200

Thr Ser Ser Ala Lys Thr Ser Ser Pro Asp Trp Pro Pro Ala Ser 10205 10210 10215

Gln Tyr Thr Glu Ile Pro Val Asp Ile Ile Thr Pro Phe Asn Ala 10220 10225 10230

Ser Pro Ser Ile Thr Glu Ser Thr Gly Ile Thr Ser Phe Pro Glu 10235 10240 10245

Ser Arg Phe Thr Met Ser Val Thr Glu Ser Thr His His Leu Ser 10250 10255 10260

Thr Asp Leu Leu Pro Ser Ala Glu Thr Ile Ser Thr Gly Thr Val 10265 10270 10275

Met Pro Ser Leu Ser Glu Ala Met Thr Ser Phe Ala Thr Thr Gly 10280 10285 10290

Val Pro Arg Ala Ile Ser Gly Ser Gly Ser Pro Phe Ser Arg Thr 10295 10300 10305

Glu Ser Gly Pro Gly Asp Ala Thr Leu Ser Thr Ile Ala Glu Ser 10310 10315 10320

Leu Pro Ser Ser Thr Pro Val Pro Phe Ser Ser Ser Thr Phe Thr 10325 10330 10335

Thr Thr Asp Ser Ser Thr Ile Pro Ala Leu His Glu Ile Thr Ser 10340 10345 10350

Ser Ser Ala Thr Pro Tyr Arg Val Asp Thr Ser Leu Gly Thr Glu 10355 10360 10365

Ser Ser Thr Thr Glu Gly Arg Leu Val Met Val Ser Thr Leu Asp 10370 10375 10380

Thr Ser Ser Gln Pro Gly Arg Thr Ser Ser Ser Pro Ile Leu Asp 10385 10390 10395

Thr Arg Met Thr Glu Ser Val Glu Leu Gly Thr Val Thr Ser Ala Page 44

6847536_1 17 Sep 2019

10400 10405 10410

Tyr Gln Val Pro Ser Leu Ser Thr Arg Leu Thr Arg Thr Asp Gly 10415 10420 10425

Ile Met Glu His Ile Thr Lys Ile Pro Asn Glu Ala Ala His Arg 10430 10435 10440

Gly Thr Ile Arg Pro Val Lys Gly Pro Gln Thr Ser Thr Ser Pro 10445 10450 10455 2019232796

Ala Ser Pro Lys Gly Leu His Thr Gly Gly Thr Lys Arg Met Glu 10460 10465 10470

Thr Thr Thr Thr Ala Leu Lys Thr Thr Thr Thr Ala Leu Lys Thr 10475 10480 10485

Thr Ser Arg Ala Thr Leu Thr Thr Ser Val Tyr Thr Pro Thr Leu 10490 10495 10500

Gly Thr Leu Thr Pro Leu Asn Ala Ser Met Gln Met Ala Ser Thr 10505 10510 10515

Ile Pro Thr Glu Met Met Ile Thr Thr Pro Tyr Val Phe Pro Asp 10520 10525 10530

Val Pro Glu Thr Thr Ser Ser Leu Ala Thr Ser Leu Gly Ala Glu 10535 10540 10545

Thr Ser Thr Ala Leu Pro Arg Thr Thr Pro Ser Val Phe Asn Arg 10550 10555 10560

Glu Ser Glu Thr Thr Ala Ser Leu Val Ser Arg Ser Gly Ala Glu 10565 10570 10575

Arg Ser Pro Val Ile Gln Thr Leu Asp Val Ser Ser Ser Glu Pro 10580 10585 10590

Asp Thr Thr Ala Ser Trp Val Ile His Pro Ala Glu Thr Ile Pro 10595 10600 10605

Thr Val Ser Lys Thr Thr Pro Asn Phe Phe His Ser Glu Leu Asp 10610 10615 10620

Thr Val Ser Ser Thr Ala Thr Ser His Gly Ala Asp Val Ser Ser 10625 10630 10635

Ala Ile Pro Thr Asn Ile Ser Pro Ser Glu Leu Asp Ala Leu Thr 10640 10645 10650

Pro Leu Val Thr Ile Ser Gly Thr Asp Thr Ser Thr Thr Phe Pro 10655 10660 10665 Page 45

6847536_1 17 Sep 2019

Thr Leu Thr Lys Ser Pro His Glu Thr Glu Thr Arg Thr Thr Trp 10670 10675 10680

Leu Thr His Pro Ala Glu Thr Ser Ser Thr Ile Pro Arg Thr Ile 10685 10690 10695

Pro Asn Phe Ser His His Glu Ser Asp Ala Thr Pro Ser Ile Ala 10700 10705 10710 2019232796

Thr Ser Pro Gly Ala Glu Thr Ser Ser Ala Ile Pro Ile Met Thr 10715 10720 10725

Val Ser Pro Gly Ala Glu Asp Leu Val Thr Ser Gln Val Thr Ser 10730 10735 10740

Ser Gly Thr Asp Arg Asn Met Thr Ile Pro Thr Leu Thr Leu Ser 10745 10750 10755

Pro Gly Glu Pro Lys Thr Ile Ala Ser Leu Val Thr His Pro Glu 10760 10765 10770

Ala Gln Thr Ser Ser Ala Ile Pro Thr Ser Thr Ile Ser Pro Ala 10775 10780 10785

Val Ser Arg Leu Val Thr Ser Met Val Thr Ser Leu Ala Ala Lys 10790 10795 10800

Thr Ser Thr Thr Asn Arg Ala Leu Thr Asn Ser Pro Gly Glu Pro 10805 10810 10815

Ala Thr Thr Val Ser Leu Val Thr His Pro Ala Gln Thr Ser Pro 10820 10825 10830

Thr Val Pro Trp Thr Thr Ser Ile Phe Phe His Ser Lys Ser Asp 10835 10840 10845

Thr Thr Pro Ser Met Thr Thr Ser His Gly Ala Glu Ser Ser Ser 10850 10855 10860

Ala Val Pro Thr Pro Thr Val Ser Thr Glu Val Pro Gly Val Val 10865 10870 10875

Thr Pro Leu Val Thr Ser Ser Arg Ala Val Ile Ser Thr Thr Ile 10880 10885 10890

Pro Ile Leu Thr Leu Ser Pro Gly Glu Pro Glu Thr Thr Pro Ser 10895 10900 10905

Met Ala Thr Ser His Gly Glu Glu Ala Ser Ser Ala Ile Pro Thr 10910 10915 10920

Page 46

6847536_1 17 Sep 2019

Pro Thr Val Ser Pro Gly Val Pro Gly Val Val Thr Ser Leu Val 10925 10930 10935

Thr Ser Ser Arg Ala Val Thr Ser Thr Thr Ile Pro Ile Leu Thr 10940 10945 10950

Phe Ser Leu Gly Glu Pro Glu Thr Thr Pro Ser Met Ala Thr Ser 10955 10960 10965 2019232796

His Gly Thr Glu Ala Gly Ser Ala Val Pro Thr Val Leu Pro Glu 10970 10975 10980

Val Pro Gly Met Val Thr Ser Leu Val Ala Ser Ser Arg Ala Val 10985 10990 10995

Thr Ser Thr Thr Leu Pro Thr Leu Thr Leu Ser Pro Gly Glu Pro 11000 11005 11010

Glu Thr Thr Pro Ser Met Ala Thr Ser His Gly Ala Glu Ala Ser 11015 11020 11025

Ser Thr Val Pro Thr Val Ser Pro Glu Val Pro Gly Val Val Thr 11030 11035 11040

Ser Leu Val Thr Ser Ser Ser Gly Val Asn Ser Thr Ser Ile Pro 11045 11050 11055

Thr Leu Ile Leu Ser Pro Gly Glu Leu Glu Thr Thr Pro Ser Met 11060 11065 11070

Ala Thr Ser His Gly Ala Glu Ala Ser Ser Ala Val Pro Thr Pro 11075 11080 11085

Thr Val Ser Pro Gly Val Ser Gly Val Val Thr Pro Leu Val Thr 11090 11095 11100

Ser Ser Arg Ala Val Thr Ser Thr Thr Ile Pro Ile Leu Thr Leu 11105 11110 11115

Ser Ser Ser Glu Pro Glu Thr Thr Pro Ser Met Ala Thr Ser His 11120 11125 11130

Gly Val Glu Ala Ser Ser Ala Val Leu Thr Val Ser Pro Glu Val 11135 11140 11145

Pro Gly Met Val Thr Ser Leu Val Thr Ser Ser Arg Ala Val Thr 11150 11155 11160

Ser Thr Thr Ile Pro Thr Leu Thr Ile Ser Ser Asp Glu Pro Glu 11165 11170 11175

Page 47

6847536_1 17 Sep 2019

Thr Thr Thr Ser Leu Val Thr His Ser Glu Ala Lys Met Ile Ser 11180 11185 11190

Ala Ile Pro Thr Leu Ala Val Ser Pro Thr Val Gln Gly Leu Val 11195 11200 11205

Thr Ser Leu Val Thr Ser Ser Gly Ser Glu Thr Ser Ala Phe Ser 11210 11215 11220

Asn Leu Thr Val Ala Ser Ser Gln Pro Glu Thr Ile Asp Ser Trp 2019232796

11225 11230 11235

Val Ala His Pro Gly Thr Glu Ala Ser Ser Val Val Pro Thr Leu 11240 11245 11250

Thr Val Ser Thr Gly Glu Pro Phe Thr Asn Ile Ser Leu Val Thr 11255 11260 11265

His Pro Ala Glu Ser Ser Ser Thr Leu Pro Arg Thr Thr Ser Arg 11270 11275 11280

Phe Ser His Ser Glu Leu Asp Thr Met Pro Ser Thr Val Thr Ser 11285 11290 11295

Pro Glu Ala Glu Ser Ser Ser Ala Ile Ser Thr Thr Ile Ser Pro 11300 11305 11310

Gly Ile Pro Gly Val Leu Thr Ser Leu Val Thr Ser Ser Gly Arg 11315 11320 11325

Asp Ile Ser Ala Thr Phe Pro Thr Val Pro Glu Ser Pro His Glu 11330 11335 11340

Ser Glu Ala Thr Ala Ser Trp Val Thr His Pro Ala Val Thr Ser 11345 11350 11355

Thr Thr Val Pro Arg Thr Thr Pro Asn Tyr Ser His Ser Glu Pro 11360 11365 11370

Asp Thr Thr Pro Ser Ile Ala Thr Ser Pro Gly Ala Glu Ala Thr 11375 11380 11385

Ser Asp Phe Pro Thr Ile Thr Val Ser Pro Asp Val Pro Asp Met 11390 11395 11400

Val Thr Ser Gln Val Thr Ser Ser Gly Thr Asp Thr Ser Ile Thr 11405 11410 11415

Ile Pro Thr Leu Thr Leu Ser Ser Gly Glu Pro Glu Thr Thr Thr 11420 11425 11430

Ser Phe Ile Thr Tyr Ser Glu Thr His Thr Ser Ser Ala Ile Pro Page 48

6847536_1 17 Sep 2019

11435 11440 11445

Thr Leu Pro Val Ser Pro Gly Ala Ser Lys Met Leu Thr Ser Leu 11450 11455 11460

Val Ile Ser Ser Gly Thr Asp Ser Thr Thr Thr Phe Pro Thr Leu 11465 11470 11475

Thr Glu Thr Pro Tyr Glu Pro Glu Thr Thr Ala Ile Gln Leu Ile 11480 11485 11490 2019232796

His Pro Ala Glu Thr Asn Thr Met Val Pro Arg Thr Thr Pro Lys 11495 11500 11505

Phe Ser His Ser Lys Ser Asp Thr Thr Leu Pro Val Ala Ile Thr 11510 11515 11520

Ser Pro Gly Pro Glu Ala Ser Ser Ala Val Ser Thr Thr Thr Ile 11525 11530 11535

Ser Pro Asp Met Ser Asp Leu Val Thr Ser Leu Val Pro Ser Ser 11540 11545 11550

Gly Thr Asp Thr Ser Thr Thr Phe Pro Thr Leu Ser Glu Thr Pro 11555 11560 11565

Tyr Glu Pro Glu Thr Thr Ala Thr Trp Leu Thr His Pro Ala Glu 11570 11575 11580

Thr Ser Thr Thr Val Ser Gly Thr Ile Pro Asn Phe Ser His Arg 11585 11590 11595

Gly Ser Asp Thr Ala Pro Ser Met Val Thr Ser Pro Gly Val Asp 11600 11605 11610

Thr Arg Ser Gly Val Pro Thr Thr Thr Ile Pro Pro Ser Ile Pro 11615 11620 11625

Gly Val Val Thr Ser Gln Val Thr Ser Ser Ala Thr Asp Thr Ser 11630 11635 11640

Thr Ala Ile Pro Thr Leu Thr Pro Ser Pro Gly Glu Pro Glu Thr 11645 11650 11655

Thr Ala Ser Ser Ala Thr His Pro Gly Thr Gln Thr Gly Phe Thr 11660 11665 11670

Val Pro Ile Arg Thr Val Pro Ser Ser Glu Pro Asp Thr Met Ala 11675 11680 11685

Ser Trp Val Thr His Pro Pro Gln Thr Ser Thr Pro Val Ser Arg 11690 11695 11700 Page 49

6847536_1 17 Sep 2019

Thr Thr Ser Ser Phe Ser His Ser Ser Pro Asp Ala Thr Pro Val 11705 11710 11715

Met Ala Thr Ser Pro Arg Thr Glu Ala Ser Ser Ala Val Leu Thr 11720 11725 11730

Thr Ile Ser Pro Gly Ala Pro Glu Met Val Thr Ser Gln Ile Thr 11735 11740 11745 2019232796

Ser Ser Gly Ala Ala Thr Ser Thr Thr Val Pro Thr Leu Thr His 11750 11755 11760

Ser Pro Gly Met Pro Glu Thr Thr Ala Leu Leu Ser Thr His Pro 11765 11770 11775

Arg Thr Glu Thr Ser Lys Thr Phe Pro Ala Ser Thr Val Phe Pro 11780 11785 11790

Gln Val Ser Glu Thr Thr Ala Ser Leu Thr Ile Arg Pro Gly Ala 11795 11800 11805

Glu Thr Ser Thr Ala Leu Pro Thr Gln Thr Thr Ser Ser Leu Phe 11810 11815 11820

Thr Leu Leu Val Thr Gly Thr Ser Arg Val Asp Leu Ser Pro Thr 11825 11830 11835

Ala Ser Pro Gly Val Ser Ala Lys Thr Ala Pro Leu Ser Thr His 11840 11845 11850

Pro Gly Thr Glu Thr Ser Thr Met Ile Pro Thr Ser Thr Leu Ser 11855 11860 11865

Leu Gly Leu Leu Glu Thr Thr Gly Leu Leu Ala Thr Ser Ser Ser 11870 11875 11880

Ala Glu Thr Ser Thr Ser Thr Leu Thr Leu Thr Val Ser Pro Ala 11885 11890 11895

Val Ser Gly Leu Ser Ser Ala Ser Ile Thr Thr Asp Lys Pro Gln 11900 11905 11910

Thr Val Thr Ser Trp Asn Thr Glu Thr Ser Pro Ser Val Thr Ser 11915 11920 11925

Val Gly Pro Pro Glu Phe Ser Arg Thr Val Thr Gly Thr Thr Met 11930 11935 11940

Thr Leu Ile Pro Ser Glu Met Pro Thr Pro Pro Lys Thr Ser His 11945 11950 11955

Page 50

6847536_1 17 Sep 2019

Gly Glu Gly Val Ser Pro Thr Thr Ile Leu Arg Thr Thr Met Val 11960 11965 11970

Glu Ala Thr Asn Leu Ala Thr Thr Gly Ser Ser Pro Thr Val Ala 11975 11980 11985

Lys Thr Thr Thr Thr Phe Asn Thr Leu Ala Gly Ser Leu Phe Thr 11990 11995 12000 2019232796

Pro Leu Thr Thr Pro Gly Met Ser Thr Leu Ala Ser Glu Ser Val 12005 12010 12015

Thr Ser Arg Thr Ser Tyr Asn His Arg Ser Trp Ile Ser Thr Thr 12020 12025 12030

Ser Ser Tyr Asn Arg Arg Tyr Trp Thr Pro Ala Thr Ser Thr Pro 12035 12040 12045

Val Thr Ser Thr Phe Ser Pro Gly Ile Ser Thr Ser Ser Ile Pro 12050 12055 12060

Ser Ser Thr Ala Ala Thr Val Pro Phe Met Val Pro Phe Thr Leu 12065 12070 12075

Asn Phe Thr Ile Thr Asn Leu Gln Tyr Glu Glu Asp Met Arg His 12080 12085 12090

Pro Gly Ser Arg Lys Phe Asn Ala Thr Glu Arg Glu Leu Gln Gly 12095 12100 12105

Leu Leu Lys Pro Leu Phe Arg Asn Ser Ser Leu Glu Tyr Leu Tyr 12110 12115 12120

Ser Gly Cys Arg Leu Ala Ser Leu Arg Pro Glu Lys Asp Ser Ser 12125 12130 12135

Ala Thr Ala Val Asp Ala Ile Cys Thr His Arg Pro Asp Pro Glu 12140 12145 12150

Asp Leu Gly Leu Asp Arg Glu Arg Leu Tyr Trp Glu Leu Ser Asn 12155 12160 12165

Leu Thr Asn Gly Ile Gln Glu Leu Gly Pro Tyr Thr Leu Asp Arg 12170 12175 12180

Asn Ser Leu Tyr Val Asn Gly Phe Thr His Arg Ser Ser Met Pro 12185 12190 12195

Thr Thr Ser Thr Pro Gly Thr Ser Thr Val Asp Val Gly Thr Ser 12200 12205 12210

Page 51

6847536_1 17 Sep 2019

Gly Thr Pro Ser Ser Ser Pro Ser Pro Thr Thr Ala Gly Pro Leu 12215 12220 12225

Leu Met Pro Phe Thr Leu Asn Phe Thr Ile Thr Asn Leu Gln Tyr 12230 12235 12240

Glu Glu Asp Met Arg Arg Thr Gly Ser Arg Lys Phe Asn Thr Met 12245 12250 12255

Glu Ser Val Leu Gln Gly Leu Leu Lys Pro Leu Phe Lys Asn Thr 2019232796

12260 12265 12270

Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr Leu Leu Arg 12275 12280 12285

Pro Glu Lys Asp Gly Ala Ala Thr Gly Val Asp Ala Ile Cys Thr 12290 12295 12300

His Arg Leu Asp Pro Lys Ser Pro Gly Leu Asn Arg Glu Gln Leu 12305 12310 12315

Tyr Trp Glu Leu Ser Lys Leu Thr Asn Asp Ile Glu Glu Leu Gly 12320 12325 12330

Pro Tyr Thr Leu Asp Arg Asn Ser Leu Tyr Val Asn Gly Phe Thr 12335 12340 12345

His Gln Ser Ser Val Ser Thr Thr Ser Thr Pro Gly Thr Ser Thr 12350 12355 12360

Val Asp Leu Arg Thr Ser Gly Thr Pro Ser Ser Leu Ser Ser Pro 12365 12370 12375

Thr Ile Met Ala Ala Gly Pro Leu Leu Val Pro Phe Thr Leu Asn 12380 12385 12390

Phe Thr Ile Thr Asn Leu Gln Tyr Gly Glu Asp Met Gly His Pro 12395 12400 12405

Gly Ser Arg Lys Phe Asn Thr Thr Glu Arg Val Leu Gln Gly Leu 12410 12415 12420

Leu Gly Pro Ile Phe Lys Asn Thr Ser Val Gly Pro Leu Tyr Ser 12425 12430 12435

Gly Cys Arg Leu Thr Ser Leu Arg Ser Glu Lys Asp Gly Ala Ala 12440 12445 12450

Thr Gly Val Asp Ala Ile Cys Ile His His Leu Asp Pro Lys Ser 12455 12460 12465

Pro Gly Leu Asn Arg Glu Arg Leu Tyr Trp Glu Leu Ser Gln Leu Page 52

6847536_1 17 Sep 2019

12470 12475 12480

Thr Asn Gly Ile Lys Glu Leu Gly Pro Tyr Thr Leu Asp Arg Asn 12485 12490 12495

Ser Leu Tyr Val Asn Gly Phe Thr His Arg Thr Ser Val Pro Thr 12500 12505 12510

Ser Ser Thr Pro Gly Thr Ser Thr Val Asp Leu Gly Thr Ser Gly 12515 12520 12525 2019232796

Thr Pro Phe Ser Leu Pro Ser Pro Ala Thr Ala Gly Pro Leu Leu 12530 12535 12540

Val Leu Phe Thr Leu Asn Phe Thr Ile Thr Asn Leu Lys Tyr Glu 12545 12550 12555

Glu Asp Met His Arg Pro Gly Ser Arg Lys Phe Asn Thr Thr Glu 12560 12565 12570

Arg Val Leu Gln Thr Leu Leu Gly Pro Met Phe Lys Asn Thr Ser 12575 12580 12585

Val Gly Leu Leu Tyr Ser Gly Cys Arg Leu Thr Leu Leu Arg Ser 12590 12595 12600

Glu Lys Asp Gly Ala Ala Thr Gly Val Asp Ala Ile Cys Thr His 12605 12610 12615

Arg Leu Asp Pro Lys Ser Pro Gly Val Asp Arg Glu Gln Leu Tyr 12620 12625 12630

Trp Glu Leu Ser Gln Leu Thr Asn Gly Ile Lys Glu Leu Gly Pro 12635 12640 12645

Tyr Thr Leu Asp Arg Asn Ser Leu Tyr Val Asn Gly Phe Thr His 12650 12655 12660

Trp Ile Pro Val Pro Thr Ser Ser Thr Pro Gly Thr Ser Thr Val 12665 12670 12675

Asp Leu Gly Ser Gly Thr Pro Ser Ser Leu Pro Ser Pro Thr Thr 12680 12685 12690

Ala Gly Pro Leu Leu Val Pro Phe Thr Leu Asn Phe Thr Ile Thr 12695 12700 12705

Asn Leu Lys Tyr Glu Glu Asp Met His Cys Pro Gly Ser Arg Lys 12710 12715 12720

Phe Asn Thr Thr Glu Arg Val Leu Gln Ser Leu Leu Gly Pro Met 12725 12730 12735 Page 53

6847536_1 17 Sep 2019

Phe Lys Asn Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu 12740 12745 12750

Thr Leu Leu Arg Ser Glu Lys Asp Gly Ala Ala Thr Gly Val Asp 12755 12760 12765

Ala Ile Cys Thr His Arg Leu Asp Pro Lys Ser Pro Gly Val Asp 12770 12775 12780 2019232796

Arg Glu Gln Leu Tyr Trp Glu Leu Ser Gln Leu Thr Asn Gly Ile 12785 12790 12795

Lys Glu Leu Gly Pro Tyr Thr Leu Asp Arg Asn Ser Leu Tyr Val 12800 12805 12810

Asn Gly Phe Thr His Gln Thr Ser Ala Pro Asn Thr Ser Thr Pro 12815 12820 12825

Gly Thr Ser Thr Val Asp Leu Gly Thr Ser Gly Thr Pro Ser Ser 12830 12835 12840

Leu Pro Ser Pro Thr Ser Ala Gly Pro Leu Leu Val Pro Phe Thr 12845 12850 12855

Leu Asn Phe Thr Ile Thr Asn Leu Gln Tyr Glu Glu Asp Met His 12860 12865 12870

His Pro Gly Ser Arg Lys Phe Asn Thr Thr Glu Arg Val Leu Gln 12875 12880 12885

Gly Leu Leu Gly Pro Met Phe Lys Asn Thr Ser Val Gly Leu Leu 12890 12895 12900

Tyr Ser Gly Cys Arg Leu Thr Leu Leu Arg Pro Glu Lys Asn Gly 12905 12910 12915

Ala Ala Thr Gly Met Asp Ala Ile Cys Ser His Arg Leu Asp Pro 12920 12925 12930

Lys Ser Pro Gly Leu Asn Arg Glu Gln Leu Tyr Trp Glu Leu Ser 12935 12940 12945

Gln Leu Thr His Gly Ile Lys Glu Leu Gly Pro Tyr Thr Leu Asp 12950 12955 12960

Arg Asn Ser Leu Tyr Val Asn Gly Phe Thr His Arg Ser Ser Val 12965 12970 12975

Ala Pro Thr Ser Thr Pro Gly Thr Ser Thr Val Asp Leu Gly Thr 12980 12985 12990

Page 54

6847536_1 17 Sep 2019

Ser Gly Thr Pro Ser Ser Leu Pro Ser Pro Thr Thr Ala Val Pro 12995 13000 13005

Leu Leu Val Pro Phe Thr Leu Asn Phe Thr Ile Thr Asn Leu Gln 13010 13015 13020

Tyr Gly Glu Asp Met Arg His Pro Gly Ser Arg Lys Phe Asn Thr 13025 13030 13035 2019232796

Thr Glu Arg Val Leu Gln Gly Leu Leu Gly Pro Leu Phe Lys Asn 13040 13045 13050

Ser Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Ile Ser Leu 13055 13060 13065

Arg Ser Glu Lys Asp Gly Ala Ala Thr Gly Val Asp Ala Ile Cys 13070 13075 13080

Thr His His Leu Asn Pro Gln Ser Pro Gly Leu Asp Arg Glu Gln 13085 13090 13095

Leu Tyr Trp Gln Leu Ser Gln Met Thr Asn Gly Ile Lys Glu Leu 13100 13105 13110

Gly Pro Tyr Thr Leu Asp Arg Asn Ser Leu Tyr Val Asn Gly Phe 13115 13120 13125

Thr His Arg Ser Ser Gly Leu Thr Thr Ser Thr Pro Trp Thr Ser 13130 13135 13140

Thr Val Asp Leu Gly Thr Ser Gly Thr Pro Ser Pro Val Pro Ser 13145 13150 13155

Pro Thr Thr Thr Gly Pro Leu Leu Val Pro Phe Thr Leu Asn Phe 13160 13165 13170

Thr Ile Thr Asn Leu Gln Tyr Glu Glu Asn Met Gly His Pro Gly 13175 13180 13185

Ser Arg Lys Phe Asn Ile Thr Glu Ser Val Leu Gln Gly Leu Leu 13190 13195 13200

Lys Pro Leu Phe Lys Ser Thr Ser Val Gly Pro Leu Tyr Ser Gly 13205 13210 13215

Cys Arg Leu Thr Leu Leu Arg Pro Glu Lys Asp Gly Val Ala Thr 13220 13225 13230

Arg Val Asp Ala Ile Cys Thr His Arg Pro Asp Pro Lys Ile Pro 13235 13240 13245

Page 55

6847536_1 17 Sep 2019

Gly Leu Asp Arg Gln Gln Leu Tyr Trp Glu Leu Ser Gln Leu Thr 13250 13255 13260

His Ser Ile Thr Glu Leu Gly Pro Tyr Thr Leu Asp Arg Asp Ser 13265 13270 13275

Leu Tyr Val Asn Gly Phe Thr Gln Arg Ser Ser Val Pro Thr Thr 13280 13285 13290

Ser Thr Pro Gly Thr Phe Thr Val Gln Pro Glu Thr Ser Glu Thr 2019232796

13295 13300 13305

Pro Ser Ser Leu Pro Gly Pro Thr Ala Thr Gly Pro Val Leu Leu 13310 13315 13320

Pro Phe Thr Leu Asn Phe Thr Ile Thr Asn Leu Gln Tyr Glu Glu 13325 13330 13335

Asp Met Arg Arg Pro Gly Ser Arg Lys Phe Asn Thr Thr Glu Arg 13340 13345 13350

Val Leu Gln Gly Leu Leu Met Pro Leu Phe Lys Asn Thr Ser Val 13355 13360 13365

Ser Ser Leu Tyr Ser Gly Cys Arg Leu Thr Leu Leu Arg Pro Glu 13370 13375 13380

Lys Asp Gly Ala Ala Thr Arg Val Asp Ala Val Cys Thr His Arg 13385 13390 13395

Pro Asp Pro Lys Ser Pro Gly Leu Asp Arg Glu Arg Leu Tyr Trp 13400 13405 13410

Lys Leu Ser Gln Leu Thr His Gly Ile Thr Glu Leu Gly Pro Tyr 13415 13420 13425

Thr Leu Asp Arg His Ser Leu Tyr Val Asn Gly Phe Thr His Gln 13430 13435 13440

Ser Ser Met Thr Thr Thr Arg Thr Pro Asp Thr Ser Thr Met His 13445 13450 13455

Leu Ala Thr Ser Arg Thr Pro Ala Ser Leu Ser Gly Pro Met Thr 13460 13465 13470

Ala Ser Pro Leu Leu Val Leu Phe Thr Ile Asn Phe Thr Ile Thr 13475 13480 13485

Asn Leu Arg Tyr Glu Glu Asn Met His His Pro Gly Ser Arg Lys 13490 13495 13500

Phe Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu Arg Pro Val Page 56

6847536_1 17 Sep 2019

13505 13510 13515

Phe Lys Asn Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu 13520 13525 13530

Thr Leu Leu Arg Pro Lys Lys Asp Gly Ala Ala Thr Lys Val Asp 13535 13540 13545

Ala Ile Cys Thr Tyr Arg Pro Asp Pro Lys Ser Pro Gly Leu Asp 13550 13555 13560 2019232796

Arg Glu Gln Leu Tyr Trp Glu Leu Ser Gln Leu Thr His Ser Ile 13565 13570 13575

Thr Glu Leu Gly Pro Tyr Thr Leu Asp Arg Asp Ser Leu Tyr Val 13580 13585 13590

Asn Gly Phe Thr Gln Arg Ser Ser Val Pro Thr Thr Ser Ile Pro 13595 13600 13605

Gly Thr Pro Thr Val Asp Leu Gly Thr Ser Gly Thr Pro Val Ser 13610 13615 13620

Lys Pro Gly Pro Ser Ala Ala Ser Pro Leu Leu Val Leu Phe Thr 13625 13630 13635

Leu Asn Phe Thr Ile Thr Asn Leu Arg Tyr Glu Glu Asn Met Gln 13640 13645 13650

His Pro Gly Ser Arg Lys Phe Asn Thr Thr Glu Arg Val Leu Gln 13655 13660 13665

Gly Leu Leu Arg Ser Leu Phe Lys Ser Thr Ser Val Gly Pro Leu 13670 13675 13680

Tyr Ser Gly Cys Arg Leu Thr Leu Leu Arg Pro Glu Lys Asp Gly 13685 13690 13695

Thr Ala Thr Gly Val Asp Ala Ile Cys Thr His His Pro Asp Pro 13700 13705 13710

Lys Ser Pro Arg Leu Asp Arg Glu Gln Leu Tyr Trp Glu Leu Ser 13715 13720 13725

Gln Leu Thr His Asn Ile Thr Glu Leu Gly Pro Tyr Ala Leu Asp 13730 13735 13740

Asn Asp Ser Leu Phe Val Asn Gly Phe Thr His Arg Ser Ser Val 13745 13750 13755

Ser Thr Thr Ser Thr Pro Gly Thr Pro Thr Val Tyr Leu Gly Ala 13760 13765 13770 Page 57

6847536_1 17 Sep 2019

Ser Lys Thr Pro Ala Ser Ile Phe Gly Pro Ser Ala Ala Ser His 13775 13780 13785

Leu Leu Ile Leu Phe Thr Leu Asn Phe Thr Ile Thr Asn Leu Arg 13790 13795 13800

Tyr Glu Glu Asn Met Trp Pro Gly Ser Arg Lys Phe Asn Thr Thr 13805 13810 13815 2019232796

Glu Arg Val Leu Gln Gly Leu Leu Arg Pro Leu Phe Lys Asn Thr 13820 13825 13830

Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr Leu Leu Arg 13835 13840 13845

Pro Glu Lys Asp Gly Glu Ala Thr Gly Val Asp Ala Ile Cys Thr 13850 13855 13860

His Arg Pro Asp Pro Thr Gly Pro Gly Leu Asp Arg Glu Gln Leu 13865 13870 13875

Tyr Leu Glu Leu Ser Gln Leu Thr His Ser Ile Thr Glu Leu Gly 13880 13885 13890

Pro Tyr Thr Leu Asp Arg Asp Ser Leu Tyr Val Asn Gly Phe Thr 13895 13900 13905

His Arg Ser Ser Val Pro Thr Thr Ser Thr Gly Val Val Ser Glu 13910 13915 13920

Glu Pro Phe Thr Leu Asn Phe Thr Ile Asn Asn Leu Arg Tyr Met 13925 13930 13935

Ala Asp Met Gly Gln Pro Gly Ser Leu Lys Phe Asn Ile Thr Asp 13940 13945 13950

Asn Val Met Gln His Leu Leu Ser Pro Leu Phe Gln Arg Ser Ser 13955 13960 13965

Leu Gly Ala Arg Tyr Thr Gly Cys Arg Val Ile Ala Leu Arg Ser 13970 13975 13980

Val Lys Asn Gly Ala Glu Thr Arg Val Asp Leu Leu Cys Thr Tyr 13985 13990 13995

Leu Gln Pro Leu Ser Gly Pro Gly Leu Pro Ile Lys Gln Val Phe 14000 14005 14010

His Glu Leu Ser Gln Gln Thr His Gly Ile Thr Arg Leu Gly Pro 14015 14020 14025

Page 58

6847536_1 17 Sep 2019

Tyr Ser Leu Asp Lys Asp Ser Leu Tyr Leu Asn Gly Tyr Asn Glu 14030 14035 14040

Pro Gly Pro Asp Glu Pro Pro Thr Thr Pro Lys Pro Ala Thr Thr 14045 14050 14055

Phe Leu Pro Pro Leu Ser Glu Ala Thr Thr Ala Met Gly Tyr His 14060 14065 14070 2019232796

Leu Lys Thr Leu Thr Leu Asn Phe Thr Ile Ser Asn Leu Gln Tyr 14075 14080 14085

Ser Pro Asp Met Gly Lys Gly Ser Ala Thr Phe Asn Ser Thr Glu 14090 14095 14100

Gly Val Leu Gln His Leu Leu Arg Pro Leu Phe Gln Lys Ser Ser 14105 14110 14115

Met Gly Pro Phe Tyr Leu Gly Cys Gln Leu Ile Ser Leu Arg Pro 14120 14125 14130

Glu Lys Asp Gly Ala Ala Thr Gly Val Asp Thr Thr Cys Thr Tyr 14135 14140 14145

His Pro Asp Pro Val Gly Pro Gly Leu Asp Ile Gln Gln Leu Tyr 14150 14155 14160

Trp Glu Leu Ser Gln Leu Thr His Gly Val Thr Gln Leu Gly Phe 14165 14170 14175

Tyr Val Leu Asp Arg Asp Ser Leu Phe Ile Asn Gly Tyr Ala Pro 14180 14185 14190

Gln Asn Leu Ser Ile Arg Gly Glu Tyr Gln Ile Asn Phe His Ile 14195 14200 14205

Val Asn Trp Asn Leu Ser Asn Pro Asp Pro Thr Ser Ser Glu Tyr 14210 14215 14220

Ile Thr Leu Leu Arg Asp Ile Gln Asp Lys Val Thr Thr Leu Tyr 14225 14230 14235

Lys Gly Ser Gln Leu His Asp Thr Phe Arg Phe Cys Leu Val Thr 14240 14245 14250

Asn Leu Thr Met Asp Ser Val Leu Val Thr Val Lys Ala Leu Phe 14255 14260 14265

Ser Ser Asn Leu Asp Pro Ser Leu Val Glu Gln Val Phe Leu Asp 14270 14275 14280

Page 59

6847536_1 17 Sep 2019

Lys Thr Leu Asn Ala Ser Phe His Trp Leu Gly Ser Thr Tyr Gln 14285 14290 14295

Leu Val Asp Ile His Val Thr Glu Met Glu Ser Ser Val Tyr Gln 14300 14305 14310

Pro Thr Ser Ser Ser Ser Thr Gln His Phe Tyr Leu Asn Phe Thr 14315 14320 14325

Ile Thr Asn Leu Pro Tyr Ser Gln Asp Lys Ala Gln Pro Gly Thr 2019232796

14330 14335 14340

Thr Asn Tyr Gln Arg Asn Lys Arg Asn Ile Glu Asp Ala Leu Asn 14345 14350 14355

Gln Leu Phe Arg Asn Ser Ser Ile Lys Ser Tyr Phe Ser Asp Cys 14360 14365 14370

Gln Val Ser Thr Phe Arg Ser Val Pro Asn Arg His His Thr Gly 14375 14380 14385

Val Asp Ser Leu Cys Asn Phe Ser Pro Leu Ala Arg Arg Val Asp 14390 14395 14400

Arg Val Ala Ile Tyr Glu Glu Phe Leu Arg Met Thr Arg Asn Gly 14405 14410 14415

Thr Gln Leu Gln Asn Phe Thr Leu Asp Arg Ser Ser Val Leu Val 14420 14425 14430

Asp Gly Tyr Ser Pro Asn Arg Asn Glu Pro Leu Thr Gly Asn Ser 14435 14440 14445

Asp Leu Pro Phe Trp Ala Val Ile Leu Ile Gly Leu Ala Gly Leu 14450 14455 14460

Leu Gly Val Ile Thr Cys Leu Ile Cys Gly Val Leu Val Thr Thr 14465 14470 14475

Arg Arg Arg Lys Lys Glu Gly Glu Tyr Asn Val Gln Gln Gln Cys 14480 14485 14490

Pro Gly Tyr Tyr Gln Ser His Leu Asp Leu Glu Asp Leu Gln 14495 14500 14505

<210> 14 <211> 24 <212> PRT <213> Artificial Sequence

<220> <223> Synthetic

<400> 14 Page 60

6847536_1 17 Sep 2019

Phe Trp Ala Val Ile Leu Ile Gly Leu Ala Gly Leu Leu Gly Leu Ile 1 5 10 15

Thr Cys Leu Ile Cys Gly Val Leu 20

<210> 15 <211> 32 <212> PRT <213> Artificial Sequence 2019232796

<220> <223> Synthetic

<400> 15

Lys Ser Tyr Phe Ser Asp Cys Gln Val Ser Thr Phe Arg Ser Val Pro 1 5 10 15

Asn Arg His His Thr Gly Val Asp Ser Leu Cys Asn Phe Ser Pro Leu 20 25 30

<210> 16 <211> 32 <212> PRT <213> Artificial Sequence

<220> <223> Synthetic

<400> 16

Val Thr Thr Arg Arg Arg Lys Lys Glu Gly Glu Tyr Asn Val Gln Gln 1 5 10 15

Gln Cys Pro Gly Tyr Tyr Gln Ser His Leu Asp Leu Glu Asp Leu Gln 20 25 30

<210> 17 <211> 58 <212> PRT <213> Artificial Sequence

<220> <223> Synthetic

<400> 17

Asn Phe Ser Pro Leu Ala Arg Arg Val Asp Arg Val Ala Ile Tyr Glu 1 5 10 15

Glu Phe Leu Arg Met Thr Arg Asn Gly Thr Gln Leu Gln Asn Phe Thr 20 25 30

Leu Asp Arg Ser Ser Val Leu Val Asp Gly Tyr Ser Pro Asn Arg Asn 35 40 45

Glu Pro Leu Thr Gly Asn Ser Asp Leu Pro 50 55 Page 61

6847536_1 17 Sep 2019

<210> 18 <211> 17 <212> PRT <213> Artificial Sequence

<220> <223> Synthetic

<400> 18

Val Thr Thr Arg Arg Arg Lys Lys Glu Gly Glu Tyr Asn Val Gln Gln 2019232796

1 5 10 15

Gln

<210> 19 <211> 21 <212> PRT <213> Artificial Sequence

<220> <223> Synthetic

<400> 19

Cys Gln Val Ser Thr Phe Arg Ser Val Pro Asn Arg His His Thr Gly 1 5 10 15

Val Asp Ser Leu Cys 20

<210> 20 <211> 18 <212> PRT <213> Artificial Sequence

<220> <223> Synthetic

<400> 20

Leu Val Thr Thr Arg Arg Arg Lys Lys Glu Gly Glu Tyr Asn Val Gln 1 5 10 15

Gln Gln

<210> 21 <211> 18 <212> PRT <213> Mus musculus

<400> 21

Thr Leu Asp Arg Lys Ser Val Phe Val Asp Gly Tyr Ser Gln Asn Arg 1 5 10 15

Asp Asp

Page 62

6847536_1 17 Sep 2019

<210> 22 <211> 33 <212> PRT <213> Mus musculus

<400> 22

Lys Ser Tyr Phe Ser Asp Cys Gln Val Leu Ala Phe Arg Ser Val Ser 1 5 10 15 2019232796

Asn Asn Asn Asn His Thr Gly Val Asp Ser Leu Cys Asn Phe Ser Pro 20 25 30

Leu

<210> 23 <211> 31 <212> PRT <213> Mus musculus

<400> 23

Ser Leu Tyr Ser Asn Cys Arg Leu Ala Ser Leu Arg Pro Lys Lys Asn 1 5 10 15

Gly Thr Ala Thr Gly Val Asn Ala Ile Cys Ser Tyr His Gln Asn 20 25 30

<210> 24 <211> 402 <212> PRT <213> Mus musculus

<400> 24

His Leu Ile Arg Pro Leu Val Gln Asn Glu Ser Leu Tyr Ser Asn Cys 1 5 10 15

Arg Leu Ala Ser Leu Arg Pro Lys Lys Asn Gly Thr Ala Thr Gly Val 20 25 30

Asn Ala Ile Cys Ser Tyr His Gln Asn Pro Asp His Pro Glu Leu Asp 35 40 45

Thr Gln Glu Leu Tyr Thr Lys Leu Thr Gln Leu Thr Gln Gly Val Thr 50 55 60

Gln Leu Gly Ser Tyr Met Leu Asp Gln Asn Ser Ile Tyr Val Asn Gly 65 70 75 80

Tyr Val Pro Leu Asn Ile Thr Ile Gln Gly Lys Tyr Gln Leu Asn Phe 85 90 95

Cys Ile Ile Asn Trp Asn Leu Asn Asn Thr Asp Pro Thr Ser Ser Glu 100 105 110 Page 63

6847536_1 17 Sep 2019

Tyr Ile Thr Leu Glu Arg Asp Ile Glu Asp Lys Val Thr Thr Leu Tyr 115 120 125

Thr Gly Ser Gln Leu Lys Glu Val Phe Gln Ser Cys Leu Val Thr Asn 130 135 140

Met Thr Ser Gly Ser Thr Val Val Thr Leu Glu Ala Leu Phe Ser Ser 145 150 155 160 2019232796

His Leu Asp Pro Asn Leu Val Lys Gln Val Phe Leu Asn Lys Thr Leu 165 170 175

Asn Ala Ser Ser His Trp Leu Gly Ala Thr Tyr Gln Leu Lys Asp Leu 180 185 190

His Val Ile Asp Met Lys Thr Ser Ile Leu Leu Pro Ala Glu Ile Pro 195 200 205

Thr Thr Ser Ser Ser Ser Gln His Phe Asn Leu Asn Phe Thr Ile Thr 210 215 220

Asn Leu Pro Tyr Ser Gln Asp Ile Ala Gln Pro Ser Thr Thr Lys Tyr 225 230 235 240

Gln Gln Thr Lys Arg Ser Ile Glu Asn Ala Leu Asn Gln Leu Phe Arg 245 250 255

Asn Ser Ser Ile Lys Ser Tyr Phe Ser Asp Cys Gln Val Leu Ala Phe 260 265 270

Arg Ser Val Ser Asn Asn Asn Asn His Thr Gly Val Asp Ser Leu Cys 275 280 285

Asn Phe Ser Pro Leu Ala Arg Arg Val Asp Arg Val Ala Ile Tyr Glu 290 295 300

Glu Phe Leu Arg Met Thr His Asn Gly Thr Gln Leu Leu Asn Phe Thr 305 310 315 320

Leu Asp Arg Lys Ser Val Phe Val Asp Gly Tyr Ser Gln Asn Arg Asp 325 330 335

Asp Asp Val Met Lys Asn Ser Gly Leu Pro Phe Trp Ala Ile Ile Leu 340 345 350

Ile Cys Leu Ala Val Leu Leu Val Leu Ile Thr Cys Leu Met Cys Cys 355 360 365

Phe Leu Val Thr Val Cys Arg Arg Lys Lys Glu Gly Asp Tyr Gln Val 370 375 380

Page 64

6847536_1 17 Sep 2019

Gln Arg His Arg Leu Ala Tyr Tyr Leu Ser His Leu Asp Leu Arg Lys 385 390 395 400

Leu Gln

<210> 25 <211> 400 <212> PRT <213> Homo sapiens 2019232796

<400> 25

His Leu Leu Arg Pro Leu Phe Gln Lys Ser Ser Met Gly Pro Phe Tyr 1 5 10 15

Leu Gly Cys Gln Leu Ile Ser Leu Arg Pro Glu Lys Asp Gly Ala Ala 20 25 30

Thr Gly Val Asp Thr Thr Cys Thr Tyr His Pro Asp Pro Val Gly Pro 35 40 45

Gly Leu Asp Ile Gln Gln Leu Tyr Trp Glu Leu Ser Gln Leu Thr His 50 55 60

Gly Val Thr Gln Leu Gly Phe Tyr Val Leu Asp Arg Asp Ser Leu Phe 65 70 75 80

Ile Asn Gly Tyr Ala Pro Gln Asn Leu Ser Ile Arg Gly Glu Tyr Gln 85 90 95

Ile Asn Phe His Ile Val Asn Trp Asn Leu Ser Asn Pro Asp Pro Thr 100 105 110

Ser Ser Glu Tyr Ile Thr Leu Leu Arg Asp Ile Gln Asp Lys Val Thr 115 120 125

Thr Leu Tyr Lys Gly Ser Gln Leu His Asp Thr Phe Arg Phe Cys Leu 130 135 140

Val Thr Asn Leu Thr Met Asp Ser Val Leu Val Thr Val Lys Ala Leu 145 150 155 160

Phe Ser Ser Asn Leu Asp Pro Ser Leu Val Glu Gln Val Phe Leu Asp 165 170 175

Lys Thr Leu Asn Ala Ser Phe His Trp Leu Gly Ser Thr Tyr Gln Leu 180 185 190

Val Asp Ile His Val Thr Glu Met Glu Ser Ser Val Tyr Gln Pro Thr 195 200 205

Ser Ser Ser Ser Thr Gln His Phe Tyr Leu Asn Phe Thr Ile Thr Asn Page 65

6847536_1 17 Sep 2019

210 215 220

Leu Pro Tyr Ser Gln Asp Lys Ala Gln Pro Gly Thr Thr Asn Tyr Gln 225 230 235 240

Arg Asn Lys Arg Asn Ile Glu Asp Ala Leu Asn Gln Leu Phe Arg Asn 245 250 255

Ser Ser Ile Lys Ser Tyr Phe Ser Asp Cys Gln Val Ser Thr Phe Arg 260 265 270 2019232796

Ser Val Pro Asn Arg His His Thr Gly Val Asp Ser Leu Cys Asn Phe 275 280 285

Ser Pro Leu Ala Arg Arg Val Asp Arg Val Ala Ile Tyr Glu Glu Phe 290 295 300

Leu Arg Met Thr Arg Asn Gly Thr Gln Leu Gln Asn Phe Thr Leu Asp 305 310 315 320

Arg Ser Ser Val Leu Val Asp Gly Tyr Ser Pro Asn Arg Asn Glu Pro 325 330 335

Leu Thr Gly Asn Ser Asp Leu Pro Phe Trp Ala Val Ile Leu Ile Gly 340 345 350

Leu Ala Gly Leu Leu Gly Val Ile Thr Cys Leu Ile Cys Gly Val Leu 355 360 365

Val Thr Thr Arg Arg Arg Lys Lys Glu Gly Glu Tyr Asn Val Gln Gln 370 375 380

Gln Cys Pro Gly Tyr Tyr Gln Ser His Leu Asp Leu Glu Asp Leu Gln 385 390 395 400

<210> 26 <211> 360 <212> DNA <213> Artificial Sequence

<220> <223> Synthetic

<400> 26 gaggtgaagc tggaggagtc aggtggagga ttggtgcagc ctaaaggatc attgaaactc 60

tcatgtgccg cctctggttt caccttcaat acctatgccg tgcactgggt ccgccaggct 120

ccaggaaagg gtatggaatg ggttgctcgc ataagaagta aaagtggaaa ttatgcaaca 180

tattatgccg attcagtgaa agacagattc accatctcca gaaatgattc acagagcatg 240

ctctatctgc aaatgaacaa cctgaaaact gaggacacag ccatatatta ctgtgtgaga 300

gcgggtaaca acggggcctt tccttactgg ggccaaggga ccacggtcac cgtctcctca 360

Page 66

6847536_1 17 Sep 2019

<210> 27 <211> 120 <212> PRT <213> Artificial Sequence

<220> <223> Synthetic

<400> 27

Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Lys Gly 1 5 10 15 2019232796

Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr 20 25 30

Ala Val His Trp Val Arg Gln Ala Pro Gly Lys Gly Met Glu Trp Val 35 40 45

Ala Arg Ile Arg Ser Lys Ser Gly Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60

Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asn Asp Ser Gln Ser Met 65 70 75 80

Leu Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Ile Tyr 85 90 95

Tyr Cys Val Arg Ala Gly Asn Asn Gly Ala Phe Pro Tyr Trp Gly Gln 100 105 110

Gly Thr Thr Val Thr Val Ser Ser 115 120

<210> 28 <211> 330 <212> DNA <213> Artificial Sequence

<220> <223> Synthetic

<400> 28 gacattgagc tcacccagtc tccatcctca ctgtctgcat ctctgggagg cagagtcacc 60

atcacttgca aggctagcca agatattaag aagtatatag cttggtacca acacaagcct 120

ggaaaaactc ctcgactact catacatttc acatctacat tacagacagg catcccatca 180

aggttcagtg gacgtgggtc tgggagagac tattccttca gcatcagcaa cctggagtct 240

gaagatattg caacttatta ttgtctacag tatgatagtc tgtacacgtt cggagggggg 300

accaagctgg agatcaaacg ggcggccgca 330

<210> 29 <211> 110 <212> PRT <213> Artificial Sequence

Page 67

6847536_1 17 Sep 2019

<220> <223> Synthetic

<400> 29

Asp Ile Glu Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15

Gly Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Lys Lys Tyr 20 25 30 2019232796

Ile Ala Trp Tyr Gln His Lys Pro Gly Lys Thr Pro Arg Leu Leu Ile 35 40 45

His Phe Thr Ser Thr Leu Gln Thr Gly Ile Pro Ser Arg Phe Ser Gly 50 55 60

Arg Gly Ser Gly Arg Asp Tyr Ser Phe Ser Ile Ser Asn Leu Glu Ser 65 70 75 80

Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp Ser Leu Tyr Thr 85 90 95

Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Ala Ala 100 105 110

<210> 30 <211> 14 <212> PRT <213> Artificial Sequence

<220> <223> Synthetic

<400> 30

Lys Ser Tyr Phe Ser Asp Cys Gln Val Asn Asn Phe Arg Ser 1 5 10

<210> 31 <211> 18 <212> PRT <213> Artificial Sequence

<220> <223> Synthetic

<400> 31

Thr Leu Asp Arg Ser Ser Val Leu Val Asp Gly Tyr Ser Gln Asn Arg 1 5 10 15

Asp Asp

Page 68

Claims

CLAIMS:

1. An isolated antibody, or an antigen-binding fragment thereof, that specifically binds to a MUC16 polypeptide or to an antigenic portion thereof, wherein the MUC16 polypeptide is

TLDRSSVLVDGYSPNRNE (SEQ ID NO:02), and

wherein the antibody comprises a variable heavy ("VH") chain encoded by SEQ ID NO:04 and a variable light ("VL") chain encoded by SEQ ID NO:05.

2. The antibody or antigen-binding fragment of claim 1, wherein the antibody is a monoclonal antibody.

3. The antibody or antigen-binding fragment of claim 1, wherein the antibody is a chimeric antibody.

4. A humanized antibody or antigen-binding fragment thereof made by substituting the complementarity determining regions of a first antibody into a human framework domain, wherein the humanized antibody or antigen-binding fragment thereof specifically binds to a MUC16 polypeptide or to an antigenic portion thereof, wherein thefirst antibody specifically binds to the MUC16 polypeptide or the antigenic portion thereof, wherein the MUC16 polypeptide is TLDRSSVLVDGYSPNRNE (SEQ ID NO:02), and wherein the first antibody comprises a VH chain encoded by SEQ ID NO:04 and a VL chain encoded by SEQ ID NO:05.

5. The antibody or antigen-binding fragment of claim 4, wherein substantially all of the framework region residues of the humanized antibody are those of a human immunoglobulin sequence, and wherein one or more of the framework region residues are replaced by corresponding nonhuman residues.

6. The antibody or antigen-binding fragment of any one of claims I to 5, wherein the antigen-binding fragment is selected from the group consisting of a Fab fragment, a F(ab')2 fragment, and a Fv fragment.

7. The antibody or antigen-binding fragment of any one of claims 1 to 6, wherein the antibody or antigen-binding fragment is covalently linked to a cytotoxic agent or a prodrug of a cytotoxic agent.

8. A composition comprising (a) the antibody or antigen-binding fragment of any one of claims 1 to 7, and (b) a pharmaceutically acceptable carrier.

9. A hybridoma cell that produces a monoclonal antibody, or an antigen-binding fragment thereof, that specifically binds to a MUC16 polypeptide or to an antigenic portion thereof, wherein the MUC16 polypeptide is

TLDRSSVLVDGYSPNRNE (SEQ ID NO:02), and

10. A method for identifying a subject as having a cancer in which MUC16 is expressed, wherein said method comprises administering the antibody of any of claims 1 to 7 to the subject, and determining the presence and location of the antibody in the subject, wherein said antibody is labeled.

11. The method of claim 10, wherein the cancer is selected from the group consisting of ovarian cancer and breast cancer.

12. An ex vivo method for identifying a subject as having a cancer in which MUC16 is expressed, wherein said method comprises:

(a) obtaining a first sample from a first subject;

(b) contacting the first sample with the antibody of any one of claims 1 to 7; and

(c) determining whether the antibody has an increased level of binding to the first sample as compared to a control sample lacking the cancer.

13. The ex vivo method of claim 12, wherein the cancer is selected from the group consisting of ovarian cancer and breast cancer.

14. A single chain variable fragment (scFv) comprising a VH chain sequence encoded by SEQ ID NO:04 and a VL chain sequence encoded by SEQ ID NO:05.

15. A single chain variable fragment (scFv) comprising a VH chain sequence and a VL chain sequence of the humanized antibody or antigen-binding fragment of claim 4.

16. A chimeric antigen receptor (CAR) comprising the scFv of claim 14 or 15.

17. A CAR comprising the scFv of claim 16 fused to a transmembrane domain.

18. The CAR of claim 17, wherein the transmembrane domain is fused to the T cell receptor ( chain cytoplasmic signaling domain.

19. The CAR of claim 18, further comprising a cytoplasmic signaling domain of a co stimulatory receptor, wherein the co-stimulatory receptor comprises CD28, 4-1BB, or OX40.

20. The CAR of claim 17, comprising in amino- to carboxy-terminal order: a human CD8 leader peptide, the scFv, a human CD28 transmembrane domain and cytoplasmic signaling domain, and a CD3-zeta signaling domain.

21. A T cell expressing the CAR of any one of claims 16 to 20.

22. A method for treating a cancer in which MUC16 is expressed, comprising administering to a subject a therapeutically effective amount of the antibody or antigen-binding fragment of any one of claims 1-7.

23. A method for treating a cancer in which MUC16 is expressed, comprising administering to a subject the T cell of claim 21.

24. The method of claim 23, wherein the administering is intraperitoneally or intravenously.

25. The method of claim 22 or 23, wherein the cancer is selected from the group consisting of ovarian cancer and breast cancer.

26. The method of any one of claims 22 to 25, which further comprises detecting a reduction in one or more symptoms of the cancer after the administering step.

27. A chimeric antibody that is the antibody of claim 3.

28. A humanized antibody that is the antibody of claim 4.

29. A method for treating a cancer in which MUC16 is expressed, comprising administering to a subject the antibody of claim 27.

30. A method for treating a cancer in which MUC16 is expressed, comprising administering to a subject the antibody of claim 28.

31. Use of a therapeutically effective amount of the antibody or antigen-binding fragment of any one of claims 1-7 in the preparation of a medicament for treating a cancer in which MUC16 is expressed.

32. Use of the T cell of claim 21 in the preparation of a medicament for treating a cancer in which MUC16 is expressed.

33. Use of the antibody of claim 27 in the preparation of a medicament for treating a cancer in which MUC16 is expressed.

34. Use of the antibody of claim 28 in the preparation of a medicament for treating a cancer in which MUC16 is expressed.